---
document_datetime: 2023-09-21 20:34:53
document_pages: 79
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/darzalex-h-c-4077-ii-0044-epar-assessment-report-variation_en.pdf
document_name: darzalex-h-c-4077-ii-0044-epar-assessment-report-variation_en.pdf
version: success
processing_time: 145.6831742
conversion_datetime: 2025-12-22 16:31:53.530896
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

20 May 2021 EMA/CHMP/266131/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Darzalex

International non-proprietary name: daratumumab

Procedure No. EMEA/H/C/004077/II/0044

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                   | 6                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6 |                                                                                                          |
| 1.2. Steps taken for the assessment of the product                                                                         | ........................................................7                                                |
| 2. Scientific discussion................................................................................                   | 7                                                                                                        |
| 2.1. Problem statement...............................................................................................7     |                                                                                                          |
| 2.1.1. Disease or condition                                                                                                | ..........................................................................................7              |
| 2.1.2. Epidemiology                                                                                                        | ....................................................................................................8    |
| 2.1.3. Biologic features, aetiology and pathogenesis                                                                       | .......................................................8                                                 |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis..............................................8                 |                                                                                                          |
| 2.1.5. Management.....................................................................................................8    |                                                                                                          |
| 2.1.6. About the product                                                                                                   | .............................................................................................8           |
| 2.1.7. The development programme/compliance with CHMP guidance/scientific                                                  | advice........9                                                                                          |
| 2.2. Non-clinical aspects..............................................................................................9   |                                                                                                          |
| 2.2.1. Ecotoxicity/environmental risk assessment...........................................................9               |                                                                                                          |
| 2.3. Clinical aspects                                                                                                      | ....................................................................................................9    |
| 2.3.1. Introduction......................................................................................................9 |                                                                                                          |
| 2.3.2. Pharmacokinetics                                                                                                    | ............................................................................................ 11          |
| 2.3.3. Pharmacodynamics..........................................................................................          | 20                                                                                                       |
| 2.3.4. PK/PD modelling                                                                                                     | ............................................................................................. 25         |
| 2.3.5. Discussion on clinical pharmacology...................................................................              | 25                                                                                                       |
| 2.3.6. Conclusions on clinical pharmacology.................................................................               | 26                                                                                                       |
| 2.4. Clinical efficacy                                                                                                     | .................................................................................................. 26    |
| 2.4.1. Dose response study........................................................................................         | 26                                                                                                       |
| 2.4.2. Main study                                                                                                          | ..................................................................................................... 27 |
| 2.4.3. Discussion on clinical efficacy............................................................................         | 50                                                                                                       |
| 2.4.4. Conclusions on the clinical efficacy                                                                                | .................................................................... 52                                  |
| 2.5. Clinical safety                                                                                                       | .................................................................................................... 53  |
| 2.5.1. Discussion on clinical safety..............................................................................         | 70                                                                                                       |
| 2.5.2. Conclusions on clinical safety............................................................................          | 71                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                          | ..................................................................................................... 71 |
| 2.6. Risk management plan                                                                                                  | ....................................................................................... 71               |
| Summary of the safety concerns ................................................................................            | 71                                                                                                       |
| Pharmacovigilance plan .............................................................................................       | 71                                                                                                       |
| Risk minimisation measures.......................................................................................          | 72                                                                                                       |
| 2.7. Update of the Product information........................................................................             | 72                                                                                                       |
| 2.7.1. User consultation ............................................................................................      | 72                                                                                                       |
| 3. Benefit-Risk Balance.............................................................................                       | 73                                                                                                       |
| 3.1. Therapeutic Context ...........................................................................................       | 73                                                                                                       |
| 3.1.1. Disease or condition                                                                                                | ........................................................................................ 73              |
| 3.1.2. Available therapies and unmet medical                                                                               | need....................................................... 73                                           |
| 3.1.3. Main clinical studies.........................................................................................      | 74                                                                                                       |
| 3.2. Favourable effects..............................................................................................      | 74                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects.............................................                   | 74                                                                                                       |

<div style=\"page-break-after: always\"></div>

3.4. Unfavourable effects  ...........................................................................................  75

3.5. Uncertainties and limitations about unfavourable effects ......................................... 75

3.6. Effects Table  ......................................................................................................  76

3.7. Benefit-risk assessment and discussion  ................................................................. 76

3.7.1. Importance of favourable and unfavourable effects  .............................................. 76

3.7.2. Balance of benefits and risks ............................................................................  77

3.7.3. Additional considerations on the benefit-risk balance ........................................... 77

3.8. Conclusions  .......................................................................................................  77

4. Recommendations  ................................................................................. 77

5. EPAR changes ....................................................................................... 78

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADA

anti-daratumumab antibodies

ALT

alanine aminotransferase

ASCT

autologous stem cell transplant

AST

aspartate aminotransferase

BLQ

below limit of quantitation

CI

confidence interval

CMH

Cochran-Mantel-Haenszel

COVID-19

Coronavirus Disease 2019

CR

complete response

CRO

clinical research organization

CSR

clinical study report

DoR

duration of response

DPd

daratumumab, pomalidomide, dexamethasone

DT

drug tolerant

ECG

electrocardiogram

ECOG

Eastern Cooperative Oncology Group

eCRF

electronic case report form

EMN

European Myeloma Network

EU

European Union

FISH

fluorescence in situ hybridization

HBV

hepatitis B virus

HIV

human immunodeficiency virus

HR

hazard ratio

HRQoL

health-related quality-of-life

IDMC

Independent Data Monitoring Committee

IEC

Institutional Ethics Committee

IMiD

immunomodulatory agents

IMWG

International Myeloma Working Group

IRB

Institutional Review Board

IRR

infusion-related reactions

ISS

International Staging System

ITT

intent-to-treat

<div style=\"page-break-after: always\"></div>

| IV      | intravenous                                              |
|---------|----------------------------------------------------------|
| IWRS    | interactive web response system                          |
| MRD     | minimal residual disease                                 |
| Nabs    | neutralizing antibodies                                  |
| NGS     | next-generation sequencing                               |
| ORR     | overall response rate                                    |
| OS      | overall survival                                         |
| Pd      | pomalidomide, dexamethasone                              |
| PI      | proteasome inhibitor                                     |
| PFS     | progression-free survival                                |
| PFS2    | progression-free survival after the next line of therapy |
| PK      | pharmacokinetic                                          |
| PO      | orally                                                   |
| PR      | partial response                                         |
| PRO     | patient-reported outcome                                 |
| rHuPH20 | Recombinant Human Hyaluronidase PH20                     |
| R-ISS   | revised International Staging System                     |
| SAP     | statistical analysis plan                                |
| SC      | subcutaneous                                             |
| sCR     | stringent complete response                              |
| SD      | standard deviation                                       |
| SOC     | standard of care                                         |
| SOP     | Standard Operating Procedure                             |
| SDR     | source data review                                       |
| SDV     | source data verification                                 |
| SPM     | secondary primary malignancy                             |
| TEAE    | treatment-emergent adverse event                         |
| TMF     | trial master file                                        |
| US      | United States                                            |
| VGPR    | very good partial response                               |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Janssen-Cilag International NV submitted to the European Medicines Agency on 11 November 2020 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication for Darzalex subcutaneous formulation to include combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated.  In addition section 4.8 of the SmPC for the intravenous formulation is also updated based on the pooled safety analysis. The Package Leaflet is updated in accordance. Version 8.2 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information relating to orphan designation

Darzalex, was designated as an orphan medicinal product EU/3/13/1153 on 17/07/2013. Darzalex was designated as an orphan medicinal product in the following indication: Treatment of plasma cell myeloma.

The  new  indication,  which  is  the  subject  of  this  application,  falls  within  the  above  mentioned  orphan designation.

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  (an)  EMA  Decision(s) P/0264/2017 on the granting of a product-specific waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Protocol assistance

The MAH did not seek Protocol assistance at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Sinan B. Sarac

Co-Rapporteur:

Blanca Garcia-Ochoa

| Timetable                                                                                                                            | Actual dates     |
|--------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Submission date                                                                                                                      | 11 November 2020 |
| Start of procedure:                                                                                                                  | 28 November 2020 |
| CHMP Co-Rapporteur Assessment Report                                                                                                 | 4 February 2021  |
| CHMP Rapporteur Assessment Report                                                                                                    | 22 January 2021  |
| PRAC Rapporteur Assessment Report                                                                                                    | 29 January 2021  |
| PRAC members comments                                                                                                                | 3 February 2021  |
| Updated PRAC Rapporteur Assessment Report                                                                                            | 4 February 2021  |
| PRAC Outcome                                                                                                                         | 11 February 2021 |
| CHMP members comments                                                                                                                | 15 February 2021 |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report                                                                                 | 19 February 2021 |
| Request for supplementary information (RSI)                                                                                          | 25 February 2021 |
| CHMP Rapporteur Assessment Report                                                                                                    | 28 April 2021    |
| CHMP members comments                                                                                                                | 10 May 2021      |
| Updated CHMP Rapporteur Assessment Report                                                                                            | 12 May 2021      |
| Opinion                                                                                                                              | 20 May 2021      |
| The CHMP adopted a report on similarity of Darzalex with Imnovid, Farydak, Kyprolis, Ninlaro and Blenrep on 20 May 2021 (Appendix 1) | 20 May 2021      |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

The proposed addition to the existing indication is only for the subcutaneous use of daratumumab.

The initial proposed addition to the existing indication statement in section 4.1 of the Summary of Product Characteristics (SmPC) was as follows (proposed text in bold) :

'DARZALEX is indicated in combination with pomalidomide and dexamethasone, or as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.'

The indication was entered as a separate one from monotherapy and updated during the procedure to better reflect the population included in study MMY3013. The following wording is agreed:

<div style=\"page-break-after: always\"></div>

'DARZALEX is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory,  or  who  have  received  at  least  two  prior  therapies  that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1).'

## 2.1.2. Epidemiology

Multiple  myeloma  is  an  incurable  malignant  plasma  cell  disorder  diagnosed  annually  in  approximately 160,000 patients worldwide (Bray 2018). The median age at diagnosis is 72 years.

## 2.1.3. Biologic features, aetiology and pathogenesis

The proliferation of the malignant clonal plasma cells leads to subsequent replacement of normal bone marrow hematopoietic precursors and overproduction of M-proteins. Characteristic hallmarks of multiple myeloma include osteolytic lesions, anemia, increased susceptibility to infections, hypercalcemia, renal insufficiency or failure, and neurological complications (Palumbo 2011).

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

Multiple myeloma is characterized by osteolytic lesions, usually in the pelvis, spine, ribs, and skull. Lesions are  caused  by  expanding  plasmacytomas  or  by  cytokines  secreted  by  myeloma  cells  that  activate osteoclasts  and  suppress  osteoblasts.  Increased  bone  loss  may  also  lead  to  hypercalcemia.  Solitary extraosseous plasmacytomas are unusual but may occur in any tissue, especially in the upper respiratory tract. In many patients, renal failure is present at diagnosis or develops during the course of the disorder and is caused by the deposition of light chains in the distal tubules or by hypercalcemia. Patients also often develop anemia due to kidney disease or suppression of erythropoiesis by cancer cells, but sometimes also due to iron deficiency. These signs and symptoms are commonly denoted as CRAB.

The prognosis of patients with multiple myeloma who become refractory to lenalidomide and a PI is poor, indicating the need for new, convenient therapeutic strategies for these patients.

## 2.1.5. Management

Different classes of drugs are approved for multiple myeloma (alkylators, steroids, proteasome inhibitors [PIs],  immunomodulatory  agents  [IMiDs],  histone  deacetylase  inhibitors  [HDACIs]  and  monoclonal antibodies).  Among  these  treatment  options,  lenalidomide  (an  IMiD)  and  bortezomib  (a  PI)  have  a prominent  role.  Both  are  approved  and  used  as  frontline  treatment  of  multiple  myeloma  and  used  in combination with other drugs at relapse. Lenalidomide is also approved as maintenance therapy after ASCT in patients with NDMM. Patients who have been treated with lenalidomide and a PI are a challenge to treat as they have already been exposed to 2 major drug classes. Patients who relapse during ongoing treatment or  within  60  days  of  last  dose  of  lenalidomide  are  per  IMWG  definition  'lenalidomide  refractory'  and represent an additional challenge for choosing an effective subsequent treatment choice.

Patients with exposure to lenalidomide and a PI as well as patients refractory to lenalidomide have a high unmet medical need, and new effective and convenient treatment options are needed (Moreau 2019).

## 2.1.6. About the product

Daratumumab  is  a  human,  CD38targeted,  IgG1κ  monoclonal  antibody  approved  as  monotherapy in subjects with relapsed and refractory multiple myeloma and in combination with standard of care regimens for transplant-ineligible and transplant-eligible newly diagnosed multiple myeloma and relapsed/refractory

<div style=\"page-break-after: always\"></div>

multiple myeloma. The addition of daratumumab to standard of care regimens in Phase 3 studies has consistently  improved  PFS,  resulting  in  a  benefit  that  is  both  significant  and  clinically  meaningful.  The addition  of  daratumumab  also  induced  higher  rates  of  deep  responses,  including  increases  in  MRDnegativity  rates  compared  with  standard  of  care  alone.  Daratumumab  in  combination  with  the  IMiD lenalidomide and dexamethasone (D-Rd) resulted in a significant PFS benefit versus Rd alone in patients with relapsed/refractory multiple myeloma with at least 1 prior line of therapy (Dimopoulos 2016).

Recently, the daratumumab SC formulation has been approved in the European Union and United States. The SC administration of daratumumab provides a convenient treatment option for patients with a reduced incidence  of  IRRs,  decreased  administration  burden  to  both  patients  and  healthcare  professionals,  and reduced in-hospital time.

## 2.1.7. The development programme/compliance with CHMP guidance/scientific advice

No CHMP advice was sought for study MMY3013.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which is considered acceptable.

## 2.2.1. Ecotoxicity/environmental risk assessment

Daratumumab is a monoclonal antibody and is consequently classified as a protein. According to the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00), amino acids, peptides and proteins are exempted because they are unlikely to result in significant risk to the environment. Consequently, no Environmental Risk Assessment for daratumumab is required.

## 2.3. Clinical aspects

## 2.3.1. Introduction

The pharmacology package contains data from two combination studies (a Phase 3 Study 54767414MMY3013 and a Phase 1b Study 54767414MMY1001) that evaluated the use of DPd in subjects with relapsed or refractory MM (RRMM) (see Table 1).

In addition, PK data from a phase 1b study (study MMY1001) is used as supporting data. MMY1001 is a multicohort study and the PK data come from the cohort of subjects who received daratumumab IV in combination with Pd (n=103).

In addition to these two studies, PK data are derived from a popPK analysis (described below).

The current work focuses on the characterization of the pharmacokinetics (PK) and exposure-response (ER) relationships of daratumumab SC or intravenous (IV) in subjects with relapsed or refractory multiple myeloma  (RRMM)  in  combination  with  pomalidomide  and  dexamethasone  (DPd),  a  new  combination therapy being developed for daratumumab SC.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

<div style=\"page-break-after: always\"></div>

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

Table 1 Overview of studies and data included in the PPK and E-R analysis

| Study No.                                                                           | Study Title and Design                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Brief Description of PK and Efficacy/Safety                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MMY3013 ongoing PK cut-off date: 06 April 2020 Clinical cut- off date: 21 July 2020 | A randomized, open-label, Phase 3 study comparing pomalidomide and dexamethasone (Pd) with or without daratumumab in subjects with relapsed or refractory MM who have received at least 1 prior line of therapy withbothlenalidomideandaPI                                                                                                                                                                                                                                                                                                    | Data 304 randomized subjects; DPd: 151, Pd: 153 PK: Subjects on daratumumab SC only C1D1+4,C3D1+4,C5-7-12D1 Subjects switched from daratumumab IV to daratumumabSC SC predose first 3 cycles (starting with Cycle 3 or later)+2 FU (possible each cycle D1 after C3) Subjects on daratumumabIV only C1D1 predose, C1D1 E0I, C3D1, C7D1, 4and8weeks afterlastdose Efficacy: Primary endpoint:Progression free survival Secondary endpoints include overall response rate Response or disease progression are derived basedonavalidated computer algorithm at Day 1 of each cycle Safety: Safety is a secondary endpoint. Monitoring for |
| MMY1001 (DPd cohort) completed                                                      | Daratumumab (DPd subjects): Doses: daratumumab SC 1800 mg or 16 mg/kg IV. Dose schedule: QW for 8 weeks (Cycles 1 and 2), then Q2W for an additional 16 weeks (Cycles 3 to 6), and then Q4W thereafter (Cycle 7 and beyond). A cycle is 4 weeks Pomalidomide (all subjects): Doses andDoseschedule:4mgPOonDays1-21of each 28-day cycle Dexamethasone (all subjects): Doses: 40 mg (20 mg for subjects ≥75 years of age) PO Dose schedule: Once daily on Days 1, 8, 15, and 22 of each 28-day cycle.Split IV/PO when together with daratumumab | TEAEs takes place continuously throughout the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                     | An open-label, multicenter, Phase 1b study of daratumumabin combination with backbone regimens for the treatment of subjects with MM in either newly diagnosed subjects or those who had received prior therapies, depending in the background treatment regimen Daratumumab: Doses: 16 mg/kg. Dose schedule: 16 mg/kg IV QW for 8 weeks (Cycles 1 and 2), then Q2Wfor an additional16weeks(Cycles3to6),and then Q4W thereafter (Cycle 7 and beyond). A cycle is 4 weeks Pomalidomide: Doses and Dose schedule: 4 mg PO once daily on Days    | 103 subjects receiving DPd PK: C1-4D1, C1D22 predose+EOI+2 FU (week 3+9) Efficacy: Secondary endpoints include overall response rate Safety: Safety is a primary endpoint. Monitoring for TEAEs takes place continuously throughout the study Note that this study was pooled with                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Study No.   | Study Title and Design                                                                    | Brief Description of PK and Efficacy/Safety Data   |
|-------------|-------------------------------------------------------------------------------------------|----------------------------------------------------|
|             | OncedailyonDays1,8,15,and22ofeach28-day cycle. Split IV/PO when together with daratumumab |                                                    |

Abbreviations: C=cycle;D=day;DPd=daratumumabSCor IVincombinationwithpomalidomideand dexamethasone;ECOG=Eastem Cooperative Oncology Group;EOI=end-of-infusion;E-R=exposure-response; FU=follow up; IV=intravenous; MM=multiple myeloma; Pd=pomalidomide-dexamethasone; PI=proteasome inhibitor; PK=pharmacokinetic(s); PO=per oral; PPK=population pharmacokinetic;QW=once weekly; Q2W=every2weeks;Q4W=every4weeks;SC=subcutaneous;TEAE=treatment-emergentadverseevent.

PK-evaluablepopulationdefinedassubjectswhoreceivedatleast1doseofdaratumumabandhadatleast1serum daratumumab concentration value after the first dosing.

SubjectswhostartedtreatmentwithdaratumumabIVandswitchedtodaratumumabSConDay1ofanycycle startingwithCycle3orlater.

Source:IVMMMod5.3.5.4/MMY1001rrmm;Mod5.3.5.1/MMY3013

## 2.3.2. Pharmacokinetics

## Bioanalysis

Validated  electro-chemiluminescent  immunoassay  (ECLIA)-based  methods  were  used  to  determine daratumumab concentrations and anti-daratumumab antibodies in human serum samples. A new enhanced drug tolerant PandA ECLIA method was used for the detection of anti-daratumumab antibodies in human serum in Study MMY3013. Daratumumab SC is a co-formulation of daratumumab and rHuPH20. A validated ECLIA  method  was  used  for  assessment  of  anti-rHuPH20  antibodies  in  human  plasma  after  SC administration. A validated in vitro hyaluronidase activity assay with a chromogenic readout was used to test for neutralising capacity.

The cut-off date for pharmacokinetic and immunogenicity data was 06. Apr 2020 (MMY3013).

## Population PK analyses

A previously developed (Xu, X et al, 2017 assessed in variations II/29, II/30) population pharmacokinetic (PPK)  model  was  used  to  characterize  the  PK  of  daratumumab  following  SC  or  IV  administration  in combination with dexamethasone and pomalidomide in subjects with RRMM. The PPK analysis was based on 1,146 daratumumab PK samples (473 SC samples and 673 IV samples) from 239 PK-evaluable subjects of Phase 3 Study MMY3013 (N=140) and the DPd cohort of Phase 1b Study MMY1001 (N=99). All subjects from  Study  MMY1001  received  daratumumab  IV  16  mg/kg.  In  Study  MMY3013,  95%  of  PK-evaluable subjects (133/140) received daratumumab  SC  1800  mg  Seven  PK-evaluable subjects received daratumumab IV 16 mg/kg (4 subjects started daratumumab IV 16 mg/kg and switched to SC 1800 mg; 3 subjects received IV 16 mg/kg only). The proportion of PK data below the limit of quantification of 0.2 μg/mL was 1.5% (27/1743) and excluded from the PPK analysis. Two serum daratumumab concentrations were regarded as data outliers and excluded.

The average baseline characteristics of subjects included in the PPK analysis were high age (median 66 years),  normal  body  weight  (median  76  kg),  White  race  (84.1%),  normal  renal  function  or  mild  renal impairment (73.6%) and normal hepatic function (84.9%). Note that 4 subjects had body weights &lt;50 kg and  3  subjects  had  body  weights  ≥120  kg.  Disease  characteristics  included  low  Eastern  Cooperative Oncology Group (ECOG) status (0 and 1: 92.9%), high number of prior therapies (2 and 3: 62.3%), IgG myeloma  (55.2%),  refractory  to  both  immunomodulatory  imide  drug  (IMiD)  and  PI  (64.9%)  and  low International Staging System (ISS) (1: 27.6%). Covariate distributions were in general similar between the 2 studies. Some differences between studies were apparent for ECOG status (lower in MMY3013), and number of prior therapies (higher in MMY1001).

The  previous  IV/SC  2-compartment  PPK  model  with  parallel  linear  and  Michaelis-Menten  nonlinear elimination pathways was used to fit the serum concentration-time data of daratumumab using the firstorder conditional estimation with the interaction method in NONMEM. PsN Version 3.4.2 or higher was used to execute NONMEM (Nonlinear Mixed Effects Modelling) analyses. Absorption was parameterised in terms

<div style=\"page-break-after: always\"></div>

of  bioavailability  and  first-order  absorption  rate  for  SC  administration.  The  linear  CL  represents  the nonspecific CL for IgG and the Michaelis-Menten elimination represents the saturable target-mediated CL. Because of the treatment effect of daratumumab, the total target (CD38) number may decrease over time.

This was investigated using the empirical function:

TDVM represents the time-dependent maximum capacity of the saturable CL and KDES represents firstorder rate constant, describing the decrease of the maximum velocity of the saturable CL process over time (t). An additive model was used to model residual variability.

The covariates (body weight, albumin concentration, type of myeloma [IgG versus non-IgG], and sex) that were previously identified were also found to be statistically significant in the PPK model (ie, the 95% CI of the estimated covariate effect did not include the value corresponding to no effect).

The final model was evaluated by means of parameter estimates (Table 5), goodness-of-fit diagnostic plots and visual predictive checks (data not shown).

<div style=\"page-break-after: always\"></div>

Table 2 Parameter Estimates of the PPK Model of DaratumumabBased on Combined Daratumumab SC and Daratumumab IV Data Following DPd Combination Therapy

| Parameter, unit   | Description                                                                                 | Estimate    | I0 %56              | RSE on Estimate (%)   | IIV (%CV)   | RSE on IIV (%)   |
|-------------------|---------------------------------------------------------------------------------------------|-------------|---------------------|-----------------------|-------------|------------------|
| CL (L/h)          | Linear clearance                                                                            | 0.00432     | (0.00351;0.00513)   | 9.51                  | 43.5        | 8.65             |
| ALB on CL         | Effect of senum albumin concentration on linear clearance                                   | -0.665      | (-1.13;-0.199)      | 35.8                  |             |                  |
| WT on CLa         | Effect of body weight on linear clearance                                                   | 0.832       | (0.483;1.18)        | 21.4                  |             |                  |
| TPMC on CL        | Effect of type of myeloma (IgG versus non-IgG) on linear clearance                          | 0.833       | (0.517;1.15)        | 19.3                  |             |                  |
| Vi (L)            | Volume of distribution in the central compartment                                           | 4.36        | (3.86;4.86)         | 5.87                  | 28.0        | 10.8             |
| WT on Vb          | Effect of body weight on volume of distribution in the central compartment                  | 0.562       | (0.25;0.874)        | 28.3                  |             |                  |
| SEX on Vb         | Effect of sex (female versus male) on volume of distribution in the central compartment     | -0.168      | (-0.28;-0.0563)     | 33.9                  |             |                  |
| V2 (L)            | Volume of distribution in the peripheral compartment                                        | 2.80        | (2.00;3.60)         | 14.6                  |             |                  |
| Q (L/h)           | Intercompartmental clearance                                                                | 0.00814     | (0.00483;0.0115)    | 20.8                  |             |                  |
| Vmx (mg/h)        | Maximum velocity of the saturable clearance process                                         | 1.47        | (1.09;1.85)         | 13.1                  | 59.6        | 13.4             |
| KDes (1/h)        | First-orderrate fordecreaseof maximum velocity of the saturable clearance process over time | 0.000282    | (0.000154;0.000410) | 23.2                  | 75.3        | 20.2             |
| Km (μg/mL)        | Michaelis-Menten constant                                                                   | 3.81        | (1.20;6.42)         | 34.9                  |             |                  |
| Ka (1/h)          | First-order absorption rate                                                                 | 0.0120      | (0.00967;0.0143)    | 9.9                   | 55.4        | 12.2             |
| F1                | Bioavailability                                                                             | 0.689 (FIX) |                     |                       |             |                  |
|                   | ADD ERR (%CV) Additive error term on the log-scale                                          | 27.7        | (26.7;28.7)         | 1.8                   |             |                  |

Abbreviations: CI=confidence interval; CV=coefficient of variation; DPd=daratumumab SC or IV in combination with pomalidomide and dexamethasone; FIX=not estimated; IgG=immunoglobulin G; IIV=interindividual variability; IV=intravenous; PK=pharmacokinetic(s); PPK=population pharmacokinetic; RSE=relative standard error; SC=subcutaneous; TV=typical values; TVCL=typical value of clearance; TVV=typical value of volume of distribution.

0.832 -0.665 TVCL=0.00432 ALB · TPMCcL where TPMCcL is a shift factor of 1 for non-IgG multiple 38 myeloma subjects and 1+ 0.833 for IgG multiple myeloma subjects.

0.562 b TVV1 = 4.36 · SEXy1, where SEXy1 is a shift factor of 1 for male and 1-0.168 for female.

Note: Objective fumction value=-780.8. Condition number=41.7. RSE% for IIV and ADD ERR are reported on the approximate standard deviation scale (standard error/variance estimate)/2.

CV% for IV and ADD ERR are computed as sqrt(o2) and sqrt (o2), respectively.

95% CIs are calculated based on standard error from covariance matrix assuming PK parameters are normally distributed.

## PK simulations and subgroup analyses

Simulations were performed to graphically show the simulated daratumumab serum concentrations versus time and their 90% variability after SC 1800 mg and IV dosing 16 mg/kg and for sub-group analysis. Subgroup analysis of Ctrough,C3D1 showed that body weight, albumin concentration, and type of myeloma (IgG versus non-IgG) had an impact of &lt;20% on Ctrough,C3D1.(data not shown).

<div style=\"page-break-after: always\"></div>

In addition, target saturation versus time and its variability was simulated and plotted according to: TSAT = 100×(Conc×(Km+Conc)), where TSAT is the saturation ratio, Conc is the simulated daratumumab serum concentration and Km is the estimated Michaelis-Menten constant in the final PK model. Target saturation versus time was simulated based on the estimated Km of 3.81 µg/mL (95% CI 1.2-6.42) in the final Pop PK model.

Figure 1 Simulated Target Saturation Over Time After Daratumumab SC 1800 mg or Daratumumab IV 16 mg/kg After Daratumumab SC 1800 mg or Daratumumab IV 16 mg/kg Administration per the Recommended Dose Schedule for DPd Combination Therapy

<!-- image -->

Abbreviations: DPd=daratumumab SC or IV in combination with pomalidomide and dexamethasone; IV=intravenous; SC=subcutaneous.

Note: The pharmacokinetics simulation was performed with N=133 subjects for SC from MMY3013 and N=106 subjects for IV (99 from MMY1001 and 7 from MMY3013).

## Absorption and bioavailability

In the phase 3 study MMY3013, a total of 140 subjects were included for the assessment of Cmax and Ctrough  of  daratumumab  as  the  PK-evaluable  population,  ie,  subjects  who  received  at  least  1  dose  of daratumumab and had at least 1 serum daratumumab concentration value after the first dose (SC or IV). Most subjects (133/140, 95%) received daratumumab SC starting from the first dose; 3 subjects received daratumumab IV only and 4 subjects received daratumumab IV initially and then switched to daratumumab SC.

Cmax of daratumumab SC 1800 mg dosed in combination with Pd was consistent with historical data following daratumumab SC 1800 mg monotherapy or in other combinations at the same dose schedule. Following  the  first  SC  dose  of  1800  mg  daratumumab,  the  mean±standard  deviation  (SD)  maximum concentration (Cycle 1 Day 4) was 138±71.2 μg/mL ( Figure 2). The accumulation ratio in mean peak Cmax from the first dose (Cycle 1 Day 4; 138±71.2 μg/mL) to the ninth dose (Cycle 3 Day 4; 625±286 μg/mL) was approximately 4.5-fold.

<div style=\"page-break-after: always\"></div>

Figure 2: Box Plot of serum daratumumab Ctrough and Cmax concentrations (μg/mL) over time; PK Analysis Set (54767414MMY3013)

<!-- image -->

C=Cycle; Cmax=peak serum concentration; Ctrough=trough concentration; D=Day; DPd=daratumumab SC or IV in combination with pomalidomide and dexamethasone; FU=follow-up; IQR=interquartile range; IV=intravenous; PK=pharmacokinetic(s); Q=quartile; SC=subcutaneous.

Note: Ctrough was defined as the observed pre-dose concentration immediately before daratumumab administration; Cmax was defined as concentrations observed at the end-of-infusion for IV treatment or on Day 4 for SC administration.

The boxplot displays a box with the 3 lines representing Q1, median (Q2), and Q3, respectively, upper whisker of Q3+1.5*IQR, and lower whisker of Q1-1.5*IQR. Outlier values beyond the whiskers are displayed as circles. The diamond inside the box represents the arithmetic mean.

DPd-IV includes subjects with daratumumab IV only and also the IV administrations of subjects who were randomized to DPd group and administrated with daratumumab IV (prior to Amendment 1) and then switched to daratumumab SC during the study.

DPd-SC after switch includes only the SC administrations of subjects who switched to daratumumab SC during the study (after Amendment 1).

The  absorption  of  the  SC  formulation  was  modeled  as  a  first-order  absorption  process.  In  the  popPK analysis, Cmax following the recommended dose schedule for DPd combination therapy was determined to be 697 μ g/mL.

In study MMY3013, trough serum concentrations increased to the maximum Ctrough on Cycle 3 Day 1 predose (537±277 μg/mL [mean±SD]).

Based  on  the  same  dosing  regimen  of  daratumumab  SC,  the  simulated  cycle  3  predose  Ctrough  of daratumumab SC as monotherapy or part of Dpd combination therapy is shown in Figure 3 below.

<div style=\"page-break-after: always\"></div>

Figure 3 . Simulated Daratumumab trough concentrations at cycle 3 day 1 after daratumumab SC 1800 mg administration for DPd combination therapy (MMY3013) and monotherapy (MMY3012) per the recommended dose schedule

<!-- image -->

Treatmentgroup

Abbreviations: C3D1=Cycle 3 Day 1; DPd=daratumumab SC or IV in combination with pomalidomide and dexamethasone; SC=subcutaneous.

A comparison of daratumumab exposure between SC DPd regimen and IV DPd regimen (most subjects from MMY1001) was made in the popPK analysis ( Figure 4 ). As shown, the SC exposure lies within the fluctuations of the IV exposure curve.

Figure 4 . Simulated Median PK Profile and 90% Prediction Interval of Daratumumab After Daratumumab SC 1800 mg or Daratumumab IV 16 mg/kg Administration per the Recommended Dose Schedule for DPd Combination Therapy

<!-- image -->

The estimated bioavailability for the SC formulation is approximately 0.69, which is consistent with other mAbs subcutaneously co-administered with rHuPH20.

<div style=\"page-break-after: always\"></div>

Peak concentrations after administration of the first SC dose (Cycle 1 Day 4) were in general comparable across monotherapy and combination therapies (ie, DPd and other combinations).

In  study  MMY3013,  peak  Cm ax  was  reached  on  cycle  3  day  4  and  averaged  625±286  μg/mL.  The accumulation ratio from the first dose was approximately 4.5-fold. The estimated bioavailability for the SC formulation is approximately 69%. Peak concentration after the first dose is in average reached on C1D4.

Median cycle 3 Ctrough (predose level) of the SC 1800 mg cohort was found to be a bit higher than in the IV 16 mg/kg cohort, although the information from the IV data is limited by the very small sample size.

## Distribution

From the popPK analysis, the volume of distribution of the central compartment was estimated to 4.36 L which is close to plasma volume.

## Elimination

Typical clearance profiles of daratumumab SC and IV in combination with Pd is shown in Figure 5 .

Figure 5: Simulated Typical Total and Linear Clearance Versus Time Profiles After Daratumumab SC 1800 mg or Daratumumab IV 16 mg/kg Administration pe r the Recommended Dose Schedule for DPd Combination Therapy

<!-- image -->

Abbreviations: DPd=daratumumab SC or IV in combination with pomalidomide and dexamethasone; IV=intravenous; SC=subcutaneous.

Key: Black arrows represent dose events.

The estimated linear CL of 0.00432 L/h [0.104 L/day] is close to the reported CL of nonspecific endogenous IgG.

The  model-derived  geometric  mean  (CV%)  half-life  associated  with  linear  elimination  was  19.7  days (15.3%),  comparable  to  the  estimated  half-life  derived  from  the  previous  monotherapy  of  20.4  days (22.4%).

<div style=\"page-break-after: always\"></div>

## Special populations

## Renal and hepatic impairment

No formal studies of daratumumab in subjects with renal or hepatic function have been conducted. The effect of renal or hepatic function on daratumumab PK for DPd has been evaluated by a popPK approach (pooled data from Studies MMY3013 and MMY1001, Figure 6), and no clinically relevant impact has been identified  for  subjects  with  mild  and  moderate  renal  or  hepatic  impairment.  As  regards  the  latter,  34 subjects had mild and only 2 subjects had moderate hepatic impairment. There were only N=3 subjects with severe renal impairment and N=0 with severe hepatic impairment so it was not possible to make any or meaningful conclusions for these subgroups. The results are consistent with the previous results from daratumumab SC monotherapy.

Figure 6. Forest Plot of Subgroup Analyses on Percent Change and 95% CI Relative to Reference Value for Simulated Trough Concentration at Cycle 3 Day 1 per the Recommended Dose Schedule for DPd Combination Therapy

<!-- image -->

%changerelativetoreference

CI=confidence interval; DPd=daratumumab SC or IV in combination with pomalidomide and dexamethasone; ECOG=Eastern Cooperative Oncology Group; IgG=immunoglobulin G; IMiD=immunomodulatory imide drug; IV=intravenous; PI=proteasome inhibitor; PK=pharmacokinetics; Q2W=every 2 weeks; Q4W=every 4 weeks; SC=subcutaneous.

Key: Solid blue point represents percentage change of geometric mean and short horizontal bar represents 95% CI. Dashed line represents reference value of 0. Numbers represent percentage of change and the associated CI. Note: Analyses assumed that all PKevaluable subjects in DPd groups of Studies MMY3013 and MMY1001 received 16 mg/kg weekly for 8 weeks (8 doses), Q2W for 16 weeks (8 doses), and then Q4W thereafter. The 4 subjects first administered daratumumab IV 16 mg/kg and then switched to SC 1800 mg were assumed to have received IV administration throughout. The number of subjects in the reference group for each covariate: route of administration IV (N=106 [99 from MMY1001 and 7 from MMY3013]), age &lt;65 years (N=109); male (N=131); White (N=201); body weight 65 to 85 kg (N=102); albumin concentration ≥38 g/L (N=111); normal hepatic function (N=203); normal renal functio n (N=82); PI/IMiD refractory status only PI or IMiD or none (N=84), number of prior lines of therapy 1 (N=18), ECOG=0 (N=113); nonIgG myeloma (N=71). IgG myeloma status of 36 subjects were missing and not present in the plot. Two subject had moderate hepatic impairment and were combined with subjects with mild hepatic impairment. Three subjects had severe renal impairment and were combined with subjects with moderate renal impairment. Subjects refractory to a certain regimen are considered refractory to all drugs in such regimen. Source: Mod5.3.3.5/PPK Report/Fig9

<div style=\"page-break-after: always\"></div>

## Gender

PopPK  simulations  (Figure  6),  based  on  post  hoc  PK  parameters,  demonstrated  that  the  simulated daratumumab Ctrough, C3D1 was 4% higher (95% CI: -7% to +16%) in females versus males.

## Weight

Body weight was a statistically significant covariate identified for CL and volume of distribution in the central compartment of daratumumab.

PopPK  simulations  (Figure  6),  based  on  post  hoc  PK  parameters,  demonstrated  that  simulated daratumumab Ctrough, C3D1 was similar in subjects with body weight &lt;65 kg versus subjects with body weight ≥65 kg to &lt;85 kg, while subjects with body weight ≥85 kg h ad 13% (95% CI: -24% to -2%) lower Ctrough, C3D1 exposure when compared with those with body weight ≥65 kg to &lt;85 kg. There was no notable impact of body weight on efficacy or safety during the E-R analyses.

## Age

Approximately 45.6% of the subjects in the PK analysis dataset were &lt;65 years (N=109/239), 41.0% between ≥65 and &lt;75 years (N=98/239), and 13.4% of subjects ≥75 years (N=32/239).

PopPK  simulations  (Figure  6),  based  on  post  hoc  PK  parameters,  demonstrated  that  simulated daratumumab Ctrough, C3D1 was approximately 4% higher (95% CI:8% to +17%) in subjects ≥65 and &lt;75 years and 16% higher (95% CI: 2% to +38%) in subjects ≥75 years, respectively, compared with subjects &lt;65 years.

## Drug-drug interaction studies

No  dedicated  drug-drug  interaction  studies  were  performed  for  daratumumab  SC.  Since  there  is  no overlapping  pathway  of  elimination,  no  interactions  are  expected  between  daratumumab  and  smallmolecule drugs including Pd.

Daratumumab SC PK data in DPd combination from study MMY3013 was assessed relative to daratumumab SC monotherapy (study MMY3012) and the exposures were comparable. The PK profiles of small-molecule combination  agents  including  pomalidomide  when  dosed  in  combination  with  daratumumab  IV  (study MMY1001) or without daratumumab (literature value) were found to be comparable. In addition, the PK of daratumumab dosed SC or IV in multiple combination therapy studies were similar to SC or IV monotherapy. These  data  indicate  a  lack  of  PK  interaction  between  daratumumab  and  the  small-molecule  medicinal products tested, including the DPd combination agents of pomalidomide and dexamethasone.

## Immunogenicity

## Anti-daratumumab Antibodies

In  the  anti-daratumumab  immunogenicity-evaluable  analysis  set,  the  cumulative  incidence  of  antidaratumumab antibodies was low in subjects who received daratumumab treatment in combination with Pd ( Table below ):

<div style=\"page-break-after: always\"></div>

Table 3 Anti-daratumumab Antibody Status; DaratumumabImmunogenicity-evaluable Analysis Set in Subjects Revived DPd Treatment (MIMY3013, MIMY100l)

|                                                                                  |                  | DPd-IV then SC   | DPd-IV   | DPd-IV    | DPd-IV    |
|----------------------------------------------------------------------------------|------------------|------------------|----------|-----------|-----------|
|                                                                                  | DPd-SC (MMY3013) | (MMY3013)        | MMY3013  | MMY1001   | Total IV  |
| Analysis set: daratumumab immunogenicity-evaluable for subjects with appropriate | 119              | 4                | 0        | 45        | 45        |
| Subjects positive for anti- daratumumab antibodiesb,c                            | 2 (1.7%)         | 0                | 0        | 0         | 0         |
| Subjects positive for neutralizing antibodiesd                                   | 2 (1.7%)         | 0                | 0        | 0         | 0         |
| Subjects negative for anti- daratumumab antibodiesb                              | 117 (98.3%)      | 4 (100%)         | 0        | 45 (100%) | 45 (100%) |

DPd=daratumumab in combination with pomalidomide and dexamethasone; IV=intravenous; SC=subcutaneous.

: Subjects who received at least 1 dose of daratumumab SC or daratumumab IV and had appropriate serum samples for detection of antibodies to daratumumab (at least 1 sample after the start of the first dose of daratumumab)

Includes all subjects who had at least 1 positive sample at any time after start of treatment, including those who did by at least 2-fold compared with baseline.

b Percentages are calculated with the number of subjects with appropriate sample as the denominators.

d Only samples positive for anti-daratumumab antibodies from anti-daratumumab positive subjects were assayed for neutralizing antibodies

Source: IV MM Study MMY1001 CSR; Mod5.3.5.1/MMY3013/Tab12

## Anti-rHuPH20 Antibodies

In  study  MMY3013,  six  (6/122,  4.9%)  subjects  had  baseline  positive  anti-rHuPH20  samples,  and  the incidence of treatment-emergent anti-rHuPH20 antibodies was 7.4% (9/122) after the first daratumumab SC administration, all non-neutralizing. Daratumumab exposure was comparable between subjects with treatment emergent anti-rHuPH20 antibodies and those who were negative for anti-rHuPH20 antibodies.

These data were consistent with the historical daratumumab SC findings in subjects with MM.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to the CD38 protein expressed at a high level on the surface of multiple myeloma tumour cells, as well as other cell types and tissues at various levels. Daratumumab has been shown to potently inhibit the in vivo growth of CD38-expressing tumour  cells.  Daratumumab  can  induce  tumour  cell  lysis  through  complement-dependent  cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis in malignancies expressing CD38. A subset of myeloid derived suppressor cells (CD38+MDSCs), regulatory T cells (CD38+Tregs) and B cells (CD38+Bregs) are decreased by daratumumab mediated cell lysis.

Translational biomarker studies of samples from subjects treated with daratumumab in Phase 1 and Phase 2 studies have revealed previously unknown immunomodulatory effects of daratumumab (Krejcik 2016). Daratumumab leads to the rapid and sustained elimination of highly immunosuppressive subsets of CD38+ regulatory T cells, CD38+ myeloid-derived suppressor cells, and CD38+ regulatory B cells (Krejcik 2016). The elimination of these immunosuppressive cells, modulation of CD38 enzymatic activity, and destruction of the malignant myeloma cells are followed by the increase in T cell clonality (Chiu 2016) and subsequent expansion of CD8+ and CD4+ subsets (Krejcik 2016). In particular, patients responding to daratumumab

<div style=\"page-break-after: always\"></div>

treatment showed an increase in the activated CD8+ T cells expressing high levels of granzyme B (Adams 2019). Together, daratumumab's cytotoxic and immunomodulatory mechanisms of action are hypothesized to synergistically result in deep anti-myeloma responses.

## Primary pharmacology

As described in the MMY3013 CSR, addition of daratumumab SC to the treatment regimen resulted in a decrease in the NK cell and CD38+ regulatory T cell populations in the blood ( Figure 8 below).

Figure 7

T14.02-11.16F: Plot of Percent CD38+Regulatory T-cells(%Lymphocytes) in Blood over Time;Biomarker Analysis Set (Study 54767414MMY3013)

<!-- image -->

Key:Pd =pomalidomide -dexamethasone;DPd =daratumumab -pomalidomide -dexamethasone.

The boxplot displays a box with the 3 lines representing Q1, Median (Q2) and Q3 respectively, upper whisker of Q3 + 1.5*IQR (interquartile range) and lower whisker of Q1 - 1.5*IQR.

Outlier values beyond the whiskers are displayed as circles. The diamond inside the box represents the arithmetic mean.

Note: The outlier values above 2.5% were not included in this graph

Filename: T14.02-11.16F.RTF / Program: T14.02-11.Plot.sas (050CT2020 20:58)

<div style=\"page-break-after: always\"></div>

Figure 8

Tl4.02-11.06F:Plotof Percent NaturalKillerCells(%Lymphocytes)inBloodoverTime;Biomarkel AnalysisSet (Study54767414MMY3013)

<!-- image -->

Key:Pd=pomalidomide-dexamethasone;DPd=daratumumab-pomalidomide-dexamethasone.

The boxplot displays a box with the 3 lines representing Q1, Median (Q2) and Q3 respectively, upper whisker of Q3 + 1.5*IQR (interquartile range) and lower whisker of Q1 -1.5*IQR. Outlier values beyond the whiskers are displayed as circles.The diamond inside the box represents the arithmetic mean. Filename: T14.02-11.06F.RTF /Program: T14.02-11.Plot.sas (050CT2020 20:58)

## Exploratory exposure-response analyses

The purpose of the Exposure response (E-R) analysis was to supplement the evidence of efficacy and safety of daratumumab in combination with Pd in subjects with RRMM and to confirm the selected dosing regimen.

The final E-R dataset, used for both efficacy and safety E-R analyses, contained data from 290 subjects in Study MMY3013 who had received at least 1 dose of Pd (N=150) or DPd (N=140). For the DPd group, only subjects with at least 1 evaluable PK concentration were included in the final E-R dataset to be able to derive individual exposure. Subjects randomized but not receiving a dose (N=3 for Pd group, N=2 for DPd group) were not included. All other subjects were pooled in the E-R analysis.

Table 4 Quantiles of the PK Exposure Metrics Used in the E-R Analysis

| Quantile   |   Cpeak first (μg/mL) |   Ctrough.first (μug/mL) |   Cpeak.max (μg/mL) |   Ctrough.max (μg/mL) |
|------------|-----------------------|--------------------------|---------------------|-----------------------|
| 0%         |                   6.5 |                      0.4 |                 125 |                  14.8 |
| 25%        |                 121   |                    109   |                 491 |                 398   |
| 50%        |                 151   |                    135   |                 651 |                 544   |
| 75%        |                 185   |                    161   |                 839 |                 722   |
| 100%       |                 374   |                    238   |                1440 |                1261   |

Abbreviations: Cpeak first=predicted peak concentration after first dose; Ctrugh,fistpredicted trough concentration after concentration; E-R=exposure-response; PK=pharmacokinetic(s).

<div style=\"page-break-after: always\"></div>

## Efficacy exposure-response analysis

Three  PK  exposure  metrics  derived  by  Pop  PK  were  used  for  the  efficacy  E-R  analysis:  Cpeak,first, Ctrough,first, and Ctrough,max. Covariates used in the case matching analysis were selected from a set of predefined covariates based on a Cox proportional hazard model.

Table 5

## Final CovariateModel forPFS (MMY3013Pd Subjects)

Abbreviations: CI=confidence interval; ISS=International Staging System; Pd=pomalidomide-dexamethasone; PFS=progression-free survival; vs=versus.

| Covariate                              |   Hazard Ratio Estimate |   Lower Limit of 95%CI |   Upper Limit of 95%CI |   p-value |
|----------------------------------------|-------------------------|------------------------|------------------------|-----------|
| ISS (≥2 vs 1)                          |                    1.73 |                   1.16 |                   2.58 |     0.007 |
| High cytogenetic risk (no vs yes)      |                    0.61 |                   0.39 |                   0.96 |     0.031 |
| Refractory to Lenalidomide (yes vs no) |                    1.75 |                   1    |                   3.05 |     0.049 |
| Race (Non-White vs White)              |                    2.13 |                   1.17 |                   3.87 |     0.013 |

The relationship between exposure and the primary efficacy endpoint PFS was investigated (Figure 9). The ORR by exposure was also compared (Figure 8). The relationship between drug exposure and PFS was analysed graphically using Kaplan-Meier plots.

Figure 9: Overall Responder Rate by Daratumumab Exposure Subgroups for DPd Combination Therapy

<!-- image -->

Abbreviations: CI=confidence interval; Cpeak,firt=predicted peak concentration after first dose; Ctough,first=predicted trough concentration after first dose; Ctoughmax=predicted overall maximum trough concentration; DPd=daratumumab SC or IV in combination with pomalidomide and dexamethasone; ORR=overallresponse rate; Pd=pomalidomide-dexamethasone; Q1=first quartile, Q2=second quartile, Q3=third quartile, Q4=fourth quartile of daratumumab exposure.

Key: The dashed red line represents the lowest exposure in the DPd group.

Estimated responder rates and 95% CIs are reported for the Pd group at concentration=0 ug/mL and for each of the daratumumab DPd exposure quartiles at the median exposure of the quartile

The quartiles for Cpeak,first were: first quartile (≤121 μg/mL). Q2 (&gt;121 to ≤151 μg/mL). Q3 (&gt;151 to ≤185 μg/mL), and Q4 (&gt;185 to ≤374 μg/mL). The quartiles for Ctough,first were: first quartile (≤109 μg/mL). Q2 (&gt;109 to ≤135 μg/mL), Q3 (&gt;135 to ≤161 μg/mL). and Q4 (&gt;161 to ≤239 μg/mL). The quartiles for Ctough,max were: first (/1971077&lt;) 0 e (z70 9&lt;) 0 (T/ 0 86&lt;) 0 ( 86&gt;) b

The same trend of lower efficacy in the lowest exposure quartile is seen for PFS (Figure below):

<div style=\"page-break-after: always\"></div>

Figure 10 Kaplan-MeierCurvesofProgression-freeSurvivalbyDaratumumabExposure SubgroupsinCombinationWithPdinStudyMMY3013

<!-- image -->

Abbreviations:DPd=daratumumabSCorIVincombinationwithpomalidomideand dexamethasone;Pd=pomalidomide-dexamethasone;Q1=firstquartile， Q2=second quartile,Q3=thirdquartile，Q4=fourthquartileof daratumumabexposure.

The quartiles for Coeakficst Were: Q1 (≤121 μg/mL), Q2 (&gt;121 to ≤151 μg/mL), Q3 (&gt;151 to ≤185μg/mL),and Q4(&gt;185 to≤374μg/mL).The quartiles for Ctcauabficstwere:Q1(≤109 μg/mL),Q2(&gt;109 to≤135μg/mL),Q3(&gt;135to≤161 μg/mL), and Q4(&gt;161to≤239 μg/mL).The quartiles for Ctowabmaxwere:Q1(≤398μg/mL),Q2(&gt;398to≤544μg/mL), Q3 (&gt;544 to ≤722 μg/mL), and Q4 (&gt;722 to ≤1,261 μg/mL).

Note:First troughistrough concentrationafter thefirstadministration;first peak ispeak concentrationafter thefirstadministration;maximumtroughistheoverallmaximum troughconcentration.

## Safety exposure-response analysis

Two PK exposure metrics were used for the safety E-R analysis: Cpeak,first for IRRs and Cpeak,max for all other TEAEs. The E-R relationship for selected TEAEs of clinical interest considered the safety endpoints: IRRs, neutropenia, anemia, thrombocytopenia, and infections. The TEAEs were stratified by the appropriate exposure  metrics  to  evaluate  whether  there  was  a  relationship  between  the  TEAEs  and  exposure  to daratumumab. The results were compared with those obtained from the DPd cohort of Study MMY1001.

There was no apparent increase in TEAEs rates with increasing exposure (Cpeak,first or Cpeak,max) for IRRs, thrombocytopenia, anemia, neutropenia, and infections (all Grades and Grades ≥3) within the studied drug concentration range in Study MMY3013 (Table 6). A decreasing trend in the event rate of neutropenia, anemia, and trombocytopenia was observed based on Cpeak,max (ie, a higher rate of TEAEs was observed in the lowest Cpeak,max at Q1). This is likely because subjects with TEAEs tended to have dose interruption or  delays,  which  led  to  lower  concentrations  in  these  subjects.  No  increase  in  the  rates  of  the  TEAEs investigated in this E-R analysis had been observed in the clinical statistical analysis with decreasing body weights subgroup, except for anemia. The increased anemia rate with low body weight was not related to an increase in exposure, as in the E-R analysis increased exposure led to lower anemia rates.

<div style=\"page-break-after: always\"></div>

Table 6: Comparison of Treatment-emergent Adverse Event Rates Across Predicted Daratumumab Exposure Subgroups for DPd Combination Therapy in Study MMY3013

|                  | Pd % (95% CI)    | DPd Exposure Quartiles, % (95% CI)   | DPd Exposure Quartiles, % (95% CI)   | DPd Exposure Quartiles, % (95% CI)   | DPd Exposure Quartiles, % (95% CI)   |
|------------------|------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
| TEAE             | N=150            | Q1 N=35                              | Q2 N=35                              | Q3 N=35                              | Q4 N=35                              |
| Neutropenia      | 53.3 (45.3;61.2) |                                      |                                      |                                      |                                      |
| Grade ≥3         | 50.7 (42.7;58.6) |                                      | 74.3 (58.4;86.7)74.3 (58.4;86.7)     | 71.4 (55.3;84.5)71.4 (55.3:84.5)     |                                      |
| Infections       | 55.3 (47.3;63.1) | 74.3 (58.4;86.7)                     | 74.3 (58.4;86.7)                     | 71.4 (55.3;84.5)                     | 71.4 (55.3:84.5)                     |
| Grade ≥3         | 23.3 (17.1;30.5) | 42.9 (27.4;59.3)                     | 31.4 (17.7;47.7)                     | 25.7 (13.3;41.6)                     | 20.0 (9.1;35.1)                      |
| Anemia           | 44.7 (36.9;52.7) | 48.6 (32.6;64.8)                     | 42.9 (27.4;59.3)                     | 28.6 (15.5;44.7)                     | 25.7 (13.3;41.6)                     |
| Grade ≥3         | 21.3 (15.3:28.3) | 34.3 (20.1;50.7)                     | 17.1 (7.2:31.7)                      | 5.7 (1.0:16.6)                       | 8.6 (2.2;20.7)                       |
| Thrombocytopenia | 33.3 (26.1;41.1) | 42.9 (27.4;59.3)                     | 37.1 (22.5;53.6)                     | 22.9 (11.2;38.4)                     | 20.0 (9.1;35.1)                      |
| Grade ≥3         | 18.0 (12.4;24.7) | 31.4 (17.7;47.7)                     | 25.7 (13.3;41.6)                     | 5.7 (1.0;16.6)                       | 8.6 (2.2;20.7)                       |
| IRRs             | 0 (0:0)          | 8.6 (2.2;20.7)                       | 5.7 (1.0;16.6)                       | 2.9 (0.2;12.0)                       | 5.7 (1.0;16.6)                       |
| Grade ≥3         | 0 (0:0)          | 0 (0:0)                              | 0 (0:0)                              | 0 (0:0)                              | 0 (0:0)                              |

Abbreviations: CI=confidence interval; Cpeak.frst=predicted peak concentration after first dose; Cpeak,maxpredicted maximum peak concentration; DPd=daratumumab SC or IV in combination with pomalidomide and dexamethasone; IRRs=infusion-related reactions; N=maximum number of subjects with data; Pd=pomalidomideexposure::TEAE=treatment-emergent adverse event.

- Key: Cpeak.max was used as the exposure measure for analyses on all adverse events except IRRs, where Cpeak.fist was used.
- The quartiles for Cpeakmax were: Q1 (≤491 μg/mL). Q2 (&gt;491 to ≤651 μg/mL). Q3 (&gt;651 to ≤839 μg/mL), and Q4 (&gt;839 to ≤1,440 μg/mL). The quartiles for Cpeak,first were: Q1 (≤121 μg/mL). Q2 (&gt;121 to ≤151 μg/mL), Q3 (&gt;151 to ≤185 μg/mL), and Q4 (&gt;185 to ≤374 μg/mL).

The absence of apparent increase in selected TEAEs rates and increasing daratumumab exposure was in line with results from the DPd cohort of Study MMY1001.

## 2.3.4. PK/PD modelling

See above.

## 2.3.5. Discussion on clinical pharmacology

The purpose of the presented PK package is to support a new indication for SC daratumumab: combination treatment with daratumumab SC, pomalidomide, and dexamethasone (DPd) for the treatment of patients with multiple myeloma (MM) who have received at least 1 prior line of therapy. The pharmacology package contains data from two combination studies; a phase 3 Study 54767414MMY3013 and a phase 1b Study 54767414MMY1001) that evaluated the use of DPd in subjects with relapsed or refractory MM (RRMM). In addition,  popPK  analyses  have  been  performed.  The  analytical  methods  were  assessed  in  previous procedures. The combination with small molecules pomalidomide and dexamethasone is not thought to interfere  with  assay  performance  or  target.  Interim  reports  for  sample  analysis  conducted  in  study MMY1001 and MMY3013 were provided

The  effect  of  daratumumab  is  known  from  both  an  IV  formulation  and  an  SC  formulation  used  as monotherapy or in combination with other anticancer medicines.

Since an identical daratumumab SC product is already marketed and in clinical use, the primary purpose of the presented PK package is to a) evaluate the exposure of daratumumab SC in combination with Pd compared  to  daratumumab  SC  monotherapy,  b)  evaluate  efficacy  and  safety  exposure-response relationships of the SC DPd regimen, and c) assess the applicability of a fixed dose of daratumumab in combination with Pd for the treatment of patients with MM.

<div style=\"page-break-after: always\"></div>

In the popPK analysis, the final parameters were estimated with reasonable precision. The variability was large on the parameters describing the non-linear elimination and Ka. Effects of weight on clearance and volume in central compartment were estimated to 0.832 and 0.562 respectively. Subgroup analysis of Ctrough,C3D1 showed that body weight, albumin concentration, and type of myeloma (IgG versus non-IgG) had an impact of &lt;20% on Ctrough,C3D1.

The subcutaneous DPd regimen resulted in similar plasma concentrations as observed with subcutaneous daratumumab monotherapy, indicating a lack of interactions between daratumumab and pomalidomide or dexamethasone. No dedicated drug-drug interaction studies were performed, this is acceptable.

From the popPK analysis, the volume of distribution of the central compartment was estimated to 4.36 L which is close to plasma volume and similar to other mAbs. No study on protein binding has been conducted which is acceptable.

The primary elimination pathways for daratumumab are clearance by the reticulo-endothelial system (in the same way as that for an endogenous IgG) and target-mediated elimination. Cytochrome P450 enzymes, efflux pumps, and protein-binding mechanisms are not involved in the clearance. Therefore, the potential risk of PK interactions between daratumumab and other drugs is low.

As  regards  special  populations,  no  clinically  relevant  impact  of  sex,  age,  or  weight  on  the  PK  of daratumumab has been reported. Mild to moderate renal and hepatic impairment do not seem to affect the PK of SC daratumumab.

The incidence of treatment emergent anti-daratumumab antibodies (1.6%) and anti-rHuPH20 antibodies (approximately 8%) is similar to previous reports, indicating a low risk of immunogenicity of daratumumab when combined with pomalidomide and dexamethasone in subjects with MM.

Evaluation of efficacy exposure-response relationship indicated a similar effect in the three upper (Q2-Q4) exposure quartiles and a lower effect for the Q1 subgroup on both PFS and ORR. The safety exposureresponse  relationship  showed  no  apparent  increase  in  TEAEs  rate  with  increasing  daratumumab  SC exposure, indicating that the obtained exposure levels overall do not exceed the tolerability threshold. These exposure-response results, together with the daratumumab plasma concentration obtained, similar to daratumumab SC monotherapy, indicate that the fixed 1800 mg dose in combination with pomalidomide and dexamethasone is applicable and reasonable.

## 2.3.6. Conclusions on clinical pharmacology

The clinical pharmacology program consists of one pivotal and one supportive study as well as pop PK analyses. Based on the comprehensive existing knowledge of daratumumab, the pharmacology package is considered  adequate to  support  the  application  of  an  extension  of  indication  and  the  proposed  dosing regimen of subcutaneous daratumumab in combination with pomalidomide and dexamethasone for the treatment of MM.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

The present application concerns a fixed dose of daratumumab SC, which has previously been established: The  effect  of  daratumumab  is  known  from  both  an  IV  formulation  and  an  SC  formulation  used  as monotherapy or in combination with other anticancer medicines.  See also section  2.1.1. regarding the approved indications and section 2.3.1.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study

## Title of Study

A Phase 3 Study Comparing Pomalidomide and Dexamethasone with or without Daratumumab in Subjects with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor: The APOLLO Study

See Figure 11 for an overview of the study.

Figure 11: Schematic Overview of Study MMY3013

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Methods

## Study participants

Main Inclusion criteria:

1. Males and females at least 18 years of age.
2. Voluntary written informed consent before performance of any study-related procedure.
3. Subject must have measurable disease of MM as defined by the criteria below:
- IgG multiple myeloma: Serum Mprotein level ≥1.0 g/dL or urine M -protein level  ≥200 mg/24 hours, or
- IgA, IgD, IgE, IgM multiple myeloma: Serum M-protein level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or
- Light  chain  multiple  myeloma,  for  subjects  without  measurable  disease  in  the  serum  or  urine: Serum immunoglobulin FLC ≥ 10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.

4. Subjects must have received prior anti-myeloma treatment. The prior treatment must have included both a PI- and lenalidomide-containing regimens. The subject must have had a response (ie, PR or better based on the investigator's determination of response as defined by the modified IMWG criteria) to prior therapy.

5. Subjects must have documented evidence of PD based on the investigator's determination of response as defined by the modified IMWG criteria on or after the last regimen.

6. Subjects who received only 1 line of prior treatment must have demonstrated PD on or within 60 days of completion of the lenalidomide-containing regimen (ie, lenalidomide refractory).

7. Eastern Coopera tive Oncology Group (ECOG) performance status score of ≤2.

8. For subjects experiencing toxicities resulting from previous therapy, the toxicities must be resolved or stabilized to ≤Grade 1.

9. All of the following laboratory test results during Screening:

- a) Absolute neutrophil count ≥1.0 × 10 9 /L;
- b) Hemoglobin level ≥7.5 g/dL (≥4.65 mmol/L) (transfusions are not permitted to reach this level);
- c) Platelet count ≥75 × 10 9 /L in subjects in whom &lt;50% of bone marrow nucleated cells are plasma cells and platelet count ≥50 x 10 9 /L in subjects in whom ≥50% of bone marrow nucleated cells are plasma cells (transfusions are not permitted to reach this level);
- d) Alanine aminotransferase (ALT) level ≤2.5 times the upper lim it of normal (ULN);
- e) Aspartate aminotransferase (AST) level ≤2.5 x ULN;
- f) Total bilirubin level ≤1.5 x ULN, (except for Gilbert Syndrome: direct bilirubin ≤1.5 × ULN);
- g) Creatinine clearance ≥30 mL/min (Appendix 6);
- h) Serum calcium corrected for albumin ≤14.0 mg/dL (≤3.5 mmol/L), or free ionized calcium ≤6.5 mg/dL (≤1.6 mmol/L).

## Main Exclusion criteria:

1. Previous therapy with any anti-CD38 monoclonal antibody.
2. Previous exposure to pomalidomide.

3. Subject has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the date of randomization. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 mg/day for a maximum of 4 days) for palliative treatment before Cycle 1, Day 1 (C1D1).

4. Previous allogenic stem cell transplant; or autologous stem cell transplantation (ASCT) within 12 weeks before C1D1.

<div style=\"page-break-after: always\"></div>

5. History of malignancy (other than MM) within 3 years before the date of randomization (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other noninvasive lesion that in the opinion of the investigator, with concurrence with the Sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years).
6. Clinical signs of meningeal involvement of MM.
7. Chronic obstructive pulmonary disease (COPD) with a Forced Expiratory Volume in 1 second (FEV1) &lt;50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 &lt;50% of predicted normal. (Appendix 4).
8. Clinically significant cardiac disease, including:
- a) Myocardial  infarction  within  6  months  before  C1D1,  or  unstable  or  uncontrolled  condition  (eg, unstable angina, congestive heart failure, New York Heart Association Class III-IV).
- b) Cardiac arrhythmia (Common Terminology Criteria for Adverse Events [CTCAE] Grade 3 or higher) or clinically significant electrocardiogram (ECG) abnormalities.
- c) Electrocardiogram showing a baseline QT interval as corrected QTc &gt;470 msec.
8. 9 . Ongoing ≥Grade 2 peripheral neuropathy.
9. 10 . Subject had ≥Grade 3 rash during prior therapy.

## Treatments

Subjects randomized to the DPd group received daratumumab (1800 mg Dara SC or 16 mg/kg Dara IV [prior to Amendment 1]) at weekly intervals for 8 weeks, then every 2 weeks for 16 weeks (Cycles 3-6), then every 4 weeks (from Cycle 7 and beyond). Subjects in both treatment arms received pomalidomide at a dose of 4 mg PO on Days 1 through 21 of each 28-day cycle, and dexamethasone at a total dose of 40 mg PO once a week (20 mg for subjects ≥ 75 years).

Figure 12: Dosing and Administration in Study MMY3013

<!-- image -->

1. On days when daratumumab is administered, dexamethasone will be administered to subjects in DPd arm in the clinicand will serve as the treatment dose of steroid as well as the required pre-medication prior to daratumumab infusion. Note 20 mg PQ weekly for subjects ≥75 years of age.

Subjects were to continue to receive study treatment until disease progression or unacceptable toxicity.

Dose delay was permitted and was the primary method for managing daratumumab-related toxicities as described in detail in the protocol . Subjects received pre- and post-dose medications to prevent IRRs and, if applicable, respiratory complications.

According to the study protocol treatment would have been withhold if any of the following criteria were met, to allow for recovery from toxicity, regardless of relationship to study drug:

- Grade 4 haematologic toxicity, except for Grade 4 lymphopenia

<div style=\"page-break-after: always\"></div>

- Grade 3 or higher thrombocytopenia
- Febrile neutropenia
- Neutropenia with infection, of any grade
- Grade 3 or higher non-haematologic toxicities with the following exceptions:
- o Grade 3 nausea that responds to antiemetic treatment within 7 days
- o Grade 3 vomiting that responds to antiemetic treatment within 7 days
- o Grade 3 diarrhea that responds to antidiarrheal treatment within 7 days
- o Grade  3  fatigue  that  was  present  at  baseline  or  that  lasts  for  &lt;7  days  after  the  last administration of daratumumab
- o Grade  3  asthenia  that  was  present  at  baseline  or  that  lasts  for  &lt;7  days  after  the  last administration of daratumumab

Study treatment would be resumed when the toxicity had resolved to ≤Grade 2. If study drug administration did not commence within the prespecified window of the scheduled administration date, then the dose would be considered a missed dose. Administration could be resumed at the next planned dosing date. A missed dose would not be made up.

## Objectives

The purpose of this study was to evaluate the effects of the addition of daratumumab to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.

## Outcomes/endpoints

The primary objective of this study was to compare PFS between treatment arms:

The time, in months, from the date of randomization to the date of the first documented disease progression (based on a validated computer algorithm using modified IMWG criteria [Durie 2006, Rajkumar 2011]) or death due to any cause, whichever comes first

Key secondary efficacy objectives were:

- To compare ORR between treatment arms: The proportion of randomized subjects who achieve a best response of PR or better (ie, sCR, CR, VGPR, or PR) based on a validated computer algorithm using the modified IMWG criteria
- To compare OS between treatment arms: The time, in months, from the date of randomization to the date of death from any cause
- To assess the depth of response by analyzing MRD negativity rate for confirmed or suspected CR or better: The proportion of subjects who have negative MRD at any timepoint after the date of randomization (threshold value of 10 -5 )

The primary analysis of efficacy variables associated with response/progression will be performed using response or disease progression as derived from a validated computer algorithm according to the modified IMWG criteria.

## Sample size

Approximately 302 subjects (151 per arm) were planned to be randomized in this study. The sample size calculation was based on the primary endpoint PFS, at a one-sided significance level of 0.025, assuming exponential survival distribution with a HR of 0.621 (DPd versus Pd). A total of 280 evaluable subjects (140 per arm) was required to observe 188 events to test the hypothesis with 90% power. The sample size calculation has taken into consideration 7% rate for permanent early censoring before the study cut-off,

<div style=\"page-break-after: always\"></div>

and 1 interim analysis to assess superiority potentially at an early timepoint (ie, approximately 113 [60% of total planned events] PFS events observed).

Long-term survival follow-up is to continue until 166 deaths have been observed or 5 years after the last subject was randomized, whichever comes first. The study was planned to achieve approximately 70% power to detect a 34% reduction in the risk of death (HR=0.66; DPd versus Pd) with a log-rank test (onesided alpha=0.025).

The sample size has taken into consideration one interim analysis to assess superiority potentially at an early timepoint (i.e. approximately 113 (60% of total planned events) PFS events observed).

## Randomisation

Subjects were assigned randomly in a 1:1 ratio to receive either DPd or Pd via the IWRS provider using a validated system. Randomization was stratified by the number of lines of prior therapy (1, 23, ≥4) and ISS stage (1, 2, 3).

## Blinding (masking)

Study MMY3013 was an open-label study.

## Statistical methods

## Primary endpoint PFS

The primary analysis was based on a stratified log-rank test for the comparison of the PFS distribution between the 2 treatment arms. The Kaplan-Meier method was used to estimate the distribution of overall PFS for each treatment. The treatment effect (hazard ratio) and its two-sided 95% CIs were estimated using a stratified Cox regression model with treatment as an explanatory variable, stratified by ISS staging (1, 2, 3), and number of lines of prior therapy (1, 23, ≥4).

Table 7: PFS Event and Censoring Method

| Situation                                                                            | Date of Progression or Censoring                                                       | Outcome   |
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-----------|
| Disease progression                                                                  | Earliest date that indicates disease progression                                       | PFS event |
| Death                                                                                | Date of death                                                                          | PFS event |
| No post-baseline disease assessment Randomization                                    |                                                                                        | Censored  |
| Other (e.g., withdrawal of consent to start of subsequent antimyeloma therapy, etc.) | study participation, lost to follow-up, Date of last disease assessment prior to Other | Censored  |

Sensitivity analyses for PFS

- PFS based on investigator assessment of disease progression.
- Censored for death/PD after missing more than one disease evaluations.
- Censored for death due to COVID-19 without PD

## Secondary endpoints: Response rate (ORR, VGPR or better, CR or better)

The overall  response  rate,  along  with  its  exact  two-sided  95%  CI  (obtained from  the  Clopper-Pearson method), would be computed within each treatment group. Overall response rate would be compared between  treatment  groups  using  a  stratified  Cochran-Mantel-Haenszel  (CMH)  chi-squared  test.  The

<div style=\"page-break-after: always\"></div>

stratification factor is that used in the randomization, i.e., number of lines of prior therapy (1, 2-3 , ≥4) and ISS stage (1, 2, 3). The CMH estimate of odds ratio and its two-sided 95% CI for the difference in overall response rates between treatment groups will be reported.

For the response rates, subjects discontinuing before reaching a response would be considered as nonresponders.

A sensitivity analysis of ORR would be performed based on the investigator assessment of response.

A supplementary analysis of ORR would be conducted by excluding those subjects who already began treatment with Dara IV prior to Amendment 1 on the ITT Set.

## Secondary endpoint: Minimal Residual Disease Negativity Rate

The MRD negativity rate would be calculated for each treatment group based. The corresponding 95% exact CI  would  be  provided.  For  each  threshold  value,  Fisher's  exact  test  would  be  used  to  test  if  the  MRD negativity rate is the same between the two treatment groups. For the purpose of hierarchical testing, the threshold value of 10 -5  will be employed.

MRD positive subjects include subjects of which all tested samples were found to be MRD positive, or ambiguous, or subjects who were not tested.

As  sensitive  analyses,  the  MRD  negativity  and  CR  or  better  rate  based  on  ITT  population  would  be calculated.

## Secondary endpoint: OS

OS in months will be analyzed similarly to PFS.

For subject who withdraw consent from study, if death information is recorded in the clinical database, the death reported after withdrawal will be considered as OS event. Subjects who have not died at the cut-off date for the final analysis will be censored at the last known alive date. The date of last known alive will be determined by the maximum collection/assessment date within the clinical database.

A sensitivity analysis of OS will be conducted using an unstratified Cox proportional hazard model with treatment arm as single factor. OS will be compared between treatment groups using the log rank test (unstratified).

## Interim analyses and multiplicity issues

An interim analysis was planned when approximately 113 PFS events occurred (60% of the total planned events). Efficacy testing boundaries of PFS at interim analysis and primary analysis were determined using the pre-specified alpha-spending function described by Lan and DeMets which approximated the boundaries of O'Brien and Fleming.  For OS, a modified linear alpha spending function will be used, i.e., the alpha to be spent on the interim efficacy analysis (113 PFS event, which is 60% of the total planned PFS events) is 0.0001 (1-sided), a total alpha of 0.0001 (1-sided) will be spent. The major secondary hypotheses are to be tested at the nominal 0.025 (1-sided) significance level by utilizing a sequential, hierarchical testing approach  as  proposed  by  Tang  and  Geller  (1999)  that  strongly  controls  Type  I  error  rate.  The  major secondary endpoints are ordered as follows:

- 1) ORR
- 2) Rate of VGPR or better
- 3) Rate of CR or better
- 4) MRD negativity rate
- 5) Overall survival

If the testing of the primary endpoint of PFS is statistically significant, these major secondary endpoints ordered above will be sequentially tested, each with an overall one-sided alpha of 0.025. The significance level at the interim analysis will be determined by the alpha-spending function specific to that endpoint.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Table 8: Subje ct Disposition by Study Phase; Intent -To-Treat Analysis Set (Study 54767414MMY3013)

|                                     | Pd n (%)    | DPd n (%)   | Total n (%)   |
|-------------------------------------|-------------|-------------|---------------|
| Analysis set: intent-to-treat       | 153         | 151         | 304           |
| Subjects randomized but not treated | 3 (1.96)    | 2 (1.32)    | 5 (1.64)      |
| Subjects treated                    | 150 (98.04) | 149 (98.68) | 299 (98.36)   |
| Treatment dispositiona              |             |             |               |
| Subject status                      |             |             |               |
| Ongoing                             | 33 (22.00)  | 60 (40.27)  | 93 (31.10)    |
| Discontinued                        | 117 (78.00) | 89 (59.73)  | 206 (68.90)   |
| Reason for discontinuation          |             |             |               |
| Adverse Event                       | 4 (2.67)    | 3 (2.01)    | 7 (2.34)      |
| Death                               | 7 (4.67)    | 10 (6.71)   | 17 (5.69)     |
| Lost to Follow-Up                   | 0           | 1 (0.67)    | 1 (0.33)      |
| Physician Decision                  | 7 (4.67)    | 4 (2.68)    | 11 (3.68)     |
| Progressive Disease                 | 87 (58.00)  | 66 (44.30)  | 153 (51.17)   |
| Non-compliance with study drugb     | 12 (8.00)   | 5 (3.36)    | 17 (5.69)     |

Key: Pd = pomalidomide - dexamethasone; DPd = daratumumab - pomalidomide - dexamethasone.

Percentages are computed on subjects in the intent-to-treat analysis set.

a. Numbers and percentages are based on the subjects treated.

b. Based on the reason 'Subject refused further study treatment' recorded on the End of Treatment case report form.

Source: Modified from Attachment T14.01-01.03.

Analysis Dataset Variables included ADSL: ITTFL, SAFFL, TRTO1PN; ADDS: AVALC, PARAMCD

## Recruitment

Study Initiation Date:

14 June 2017

Data cut off:

21 July 2020. The study is ongoing.

Study Centers: Greece (5), Turkey (7), Italy (6), Spain (7), France (6), Belgium (4), Germany (5),

Netherlands (3), Czech Republic (2), Serbia (1), Denmark (1), Poland (1)

## Conduct of the study

## Amendments:

There were 2 global amendments to the protocol. Details of each amendment are included in the summary of changes (Appendix 1). The rationale for each amendment is summarized below:

<div style=\"page-break-after: always\"></div>

Table 9: Summary of Protocol Amendments for 54767414MMY3013

| Amendment 1 (13 0ct 2017)   | To  expand  the study design toi include the SC administrationof daratumumab Other changes including updateto IMWG criteria definition of progressive disease                                                                                                                                                                                                                    |
|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 2 (03 Apr 2018)   | Toupdate the Pomalidomide Risk Evaluation Mitigation Strategy or Global Pregnancy 1PreventionPlan based on recommendations from a health authority To update exclusion criteria with regards to hepatitis and HIV testing, hypersensitivity, and prior vaccinations based on recommendations from a health authority Other changes to provide clarification through the protocol |

In addition, 2 country-specific protocol amendments were adopted:

- Germany: amended to include baseline hepatitis C and HIV testing
- France: amended to include HBV testing at 6 months after the last dose of daratumumab for subjects who are being monitored for HBV reactivation, and serology hepatitis B testing for subjects with unknown HBV status receiving daratumumab on the study (DPd arm) or within 6 months after the last dose of daratumumab.

## Protocol deviations:

Table 10 : Summary of Subjects with Major Protocol Deviations; Intent -To-Treat Analysis Set (Study 54767414MMY3013)

|                                                         | pd n (%)   | DPd n (%)   | Total n (%)   |
|---------------------------------------------------------|------------|-------------|---------------|
| Analysis set: intent-to-treat                           | 153        | 151         | 304           |
| Total number of subjects with major protocol deviations | 2 (1.31)   | 7 (4.64)    | 9 (2.96)      |
| Type of major protocol deviations                       |            |             |               |
| Entered but did not satisfy criteria                    | 2 (1.31)   | 2 (1.32)    | 4 (1.32)      |
| Received wrong treatment or incorrect dose              | 0          | 5 (3.31)    | 5 (1.64)      |
| COVID-19 related                                        | 0          | 0           | 0             |
| Developed withdrawal criteria but not withdrawn         | 0          | 0           | 0             |
| Received a disallowed concomitant treatment             | 0          | 0           | 0             |
| Other                                                   | 0          | 0           | 0             |

Keys: Pd = pomalidomide - dexamethasone; DPd = daratumumab - pomalidomide - dexamethasone.

Percentages are computed on subjects in the intent-to-treat analysis set.

Each subject could have more than one protocol deviation; subjects are counted only once in each row.

Filename: T14.01-01.05.RTF / Pr0gram: T14.01-01.05.sas (05OCT2020 20:41)

Analysis Dataset Variables included ADSL: ITTFL, TRTO1PN; DV: DVDECOD

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 11 : Demography and Baseline Characteristics; Intent -To-Treat Analysis Set (Study 54767414MMY3013)

|                                         | pd           | DPd          | Total        |
|-----------------------------------------|--------------|--------------|--------------|
| Analysis set: intent-to-treat           | 153          | 151          | 304          |
| Age (years)                             |              |              |              |
| n                                       | 153          | 151          | 304          |
| Mean (SD)                               | 66.5 (9.70)  | 65.4 (9.57)  | 66.0 (9.63)  |
| Median                                  | 68.0         | 67.0         | 67.0         |
| Range                                   | 35; 90       | 42: 86       | 35; 90       |
| Age class, n (%)                        |              |              |              |
| 1n                                      | 153          | 151          | 304          |
| <65 years                               | 60 (39.22)   | 63 (41.72)   | 123 (40.46)  |
| 65 - <75 years                          | 62 (40.52)   | 63 (41.72)   | 125 (41.12)  |
| ≥75 years                               | 31 (20.26)   | 25 (16.56)   | 56 (18.42)   |
| Gender, n (%)                           |              |              |              |
| n                                       | 153          | 151          | 304          |
| Male                                    | 82 (53.59)   | 79 (52.32)   | 161 (52.96)  |
| Female                                  | 71 (46.41)   | 72 (47.68)   | 143 (47.04)  |
| Race, n (%)                             |              |              |              |
| n                                       | 153          | 151          | 304          |
| White                                   | 137 (89.54)  | 135 (89.40)  | 272 (89.47)  |
| Black or African American               | 0            | 1 (0.66)     | 1 (0.33)     |
| Asian                                   | 1 (0.65)     | 1 (0.66)     | 2 (0.66)     |
| Other                                   | 1 (0.65)     | 0            | 1 (0.33)     |
| Unknown                                 | 14 (9.15)    | 14 (9.27)    | 28 (9.21)    |
| Ethnicity, n (%)                        |              |              |              |
| n                                       | 153          | 151          | 304          |
| Hispanic or Latino                      | 4 (2.61)     | 4 (2.65)     | 8 (2.63)     |
| Not Hispanic or Latino                  | 138 (90.20)  | 134 (88.74)  | 272 (89.47)  |
| Unknown                                 | 2 (1.31)     | 4 (2.65)     | 6 (1.97)     |
| Not Reported                            | 9 (5.88)     | 9 (5.96)     | 18 (5.92)    |
| Baseline ECOG performance status, n (%) |              |              |              |
| n                                       | 153          | 151          | 304          |
| 0                                       | 77 (50.33)   | 91 (60.26)   | 168 (55.26)  |
| 1                                       | 57 (37.25)   | 54 (35.76)   | 111 (36.51)  |
| 2                                       | 19 (12.42)   | 6 (3.97)     | 25 (8.22)    |
| Height (cm)                             |              |              |              |
| n                                       | 153          | 151          | 304          |
| Mean (SD)                               | 166.4 (9.49) | 166.8 (9.93) | 166.6 (9.70) |
| Median                                  | 168.0        | 165.5        | 167.0        |
| Range                                   | 142; 189     | 144; 192     | 142; 192     |
| Weight (kg)                             |              |              |              |
| n                                       | 153          | 151          | 304          |
| Mean (SD)                               | 75.5 (15.06) | 75.1 (14.62) | 75.3 (14.82) |
| Median                                  | 74.2         | 74.0         | 74.1         |
| Range                                   | 44; 142      | 49; 111      | 44; 142      |
| Weight class, n (%)                     |              |              |              |
| n                                       | 153          | 151          | 304          |
| <65 kg                                  | 30 (19.61)   | 45 (29.80)   | 75 (24.67)   |
| 65 -<85 kg                              | 89 (58.17)   | 69 (45.70)   | 158 (51.97)  |

<div style=\"page-break-after: always\"></div>

|             | Pd            | DPd           | Total         |
|-------------|---------------|---------------|---------------|
| ≥85 kg      | 34 (22.22)    | 37 (24.50)    | 71 (23.36)    |
| BMI (kg/m2) |               |               |               |
| n           | 153           | 151           | 304           |
| Mean (SD)   | 27.22 (4.589) | 26.90 (4.139) | 27.06 (4.367) |
| Median      | 26.45         | 26.06         | 26.20         |
| Range       | 18.1; 44.8    | 19.9; 37.1    | 18.1; 44.8    |

Key: Pd =pomalidomide -dexamethasone; DPd =daratumumab -pomalidomide- dexamethasone.

SD = Standard deviation.

Percentages are computed on subjects in the intent-to-treat analysis set with available data.

Subject's age is computed in years elapsed from the date of birth to the date of the informed consent signature.

Forsubjects whose ages were enteredby the investigator, their ages are used without any computation.

Filename: T14.01-03.01.RTF / Program: T14.01-03.01.sas (050CT2020 20:41)

Analysis Dataset Variables included ADSL:ITTFL, TRT01PN, AGE,AGEGR2, SEX, RACE,ETHNIC ECOGBL; ADVS:

ABLFL, AVAL, PARAMCD in (HEIGHT WEIGHT BMI)

<div style=\"page-break-after: always\"></div>

Table 12: Baseline Disease and Other Baseline Characteristics; Intent -To-Treat Analysis Set (Study 54767414MMY3013)

|                                                 | Pd           | DPd          | Total        |
|-------------------------------------------------|--------------|--------------|--------------|
| Analysis set: intent-to-treat                   | 153          | 151          | 304          |
| Type of myeloma by immumofixation, n (%)        |              |              |              |
|                                                 | 153          | 151          | 304          |
| IgG                                             | 87 (56.86)   | 83 (54.97)   | 170 (55.92)  |
| IgA                                             | 30 (19.61)   | 34 (22.52)   | 64 (21.05)   |
| IgM                                             | 1 (0.65)     | 0            | 1 (0.33)     |
| IgD                                             | 2 (1.31)     | 2 (1.32)     | 4 (1.32)     |
| Light chain                                     | 30 (19.61)   | 26 (17.22)   | 56 (18.42)   |
| Light chain - Kappa                             | 20 (13.07)   | 14 (9.27)    | 34 (11.18)   |
| Light chain - Lambda                            | 10 (6.54)    | 12 (7.95)    | 22 (7.24)    |
| Biclonal                                        | 0            | 2 (1.32)     | 2 (0.66)     |
| Negative immumofixation                         | 3 (1.96)     | 4 (2.65)     | 7 (2.30)     |
| Type of measurable disease\", n (%)              |              |              |              |
| n                                               | 153          | 151          | 304          |
| Serum only                                      | 83 (54.25)   | 87 (57.62)   | 170 (55.92)  |
| IgG                                             | 63 (41.18)   | 62 (41.06)   | 125 (41.12)  |
| IgA                                             | 20 (13.07)   | 24 (15.89)   | 44 (14.47)   |
| Otherb                                          | 0            | 1 (0.66)     | 1 (0.33)     |
| Urine only                                      | 17 (11.11)   | 17 (11.26)   | 34 (11.18)   |
| Senum and Urine                                 | 28 (18.30)   | 23 (15.23)   | 51 (16.78)   |
| Senum FLC only                                  | 25 (16.34)   | 24 (15.89)   | 49 (16.12)   |
| ISS staging at study entry. n (%)               |              |              |              |
|                                                 | 153          | 151          | 304          |
| 1                                               | 69 (45.10)   | 68 (45.03)   | 137 (45.07)  |
| 2                                               | 51 (33.33)   | 50 (33.11)   | 101 (33.22)  |
| 3                                               | 33 (21.57)   | 33 (21.85)   | 66 (21.71)   |
| Revised ISS staging. n (%)                      |              |              |              |
| n1                                              | 127          | 119          | 246          |
| 1                                               | 25 (19.69)   | 26 (21.85)   | 51 (20.73)   |
| 2                                               | 88 (69.29)   | 74 (62.18)   | 162 (65.85)  |
| 3                                               | 14 (11.02)   | 19 (15.97)   | 33 (13.41)   |
| Time from MM diagnosis to randomization (years) |              |              |              |
| n                                               | 153          | 151          | 304          |
| Mean (SD)                                       | 5.20 (3.546) | 5.19 (3.633) | 5.20 (3.584) |
| Median                                          | 4.48         | 4.39         | 4.41         |
| Range                                           | 0.6; 19.0    | 0.5; 20.0    | 0.5; 20.0    |
| Number of lytic bone lesions, n (%)             |              |              |              |
| n1                                              | 153          | 151          | 304          |
| None                                            | 38 (24.84)   | 33 (21.85)   | 71 (23.36)   |
| 1-3                                             | 25 (16.34)   | 24 (15.89)   | 49 (16.12)   |
| 4-10                                            | 28 (18.30)   | 44 (29.14)   | 72 (23.68)   |
| More than 10                                    | 62 (40.52)   | 50 (33.11)   | 112 (36.84)  |
| Presence of extramedullary (soft tissue)        |              |              |              |
| plasmacytomas at baseline, n (%)                |              |              |              |
| n                                               | 153          | 151          | 304          |
| No                                              | 145 (94.77)  | 136 (90.07)  | 281 (92.43)  |

<div style=\"page-break-after: always\"></div>

|                                                       | Pd          | DPd         | Total       |
|-------------------------------------------------------|-------------|-------------|-------------|
| Yes                                                   | 8 (5.23)    | 15 (9.93)   | 23 (7.57)   |
| Plasma cells, bone marrow biopsy, n (%)               |             |             |             |
|                                                       | 11          | 17          | 28          |
| <10%                                                  | 4 (36.36)   | 2 (11.76)   | 6 (21.43)   |
| 10% -30%                                              | 3 (27.27)   | 6 (35.29)   | 9 (32.14)   |
| >30%                                                  | 4 (36.36)   | 9 (52.94)   | 13 (46.43)  |
| Plasma cells, bone mairow aspirate, n (%)             |             |             |             |
| n                                                     | 149         | 147         | 296         |
| <10%                                                  | 33 (22.15)  | 35 (23.81)  | 68 (22.97)  |
| 10% -30%                                              | 59 (39.60)  | 54 (36.73)  | 113 (38.18) |
| >30%                                                  | 57 (38.26)  | 58 (39.46)  | 115 (38.85) |
| Plasma cells, bone marrow biopsy/aspirate, n (%)      |             |             |             |
|                                                       | 152         | 151         | 303         |
| <10%                                                  | 34 (22.37)  | 35 (23.18)  | 69 (22.77)  |
| 10%-30%                                               | 59 (38.82)  | 52 (34.44)  | 111 (36.63) |
| >30%                                                  | 59 (38.82)  | 64 (42.38)  | 123 (40.59) |
| Any cytogenetic abnormalities, n (%)                  |             |             |             |
|                                                       | 108         | 103         | 211         |
| Standard risk                                         | 73 (67.59)  | 64 (62.14)  | 137 (64.93) |
| High risk                                             | 35 (32.41)  | 39 (37.86)  | 74 (35.07)  |
| del17p                                                | 18 (16.67)  | 16 (15.53)  | 34 (16.11)  |
| t(4;14)                                               | 16 (14.81)  | 19 (18.45)  | 35 (16.59)  |
| t(14;16)                                              | 6 (5.56)    | 7 (6.80)    | 13 (6.16)   |
| Baseline renal function (Creatinine Clearance), n (%) |             |             |             |
|                                                       | 153         | 151         | 304         |
| ≤60 mL/min                                            | 47 (30.72)  | 40 (26.49)  | 87 (28.62)  |
| >60 mL/min                                            | 106 (69.28) | 111 (73.51) | 217 (71.38) |

Key: Pd = pomalidomide - dexamethasone; DPd = daratumumab - pomalidomide - dexamethasone.

Ig = Immunoglobulin; FLC = Free light chain; ISS = Intemational staging system; NE = Not evaluable; MM = Multiple Myeloma; SD = Standard deviation.

ISS staging at study entry is as recorded on the MM medical diagnosis/history case report form.

Percentages are computed on subjects in the intent-to-treat analysis set with available data.

a. Includes subjects without measurable disease in serum and urine.

b. Includes IgD, IgM, IgE and biclonal.

Each subject could have more than one cytogenetic abnormality but is only counted once for each abnormality.

Cytogenetic abnormalities are based on the FISH testing with a 50% cut-off for del17p and 30% for t(4;14) and t(14;16)

Filename: T14.01-03.03.RTF / Program: T14.01-03.03.sas (050CT2020 20:41) Analysis Dataset Variables included ADSL: ITTFL, TRT01PN; ADBL: AVALC, AVALCAT1, PARAMCD in (IMMFIX MEAS CANSTGRISS DIARND LESNUMEXPLCYT PLCEBMB PLCEBMA PLCEBMBACYTABNDEL17P13 T414 T14 16 CRCLBL)

Subjects received a median of 2 prior lines of therapy, with approximately 11% of subjects receiving 1 prior line of therapy (Table 13).

<div style=\"page-break-after: always\"></div>

Table 13 : Prior Therapies for Multiple Myeloma; Intent -To-Treat Analysis Set (Study 54767414MMY3013)

|                                                                       | Pd           | DPd          | Total        |
|-----------------------------------------------------------------------|--------------|--------------|--------------|
| Analysis set: intent-to-treat                                         | 153          | 151          | 304          |
| Number of subjects with any prior therapy for multiple myeloma, n (%) | 153 (100.00) | 151 (100.00) | 304 (100.00) |
| Prior systemic therapy                                                | 153 (100.00) | 151 (100.00) | 304 (100.00) |
| Prior autologous stem cell transplant (ASCT)                          | 81 (52.94)   | 90 (59.60)   | 171 (56.25)  |
| Prior radiotherapy                                                    | 35 (22.88)   | 36 (23.84)   | 71 (23.36)   |
| Prior cancer-related surgery                                          | 29 (18.95)   | 21 (13.91)   | 50 (16.45)   |
| Number of prior lines of therapy, n (%)                               |              |              |              |
| 1                                                                     | 18 (11.76)   | 16 (10.60)   | 34 (11.18)   |
| 2-3                                                                   | 113 (73.86)  | 114 (75.50)  | 227 (74.67)  |
| ≥4                                                                    | 22 (14.38)   | 21 (13.91)   | 43 (14.14)   |
| Number of prior lines of therapy                                      |              |              |              |
| n1                                                                    | 153          | 151          | 304          |
| Mean (SD)                                                             | 2.4 (0.91)   | 2.4 (0.94)   | 2.4 (0.92)   |
| Median                                                                | 2.0          | 2.0          | 2.0          |
| Range                                                                 | 1;5          | 1; 5         | 1; 5         |
| Number of subjects with any prior PI, n (%)                           | 153 (100.00) | 151 (100.00) | 304 (100.00) |
| Bortezomib                                                            | 146 (95.42)  | 145 (96.03)  | 291 (95.72)  |
| Carfilzomib                                                           | 47 (30.72)   | 36 (23.84)   | 83 (27.30)   |
| Ixazomib                                                              | 16 (10.46)   | 18 (11.92)   | 34 (11.18)   |
| Number of subjects with any prior IMiD, n (%)                         | 153 (100.00) | 151 (100.00) | 304 (100.00) |
| Lenalidomide                                                          | 153 (100.00) | 151 (100.00) | 304 (100.00) |
| Thalidomide                                                           | 46 (30.07)   | 43 (28.48)   | 89 (29.28)   |
| Number of subjects with any prior corticosteroids, n (%)              | 153 (100.00) | 151 (100.00) | 304 (100.00) |
| Dexamethasone                                                         | 152 (99.35)  | 150 (99.34)  | 302 (99.34)  |
| Prednisone                                                            | 45 (29.41)   | 26 (17.22)   | 71 (23.36)   |
| Prior alkylating agents, n (%)                                        | 139 (90.85)  | 135 (89.40)  | 274 (90.13)  |
| Prior anthracyclines, n (%)                                           | 38 (24.84)   | 40 (26.49)   | 78 (25.66)   |
| Prior PI+IMiD, n (%)                                                  | 153 (100.00) | 151 (100.00) | 304 (100.00) |
| Prior PI+IMiD+ALKY, n (%)                                             | 139 (90.85)  | 135 (89.40)  | 274 (90.13)  |
| Prior BORT+LEN, n (%)                                                 | 146 (95.42)  | 145 (96.03)  | 291 (95.72)  |
| Prior ELOT, n (%)                                                     | 6 (3.92)     | 8 (5.30)     | 14 (4.61)    |
| Prior PANO, n (%)                                                     | 5 (3.27)     | 4 (2.65)     | 9 (2.96)     |
| Prior BORT+LEN+CARF, n (%)                                            | 41 (26.80)   | 31 (20.53)   | 72 (23.68)   |
| Prior BORT+LEN+CARF+THAL, n (%)                                       | 17 (11.11)   | 15 (9.93)    | 32 (10.53)   |

Key:Pd=pomalidomide-dexamethasone;DPd=daratumumab-pomalidomide-dexamethasone

LEN = Lenalidomide; PANO = Panobinostat; PI =Proteasome inhibitor; SD = Standard deviation; THAL = Thalidomide.

ALKY = Alkylating agents; BORT = Bortezomib; CARF = Carfilzomib; ELOT=Elotuzumab; IMiD = Immunomodulatory agent;

Percentages are computed on subjects in the intent-to-treat analysis set.

Number of lines of prior therapy are recorded on the Prior systemic therapy case report fomm. Terms are coded using WHO dictionary, version Q1 2020.

Filename: T14.01-03.04.RTF / Program: T14.01-03.04.sas (230CT2020 9:38) Analysis Dataset Variables included ADSL: ITTFL, TRTO1PN; ADCM: CMCAT, CMDECOD; ADPR: PRCAT, PRDECOD; ADBL:AVAL,PARAMCD=PNLINE; ADCMD:AVALC,PARAMCDin(ALKY ANTHPIMIDPIMIDAL BORTLEN ELOT PANO BORTLENC BOLECATH)

## Numbers analysed

The primary analysis population was the ITT population, which included all randomized subjects.

<div style=\"page-break-after: always\"></div>

Table 14 : Analysis Sets; Intent -To-Treat Analysis Set (Study 54767414MMY3013)

|                                         | pd n (%)     | DPd n (%)    | Total n (%)   |
|-----------------------------------------|--------------|--------------|---------------|
| Analysis set: intent-to-treat           | 153          | 151          | 304           |
| Intent-to-treat analysis set            | 153 (100.00) | 151 (100.00) | 304 (100.00)  |
| Response-evaluable analysis set         | 142 (92.81)  | 145 (96.03)  | 287 (94.41)   |
| Safety analysis set                     | 150 (98.04)  | 149 (98.68)  | 299 (98.36)   |
| Pharmacokinetic analysis set            |              | 140 (92.72)  | 140 (46.05)   |
| Daratumumab immunogenicity analysis set |              | 123 (81.46)  | 123 (40.46)   |
| rHuPH20 immunogenicity analysis set     |              | 122 (80.79)  | 122 (40.13)   |
| Biomarker analysis set                  | 150 (98.04)  | 147 (97.35)  | 297 (97.70)   |

Keys: Pd = pomalidomide - dexamethasone; DPd = daratumumab - pomalidomide - dexamethasone.

Percentages are computed on subjects in the intent-to-treat analysis set.

The intent-to-treat analysis set comprises all subjects to whom study treatment has been assigned by randomization in the interactive web response system (IWRS).

The response-evaluable analysis set includes subjects who had a confirmed diagnosis of multiple myeloma and measurable disease at baseline or screening. In addition, subjects must have received at least one component of study treatment and have adequate post-baseline disease assessment prior to the start of subsequent therapy.

The safety analysis set consists of all subjects who received at least one administration of any study treatment (partial or complete). The pharmacokinetic analysis set consists of subjects who received at least one administration of daratumumab and had at least one pharmacokinetic sample concentration value after their first daratumumab administration.

The daratumumab immunogenicity analysis set consists of all subjects who received at least one dose of daratumumab IV (intravenous) or SC (subcutaneous)

and had at least one immunogenicity sample after the first dose of daratumumab for detection of anti-daratumumab antibodies.

The rHuPH20 immunogenicity analysis set consists of all subjects who received at least one dose of daratumumab SC and had at least one immunogenicity sample after the first dose of daratumumab SC for detection of anti-rHuPH20 antibodies.

The biomarker analysis set consists of all subjects from the intent-to-treat analysis set who had appropriate samples for biomarker evaluations.

The intent-to-treat analysis set, response-evaluable analysis set and biomarker analysis set are presented according to the randomized treatment groups.

The safety analysis set, pharmacokinetic analysis set, daratumumab immunogenicity analysis set and rHuPH20 immunogenicity analysis set are presented according to the actual treatment received.

Filename: T14.01-02.01.RTF / Pr0gram: T14.01-02.01.sas (05OCT2020 20:41 Analysis Dataset Variables included ADSL:ITTFL, RESEVFL, SAFFL, PKFL, IMDARAFL, IMRHUPFL, BMFL, TRTO1PN

## Outcomes and estimation

## Primary endpoint: PFS

At a median overall follow-up of 16.9 months (DPd: 17.5 months; Pd: 16.4 months), the addition of daratumumab SC to Pd resulted in a statistically significant and clinically meaningful improvement in PFS, with a 37% reduction in the risk of disease progression or death compared with Pd alone (HR=0.63; 95% CI: 0.47, 0.85; 2-sided p=0.0018; Table 15 and Figure 13).

The median PFS and 95% CI was 12.4 months (8.3, 19.3) for the DPd treatment group and 6.9 months (5.5, 9.3) for the Pd treatment group.

Most PFS events were attributed to disease progression (46.4% in the DPd group and 61.4% in the Pd group). Data from 44.4% of subjects in the DPd group and 30.7% of subjects in the Pd group were censored for the primary endpoint analysis. The majority of these subjects were censored due to clinical cut-off. No subjects were censored for death due to COVID-19 without disease progression.

<div style=\"page-break-after: always\"></div>

Table 15 : Summary of Progression-free Survival based on Computerized Algorithm; Intent-to-Treat Analysis Set (Study 54767414MMY3013)

|                                    | Pd                   | DPd                 |
|------------------------------------|----------------------|---------------------|
| Analysis set: intent-to-treat      | 153                  | 151                 |
| Progression-free survival (PFS)    |                      |                     |
| Number of events, n (%)            | 106 (69.28)          | 84 (55.63)          |
| Disease progression                | 94 (61.44)           | 70 (46.36)          |
| Death                              | 12 (7.84)            | 14 (9.27)           |
| Number of censored, n (%)          | 47 (30.72)           | 67 (44.37)          |
| Kaplan-Meier estimates (months)    |                      |                     |
| 25% quantile (95% CI)              | 2.92 (2.20, 3.98)    | 4.63 (3.22, 6.34)   |
| Median (95% CI)                    | 6.93 (5.52, 9.26)    | 12.42 (8.34, 19.32) |
| 75% quantile (95% CI)              | 19.12 (13.14, 26.68) | NE (NE, NE)         |
| p-value (two-sided)                |                      | 0.0018              |
| Hazard ratio (DPd vs. Pd) (95% CI) |                      | 0.63 (0.47, 0.85)   |
| 6-month PFS rate (%) (95% CI)      | 56.7 (48.1, 64.3)    | 69.9 (61.8, 76.7)   |
| 12-month PFS rate (%) (95% CI)     | 34.6 (26.7, 42.5)    | 51.7 (43.3, 59.5)   |
| 18-month PFS rate (%) (95% CI)     | 25.5 (18.2, 33.4)    | 42.1 (33.6, 50.2)   |

Key: Pd = pomalidomide - dexamethasone; DPd = daratumumab - pomalidomide - dexamethasone.

CI = Confidence Interval; PFS = Progression-free survival.

Percentages are computed on subjects in the intent-to-treat analysis set.

P-value is obtained from the two-sided log-rank test stratified with ISS (1, 2, 3), and number of lines of prior therapy (1, 23,≥4).

Hazard ratio and 95% CI are obtained from a Cox proportional hazards model with treatment as an explanatory variable in the model, stratified with ISS (1, 2, 3), and number of lines of prior therapy (1, 2-3, ≥ 4). A hazard ratio &lt; 1 favors DPd.

Filename: T14.02-01.01.01.RTF / Program: T14.02-PFS.sas (05OCT2020 20:43) Analysis Dataset Variables included ADTTE: ITTFL TRT01PN, STRAT1N, STRAT2N, AVAL, CNSR, PARAMCD=PFS

<div style=\"page-break-after: always\"></div>

Figure 13: Kaplan-Meier Plot of Progressionfree Survival based on Computerized Algorithm; Intent -toTreat Analysis Set (Study 54767414MMY3013)

<!-- image -->

Filename: T14.02-01.01.01F.RTF / Program: T14.02-KMFig.sas (05OCT2020 20:44) Analysis Dataset Variables included ADTTE: ITTFL TRT01PN, AVAL, CNSR, PARAMCD=PFS

## Subgroup Analyses of Progression-free Survival

The PFS results were generally consistent across subgroups demonstrating improvement for subjects in the DPd group compared with subjects in the Pd group, including subgroups for subjects refractory to lenalidomide, high-risk cytogenetics, ISS staging, number of lines of prior therapy, and baseline ECOG performance score (Figure 4).

No analyses were performed for extreme high body weight as too few subjects were available (no subjects in the DPd group and 1 subject in Pd group weighed &gt;120 kg at baseline).

All 'number of prior therapies' subgroups consistently favoured DPd, including subjects with only 1 prior line of therapy.

<div style=\"page-break-after: always\"></div>

Figure 14: Forest Plot of Subgroup Analysis of Progression-free Survival based on Computerized Algorithm; Intent-to-Treat Analysis Set (Study 54767414MMY3013)

<!-- image -->

|                                             |                     | Pd      | Pd     | DPd    | DPd         | Hazard Ratio      |
|---------------------------------------------|---------------------|---------|--------|--------|-------------|-------------------|
|                                             | HazardRatioand95%Cl | EVT/N   | Median |        | EVT/NMedian | 95%CI             |
| Overall                                     |                     | 106/153 | 6.93   | 84/151 | 12.42       | 0.63 (0.47, 0.85) |
| Age                                         |                     |         |        |        |             |                   |
| <65years                                    |                     | 41/60   | 5.78   | 36/63  | 9.23        | 0.69 (0.44, 1.09) |
| >=65years                                   |                     | 65/93   | 7.03   | 48/88  | 14.16       | 0.55 (0.38, 0.81) |
| Sex                                         |                     |         |        |        |             |                   |
| Male                                        |                     | 54/82   | 7.23   | 46/79  | 10.74       | 0.69 (0.47, 1.03) |
| Female                                      |                     | 52/71   | 6.54   | 38/72  | 15.01       | 0.54 (0.35, 0.82) |
| Race                                        |                     |         |        |        |             |                   |
| White                                       |                     | 93/137  | 7.43   | 75/135 | 12.09       | 0.66 (0.48, 0.89) |
| Non-White                                   |                     | 13/16   | 5.03   | 9/16   | 16.21       | 0.34 (0.14, 0.82) |
| ISS staging                                 |                     |         |        |        |             |                   |
| 1                                           |                     | 43/69   | 9.53   | 31/68  | 19.32       | 0.62(0.39,0.98)   |
| 2                                           |                     | 36/51   | 6.08   | 32/50  | 12.25       | 0.54(0.33,0.87)   |
| 3                                           |                     | 27/33   | 5.03   | 21/33  | 6.05        | 0.75 (0.42,1.32)  |
| Revised ISSstaging                          |                     |         |        |        |             |                   |
| 1                                           |                     | 17/25   | 10.35  | 11/26  | NE          | 0.51(0.24,1.10)   |
| 2                                           |                     | 64/88   | 6.47   | 45/74  | 12.25       | 0.58 (0.39, 0.85) |
| 3                                           |                     | 11/14   | 3.38   | 15/19  | 2.83        | 1.38 (0.62, 3.11) |
| Number of lines of prior therapy            |                     |         |        |        |             |                   |
| 1                                           |                     | 12/18   | 12.55  | 9/16   | 14.06       | 0.70 (0.30,1.67)  |
| 2-3                                         |                     | 79/113  | 6.54   | 65/114 | 10.74       | 0.66 (0.48,0.92)  |
| >=4                                         |                     | 15/22   | 6.57   | 10/21  | 19.32       | 0.40 (0.18, 0.90) |
| Typeofmeasurablemultiplemyeloma             |                     |         |        |        |             |                   |
| IgG                                         |                     | 52/79   | 8.54   | 43/76  | 11.37       | 0.67 (0.45, 1.01) |
| Non-lgG                                     |                     | 25/32   | 6.93   | 20/34  | 13.11       | 0.44 (0.24, 0.81) |
| Cytogeneticriskat study entry               |                     |         |        |        |             |                   |
| High risk                                   |                     | 26/35   | 3.98   | 28/39  | 5.78        | 0.85 (0.49, 1.44) |
| Standard risk                               |                     | 50/73   | 7.43   | 30/64  | 21.03       | 0.51(0.32,0.81)   |
| Baselinehepaticfunctionstatus               |                     |         |        |        |             |                   |
| Normal                                      |                     | 88/127  | 6.93   | 69/136 | 15.18       | 0.56 (0.41, 0.77) |
| Impaired                                    |                     | 18/26   | 8.34   | 15/15  | 6.05        | 1.72 (0.84, 3.50) |
| BaselineECoGperformancescore                |                     |         |        |        |             |                   |
| 0                                           |                     | 53/77   | 6.93   | 49/91  | 12.65       | 0.61(0.41,0.90)   |
| >=1                                         |                     | 53/76   | 7.23   | 35/60  | 12.09       | 0.65 (0.42, 1.00) |
| Baselinerenal function(CreatinineClearance) |                     |         |        |        |             |                   |
| <=60 mL/min                                 |                     | 36/47   | 6.14   | 23/40  | 12.09       | 0.59(0.35,0.99)   |
| >60mL/min                                   |                     | 70/106  | 7.75   | 61/111 | 12.65       | 0.64 (0.45, 0.90) |
| Baseline weight                             |                     |         |        |        |             |                   |
| <65 kg                                      |                     | 20/30   | 7.13   | 26/45  | 10.97       | 0.88 (0.49,1.57)  |
| 65-<85kg                                    |                     | 63/89   | 7.03   | 37/69  | 15.18       | 0.51 (0.34, 0.76) |
| >=85kg Refractory toLenalidomide            |                     | 23/34   | 6.93   | 21/37  | 8.34        | 0.65 (0.36,1.17)  |
| No                                          |                     | 17/31   | 10.64  | 8/31   | NE          |                   |
|                                             | FavorsDPd →FavorsPd | 89/122  | 6.51   |        |             | 0.36 (0.15, 0.83) |
| Yes                                         | T 0 1 2             |         |        | 76/120 | 9.89        | 0.66 (0.49, 0.90) |

Filename: T14.02-01.10F.RTF / Program: T14.02-PFS FPlot.sas (23OCT2020 9:40)

Analysis Dataset Variables included ADTTE: AVAL,CNSR, PARAMCD=PFS; ADSL:ITTFL TRT01PN, AGEGR1N, SEXN, LENREFN

Key Secondary Analyses

Overall Response Rate

<div style=\"page-break-after: always\"></div>

Table 16 : Summary of Overall Best Confirmed Response based on Computerized Algorithm; Intent -toTreat Analysis Set (Study 54767414MMY3013)

|                                                      | pd         | pd                 | DPd         | DPd            |                                        |                                        |
|------------------------------------------------------|------------|--------------------|-------------|----------------|----------------------------------------|----------------------------------------|
|                                                      | n (%)      | Exact 95% CI for % | n (%)       | Exact95%CIfor% | Odds ratio (95% C1)p-value (two-sided) | Odds ratio (95% C1)p-value (two-sided) |
| Analysis set:intent-to-treat                         | 153        |                    | 151         |                |                                        |                                        |
| Response categories                                  |            |                    |             |                |                                        |                                        |
| Stringent Complete Response (sCR)                    | 2 (1.31)   | 0.16, 4.64         | 14 (9.27)   | 5.16, 15.07    |                                        |                                        |
| Complete Response (CR)                               | 4 (2.61)   | 0.72, 6.56         | 23 (15.23)  | 9.91, 21.97    |                                        |                                        |
| Very Good Partial Response (VGPR)                    | 24 (15.69) | 10.32, 22.43       | 40 (26.49)  | 19.65, 34.28   |                                        |                                        |
| Partial Response (PR)                                | 41 (26.80) | 19.97, 34.55       | 27 (17.88)  | 12.13, 24.94   |                                        |                                        |
| Minimal Response (MR)                                | 15 (9.80)  | 5.59, 15.65        | 11 (7.28)   | 3.69, 12.66    |                                        |                                        |
| Stable Disease (SD)                                  | 49 (32.03) | 24.72, 40.04       | 26 (17.22)  | 11.57, 24.20   |                                        |                                        |
| Progressive Disease (PD)                             | 7 (4.58)   | 1.86, 9.20         | 4 (2.65)    | 0.73, 6.64     |                                        |                                        |
| Not Evaluable (NE)                                   | 11 (7.19)  | 3.64, 12.50        | 6 (3.97)    | 1.47, 8.45     |                                        |                                        |
| Overallresponse(sCR+CR+VGPR+PR)                      | 71 (46.41) | 38.32, 54.64       | 104 (68.87) | 60.84, 76.15   | 2.68 (1.65, 4.35)                      | <.0001                                 |
| Clinicalbenefit(Overallresponse+MR)                  | 86 (56.21) | 47.97, 64.21       | 115 (76.16) | 68.55, 82.71   | 2.57 (1.55, 4.25)                      | 0.0002                                 |
| Very good partial response or better(sCR + CR+ VGPR) | 30 (19.61) | 13.64, 26.79       | 77 (50.99)  | 42.74, 59.21   | 4.32 (2.57, 7.26)                      | <.0001                                 |
| Complete response or better(sCR + CR)                | 6 (3.92)   | 1.45, 8.34         | 37 (24.50)  | 17.88, 32.16   | 8.24 (3.35, 20.26)                     | <.0001                                 |

Key:Pd=pomalidomide-dexamethasone;DPd=daratumumab-pomalidomide-dexamethasone.

CI=ConfidenceInterval.

Percentages are computed on subjects in the intent-to-treat analysis set.

Odds ratio andits two-sided 95%CI are obtained from the Mantel-Haenszel estimate of the common odds ratio,stratified with ISS (1,2,3),and number of lines ofprior therapy(1, 2-

The exact two-sided 95% CI for a percentage is obtained from the Clopper-Pearson method.

3,≥4).An odds ratio &gt;1 favors DPd.

## Minimal Residual Disease

Table 17: Summary of MRD Negative Rate at 105 in Bone Marrow; Intent -to-Treat Analysis Set (Study 54767414MMY3013)

|                               | Pd         | DPd                |
|-------------------------------|------------|--------------------|
| Analysis set: intent-to-treat | 153        | 151                |
| MRD negativity rate (10-5)    | 3 (1.96%)  | 13 (8.61%)         |
| 95% CI MRD negativity rate    | 0.41, 5.62 | 4.66, 14.27        |
| Odds ratio with 95% CIb       |            | 4.71 (1.31, 16.88) |
| p-value (two-sided)c          |            | 0.0102             |

Key: Pd = pomalidomide - dexamethasone; DPd = daratumumab - pomalidomide - dexamethasone.

CI = Confidence Interval; MRD = Minimal Residual Disease.

Percentages are computed on subjects in the intent-to-treat analysis set.

a.Exact 95% confidence inteival.

b. Mantel-Haenszel estimate of the odds ratio for unstratified tables is used. An odds ratio &gt; 1 indicates an advantage for DPd. c. p-value from Fisher's exact test.

MRD negativity status is based on post-randomization assessments prior to progressive disease or subsequent antimyeloma therapy.

Filename: T14.02-07.01.RTF / Pr0gram: T14.02-07.01to03.sas (05OCT2020 20:45) Analysis Dataset Variables included ADSL: ITTFL TRTO1PN; ADMARD: AVALC PARAMCD=MRD5

## Overall Survival

With a median overall follow-up of 16.9 months (DPd: 17.5 months; Pd: 16.4 months; Attachment T14.0208.01),  median  OS  was  not  reached  in  either  treatment  group  (see  Table  and  Figure  below).  Similar numbers of deaths were observed for DPd and Pd treatment groups (DPd: 48 [31.8%]; Pd: 51 [33.3%]), with an HR=0.91 (95% CI: 0.61, 1.35; 2-sided p=0.6359). The participants will continue to be followed up for the OS data until 166 deaths have been observed or 5 years after the last subject was randomized.

P-value is obtainedfrom the two-sided Cochran-Mantel-Haenszel chi-squared test, stratified forISS(1, 2, 3), and number of lines of prior therapy (1, 2-3,≥4).

AnalysisDatasetVariablesincludeADSL:ITTFLTRT0iPN;ADEFF1:AVALCPARAMCD=BRESP

Filename: T14.02-02.01.01.RTF/Program: T14.02-Resp.sas (05OCT2020 20:43)

<div style=\"page-break-after: always\"></div>

Table 18 : Summary of Overall Survival; Intent -to-Treat Analysis Set (Study 54767414MMY3013)

|                                     | Pd                  | DPd                |
|-------------------------------------|---------------------|--------------------|
| Analysis set:intent-to-treat        | 153                 | 151                |
| Overall survival (OS)               |                     |                    |
| Number of deaths, n (%)             | 51 (33.33)          | 48 (31.79)         |
| Number of censored, n (%)           | 102 (66.67)         | 103 (68.21)        |
| Kaplan-Meier estimates(months)      |                     |                    |
| 25% quantile (95% CI)               | 12.55 (9.49, 15.44) | 13.90 (9.79,17.18) |
| Median (95% CI)                     | NE (19.61, NE)      | NE (22.54, NE)     |
| 75% quantile (95% CI)               | NE (NE, NE)         | NE (NE, NE)        |
| p-value (two-sided)                 |                     | 0.6359             |
| Hazard ratio (DPd vs. Pd) (95% CI)  |                     | 0.91 (0.61, 1.35)  |
| 6-month survival rate (%) (95% CI)  | 88.7 (82.4, 92.8)   | 89.1 (82.9, 93.2)  |
| 12-month survival rate (%) (95% CI) | 76.3 (68.4, 82.5)   | 78.5 (70.8, 84.4)  |
| 18-month survival rate (%) (95%CI)  | 63.4 (54.0, 71.5)   | 67.3 (58.2, 74.9)  |

Key:Pd=pomalidomide-dexamethasone:DPd=daratumumab-pomalidomide-dexamethasone.

CI=ConfidenceInterval;OS=Overallsurvival.

Percentages are computed onsubjectsin the intent-to-treat analysis set.

P-value is obtained from the two-sided log-rank test stratified with ISS (1, 2, 3), and number of lines of prior therapy (1, 2-3,

≥4).

Hazard ratio and 95% CI are obtained from a Cox proportional hazards model with treatment as an explanatory variable in the model, stratified with ISS (1, 2, 3), and number of lines of prior therapy (1, 2-3, ≥4). A hazard ratio &lt; 1 favors DPd. Filename:T14.02-03.01.RTF/Program:T14.02-OS.sas(05OCT202020:43) Analysis DatasetVariables included ADTTE:ITTFL TRT01PN,STRATIN,STRAT2N,AVAL,CNSR,PARAMCD=OS

Figure 15: KaplanMeier Plot of Overall Survival; Intent -to-Treat Analysis Set (Study 54767414MMY3013)

<!-- image -->

Filename: T14.02-03.01F.RTF /Program: T14.02-KMFig.sas (05OCT2020 20:44) Analysis Dataset Variables included ADTTE: ITTFL TRT01PN, AVAL, CNSR, PARAMCD=OS

<div style=\"page-break-after: always\"></div>

## Summary of main study

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 19: Summary of Efficacy for trial MMY3013

<!-- image -->

| Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor   | Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor   | Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor   | Title: A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor                |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                              | 54767414MMY3013 / 2017-001618-27                                                                                                                                                                                                                              | 54767414MMY3013 / 2017-001618-27                                                                                                                                                                                                                              | 54767414MMY3013 / 2017-001618-27                                                                                                                                                                                                                                           |
| Design                                                                                                                                                                                                                                                        | Multicentre, Phase 3, randomized, open-label, active-controlled study                                                                                                                                                                                         | Multicentre, Phase 3, randomized, open-label, active-controlled study                                                                                                                                                                                         | Multicentre, Phase 3, randomized, open-label, active-controlled study                                                                                                                                                                                                      |
| Design                                                                                                                                                                                                                                                        | Duration of main phase:                                                                                                                                                                                                                                       | Duration of main phase:                                                                                                                                                                                                                                       | Study initiation date: 14-June-2017, data cut-off 21 July 2020, ongoing                                                                                                                                                                                                    |
| Hypothesis                                                                                                                                                                                                                                                    | Superiority                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                                                             | D-Pd                                                                                                                                                                                                                                                          | D-Pd                                                                                                                                                                                                                                                          | • Daratumumab: 1800 mg SC,QW Cycles 1-2, Q2W: Cycles 3-6, Q4W Cycles 7 + until PD • Pomalidomide: 4mg PO on days 1- 21 of every cycle until PD • Dexamethasone: 40 mg (or 20 mg) PO or IV QWuntil PD                                                                       |
| Treatments groups                                                                                                                                                                                                                                             | Pd                                                                                                                                                                                                                                                            | Pd                                                                                                                                                                                                                                                            | • Pomalidomide: 4mg PO on days 1- 21 of every cycle until PD • Dexamethasone: 40 mg (or 20 mg) PO or IV QWuntil PD                                                                                                                                                         |
| Endpoints and definitions                                                                                                                                                                                                                                     | Primary endpoint                                                                                                                                                                                                                                              | PFS                                                                                                                                                                                                                                                           | Progression Free Survival, defined as the time, in months, from the date of randomization to the date of the first documented disease progression (based on a validated computer algorithm using modified IMWG criteria) or death due to any cause, whichever comes first. |
| Endpoints and definitions                                                                                                                                                                                                                                     | Secondary endpoint                                                                                                                                                                                                                                            | ORR                                                                                                                                                                                                                                                           | Response Rate, defined as the proportion of randomized subjects who achieve a best response of PR or better (ie, sCR, CR, VGPR, or PR) based on a validated computer algorithm using the modified IMWG criteria.                                                           |
| Endpoints and definitions                                                                                                                                                                                                                                     | Secondary endpoint                                                                                                                                                                                                                                            | VGPR or better                                                                                                                                                                                                                                                | Rate of Very Good Partial Response or better, defined as the proportion of randomized subjects who achieve a best response of VGPR or better (ie, VGPR, or PR) based on a validated computer algorithm using the modified IMWG criteria.                                   |
| Endpoints and definitions                                                                                                                                                                                                                                     | Secondary endpoint                                                                                                                                                                                                                                            | CR or better                                                                                                                                                                                                                                                  | Rate of Complete Response or better, defined as the proportion of randomized subjects who achieve a best response of CR or better (ie, CR, VGPR, or PR) based on a validated computer algorithm using the modified IMWG criteria.                                          |

<div style=\"page-break-after: always\"></div>

|                                        | Secondary endpoint                     | Secondary endpoint                                     | MRD negativity rate MRD MRD at                         | MRD negativity rate MRD MRD at                         | negativity rate, defined as the proportion of subjects who have negative any timepoint after the date of randomization (threshold value of 10-5). Overall Survival, defined as the time, in   | negativity rate, defined as the proportion of subjects who have negative any timepoint after the date of randomization (threshold value of 10-5). Overall Survival, defined as the time, in   |
|----------------------------------------|----------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                        | Secondary endpoint                     | Secondary endpoint                                     | OS                                                     | OS                                                     | months, from the date of randomization to the date of death from any cause.                                                                                                                   | months, from the date of randomization to the date of death from any cause.                                                                                                                   |
| Database lock                          | Database lock:                         | Database lock:                                         | Database lock:                                         | 28 July 2020 21 July 2020                              | 28 July 2020 21 July 2020                                                                                                                                                                     | 28 July 2020 21 July 2020                                                                                                                                                                     |
| Results and Analysis                   | Results and Analysis                   | Results and Analysis                                   | Results and Analysis                                   | Results and Analysis                                   | Results and Analysis                                                                                                                                                                          | Results and Analysis                                                                                                                                                                          |
| Analysis description                   | Analysis description                   | Primary Analysis                                       | Primary Analysis                                       | Primary Analysis                                       | Primary Analysis                                                                                                                                                                              | Primary Analysis                                                                                                                                                                              |
| Analysis population and time point     | Analysis population and time point     | Intent to treat / clinical cut-off date (21 July 2020) | Intent to treat / clinical cut-off date (21 July 2020) | Intent to treat / clinical cut-off date (21 July 2020) | Intent to treat / clinical cut-off date (21 July 2020)                                                                                                                                        | Intent to treat / clinical cut-off date (21 July 2020)                                                                                                                                        |
| description Descriptive statistics and | description Descriptive statistics and | Treatment group                                        | Treatment group                                        | Pd                                                     | Pd                                                                                                                                                                                            | D-Pd                                                                                                                                                                                          |
| estimate variability                   | estimate variability                   | Number of subjects                                     | Number of subjects                                     | 153                                                    | 153                                                                                                                                                                                           | 151                                                                                                                                                                                           |
|                                        |                                        | PFS                                                    | PFS                                                    | 6.9 months                                             | 6.9 months                                                                                                                                                                                    | 12.4 months                                                                                                                                                                                   |
|                                        |                                        | 95% CI                                                 | 95% CI                                                 | (5.5 - 9.3) months                                     | (5.5 - 9.3) months                                                                                                                                                                            | (8.3 - 19.3) months                                                                                                                                                                           |
|                                        |                                        | ORR                                                    | ORR                                                    | 46.4%                                                  | 46.4%                                                                                                                                                                                         | 68.9%                                                                                                                                                                                         |
|                                        |                                        | 95% CI                                                 | 95% CI                                                 | 38.3 %- 54.6%                                          | 38.3 %- 54.6%                                                                                                                                                                                 | 60.8 %- 76.2%                                                                                                                                                                                 |
|                                        |                                        | VGPR or better                                         | VGPR or better                                         | 19.6%                                                  | 19.6%                                                                                                                                                                                         | 51.0%                                                                                                                                                                                         |
|                                        |                                        | 95% CI                                                 | 95% CI                                                 | 13.6 %- 26.8%                                          | 13.6 %- 26.8%                                                                                                                                                                                 | 42.7 %- 59.2%                                                                                                                                                                                 |
|                                        |                                        | CR or better                                           | CR or better                                           | 3.9%                                                   | 3.9%                                                                                                                                                                                          | 24.5%                                                                                                                                                                                         |
|                                        |                                        | 95% CI                                                 | 95% CI                                                 | 1.5 %- 8.3%                                            | 1.5 %- 8.3%                                                                                                                                                                                   | 17.9 %- 32.2%                                                                                                                                                                                 |
|                                        |                                        | MRD negativity rate                                    | MRD negativity rate                                    | 2.0%                                                   | 2.0%                                                                                                                                                                                          | 8.6%                                                                                                                                                                                          |
|                                        |                                        | 95% CI                                                 | 95% CI                                                 | 0.4 %- 5.6%                                            | 0.4 %- 5.6%                                                                                                                                                                                   |                                                                                                                                                                                               |
|                                        |                                        | OS                                                     | OS                                                     | Median not reached, deaths                             | Median not reached, deaths                                                                                                                                                                    | 4.7 %- 14.3% Median not reached, deaths observed: 48                                                                                                                                          |
|                                        |                                        | 95% CI                                                 | 95% CI                                                 | (33.3%) n/a                                            | (33.3%) n/a                                                                                                                                                                                   | (31,8%)                                                                                                                                                                                       |
| Effect estimates per                   | Effect estimates per                   |                                                        |                                                        | n/a D-Pd                                               | n/a D-Pd                                                                                                                                                                                      | n/a D-Pd                                                                                                                                                                                      |
| comparison                             | comparison                             | Primary endpoint PFS                                   | Primary endpoint PFS                                   | Hazard ratio (D-Pd vs Pd) 95% CI P-value (2-sided)     | Hazard ratio (D-Pd vs Pd) 95% CI P-value (2-sided)                                                                                                                                            | 0.63 0.47 - 0.85 0.0018                                                                                                                                                                       |
|                                        |                                        | Secondary endpoint ORR                                 | Secondary endpoint ORR                                 | Odds ratio 95% CI P-value (2-sided)                    | Odds ratio 95% CI P-value (2-sided)                                                                                                                                                           | 2.68 1.65 - 4.35 <0.0001                                                                                                                                                                      |
|                                        |                                        | Secondary endpoint VGPR or better                      | Secondary endpoint VGPR or better                      | Odds ratio 95% CI                                      | Odds ratio 95% CI                                                                                                                                                                             | 4.32 2.57 - 7.26 <0.0001                                                                                                                                                                      |
|                                        |                                        | Secondary endpoint CR better                           | Secondary endpoint CR better                           | P-value (2-sided) Odds ratio                           | P-value (2-sided) Odds ratio                                                                                                                                                                  | 8.24 3.35 -                                                                                                                                                                                   |
|                                        |                                        |                                                        |                                                        | 95% CI P-value (2-sided)                               | 95% CI P-value (2-sided)                                                                                                                                                                      | 20.26 <0.0001                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|       | Secondary endpoint MRD negativity rate                                                                                                                                                                                                                           | Odds ratio 95% CI P-value (2-sided)                                                                                                                                                                                                                              | 4.71 1.31 - 16.88 0.0102                                                                                                                                                                                                                                         |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|       | Secondary endpoint OS (median OS not reached in either group)                                                                                                                                                                                                    | Hazard ratio (D-Pd vs Pd) 95% CI P-value (2-sided)                                                                                                                                                                                                               | 0.91 0.61 - 1.35 0.6359                                                                                                                                                                                                                                          |
| Notes | The participants will continue to be followed up for the OS data until 166 deaths have been observed or 5 years after the last subject was randomized. Deaths for subjects with COVID-19 were limited (1 DPd subject) and did not impact interpretation of data. | The participants will continue to be followed up for the OS data until 166 deaths have been observed or 5 years after the last subject was randomized. Deaths for subjects with COVID-19 were limited (1 DPd subject) and did not impact interpretation of data. | The participants will continue to be followed up for the OS data until 166 deaths have been observed or 5 years after the last subject was randomized. Deaths for subjects with COVID-19 were limited (1 DPd subject) and did not impact interpretation of data. |

## Supportive study

Study MMY1001 was a Phase 1b open-label, non-randomized, multicenter study to evaluate the safety, tolerability,  and  dose  regimen  of  daratumumab  IV  when  administered  in  combination  with  various background treatment regimens for multiple myeloma in either newly diagnosed patients or those who had received  prior  therapies,  depending  on  the  background  treatment  regimen.  The  treatment  regimens combined with daratumumab IV in this study included regimens used for newly diagnosed patients (ie, VELCADE-dexamethasone [Vd], VELCADE-melphalan-prednisone [VMP], VELCADE-thalidomidedexamethasone  [VTd],  carfilzomib  +  lenalidomide  +  dexamethasone  [KRd]  and  regimens  used  for previously treated patients (ie, Pd, and carfilzomib-dexamethasone [Kd]. Among relapsed and refractory subjects, 1 cohort, daratumumab IV in combination with Pom-dex (DPd), was expanded to 103 subjects to evaluate the safety and efficacy of DPd. Efficacy data from this DPd cohort is summarized below.

Figure 16: Schematic Overview of Study MMY1001

<!-- image -->

a:DPdcohort providesdatafor thisSCE.

Note: Other treatment cohorts in Study MMY1001 are not represented in the figure above.

The  primary  objective  for  the  DPd  cohort  was  to  evaluate  the  safety,  tolerability,  and  dosing  of daratumumab IV in combination with Pd when administered to subjects with multiple myeloma who had received ≥2 prior lines of therapy. The primary efficacy endpoint was ORR, defined as the proportion of subjects with PR or better. Secondary efficacy endpoints included DOR, TTR, TTP, PFS, and OS. Efficacy assessment was performed in accordance with IMWG guidelines (Durie 2006; Rajkumar 2011). The primary analysis was based on response assessed by an IDSMB; investigator assessment and algorithm assessment were performed as sensitivity analyses.

One hundred three (103) subjects were enrolled in the DPd cohort with median age of 64 years (range: 3586 years), with 50% of subjects ≥65 years of age and 55% of subjects were male. A majority of subjects had an ECOG status score of 0-1 (88%). All subjects in the DPd cohort received prior therapy for multiple myeloma. The majority of subjects (51%) received &gt;3 lines of prior multiple myeloma therapy; median number of prior therapies was 4. Ninety-eight percent of subjects had previous exposure to both bortezomib and lenalidomide.

<div style=\"page-break-after: always\"></div>

As of the clinical cut-off, median duration of study treatment for the 103 subjects in the DPd cohort was 6.0 months (range: 0-17 months). Median relative dose intensity was 97% for daratumumab, 78% for pomalidomide and 90% for dexamethasone.

## Primary Efficacy Endpoint - Overall Response Rate

The ORR (PR or better) based on IDSMB assessment was 59.2%, with 42% of subjects having a rate of VGPR or better and 14% of subjects having a rate of CR or better.

Table 20: Overall Best Response based on IDSM B Assessment; Dara + Pom/Dex Treated (Study 54767414MMY1001)

|                                          | D-Pom-dex   | D-Pom-dex      |
|------------------------------------------|-------------|----------------|
|                                          | n (%)       | 95% CI for %   |
| Analysis set: : Dara + Pom/Dex treated   | 103         |                |
| Best response                            |             |                |
| Stringent complete response (sCR)        | 8 (7.8%)    | (3.4%, 14.7%)  |
| Complete response (CR)                   | 6 (5.8%)    | (2.2%, 12.2%)  |
| Very good partial response (VGPR)        | 29 (28.2%)  | (19.7%, 37.9%) |
| Partial response (PR)                    | 18 (17.5%)  | (10.7%, 26.2%) |
| Minimal response (MR)                    | 3 (2.9%)    | (0.6%, 8.3%)   |
| Stable disease (SD)                      | 26 (25.2%)  | (17.2%, 34.8%) |
| Progressive disease (PD)                 | 3 (2.9%)    | (0.6%, 8.3%)   |
| Not evaluable (NE)                       | 10 (9.7%)   | (4.8%, 17.1%)  |
| Overall response (sCR+CR+VGPR+PR)        | 61 (59.2%)  | (49.1%, 68.8%) |
| Clinical benefit (Overall response + MR) | 64 (62.1%)  | (52.0%, 71.5%) |
| VGPR or better (sCR + CR + VGPR)         | 43 (41.7%)  | (32.1%, 51.9%) |
| CR or better (sCR + CR)                  | 14 (13.6%)  | (7.6%, 21.8%)  |

Keys: CI = exact confidence interval; D-Pom-dex = daratumumab-pomalidomide-dexamethasone.

Note: Response was assessed by IDSMB, based on international Uniform Response Criteria Consensus Recommendations.

Note: Percentages are calculated with the number of subjects in each group as denominator.

[TEFRSP01.RTF] [NJ-54767414\\MMY1001\\DBR\\_SBLA\\_2016\\RE\\_SBLA\\_2016\\PROD\\TEFRSP01.SAS] 05MAY2016, 09:26

## Key Secondary Efficacy Endpoints

Based on IDSMB assessment of response, median DOR was 13.6 months for responders (61 subjects) in the response-evaluable cohort. Estimated DOR was 84% at 6 months, and 67% at 12 months.

Based on IDSMB assessment, time to response (61 subjects) in the response-evaluable cohort was as follows. Median time to first response (PR or better) was 0.99 months; median time to best response (PR or better) was 2.1 months; median time to VGPR or better response (43 subjects) was 1.9 months; and median time to CR or better response (14 subjects) was 5.4 months.

Based on IDSMB assessment, 49 (48%) PFS events were observed; median PFS was 10.4 months (CI: 4.63, NE). Three-month disease progression-free rate was 74%; 6-month disease progression-free rate was 57%; and 12-month disease progression-free rate was 45%.

<div style=\"page-break-after: always\"></div>

Based on IDSMB assessment, 42 (41%) TTP events were observed; median TTP was 10.9 months (CI: 6.70, NE). Three-month disease progression-free rate was 78%; 6-month disease progression-free rate was 62%; and 12-month disease progression-free rate was 48%.

At the clinical data cut-off, with a median follow-up of 9.8 months, 28 deaths (27%) were observed and 75 subjects (73%) were censored. Median survival was not estimable. Estimated survival rates were 89% at 3 months; 79% at 6 months; and 72% at 12 months.

## 2.4.3. Discussion on clinical efficacy

The current submission is supported by study MMY3013, which is a Phase 3 study comparing pomalidomide and dexamethasone with or without daratumumab in subjects with relapsed or refractory multiple myeloma who have received at least one prior line of therapy with both lenalidomide and a proteasome inhibitor.

The proposed daratumumab SC dose is the same proposed as part of other drug-combinations. Safety and tolerability data have been generated with IV daratumumab in combination with Pd in the DPd cohort of study MMY1001 and confirmed in the phase 3 randomized clinical study MMY3013 (where daratumumab was given subcutaneously). The view of the Applicant that no additional dose studies need to be conducted is supported.

## Design and conduct of clinical studies

The purpose of the pivotal phase 3 study MMY3013 was to evaluate the efficacy and safety of DPd to Pd in subjects with relapsed or refractory multiple myeloma having received prior lenalidomide and an IMiD (96% had received bortezomib) using the primary endpoint of PFS based on IMWG criteria.

Daratumumab was given SC (7 patients received IV before amendment 2). Pd dose was given according to Imnovid SmPC. Treatment continued until PD or unacceptable toxicity.

Subjects were randomized 1:1 to DPd or Pd. Randomization was stratified by number of lines of prior therapy and ISS stage. The study was open-label. An IDMC conducted the interim analysis.

The primary population for the efficacy analysis is the ITT, which includes all randomized subjects. This is endorsed. PFS was analysed using a stratified log-rank test and the hazard ratio was estimated using a stratified  Cox  model.  In  both  cases,  the  stratification  factors  were  those  used  at  randomisation.  The implementation of a stratified log-rank test and a stratified Cox model is endorsed. The censoring rules are not fully agreed, since censoring due to start of a subsequent therapy before PD or withdrawal of consent could bias the results. However, the MAH presented sensitivity analyses, which yielded similar results as those corresponding to the primary analysis.

An interim analysis for PFS with the possibility of stopping for superiority was planned. To control the type I  error  due  to  multiple  looks,  alpha  spending  functions  were  used.  There  are  several  key  secondary endpoints, which were to be tested using a pre-define hierarchical approach. The implemented strategy to control for multiplicity issues is agreed.

The baseline characteristics including disease characteristics and prior treatment were generally comparable between the two arms in study 3013.

Subjects received a median of 2 prior lines of therapy, with approximately 11% of subjects receiving 1 prior line of therapy. The MAH is applying for DPd after at least one prior therapy as long as the 'prior therapy included a proteasome inhibitor and an immunomodulatory agent'.

The  indication  sought  is  for  patients  having  received  a  prior  PI  and  IMiD.  All  patients  had  received lenalidomide (this was an inclusion criterion) and 96% of patients had received prior bortezomib treatment. The fact that all patients received lenalidomide has now been reflected in the indication (instead of IMiD), also in line with other approved products. Thirty percent of patients had also received thalidomide, and for the PI category approximately 25% had received carfilzomib and 11% ixazomib (in the DPd arm). Based

<div style=\"page-break-after: always\"></div>

on that and to better reflect the study population the CHMP considered that the most appropriate indication would be

'DARZALEX is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients  with  multiple  myeloma  who  have  received one  prior  therapy  containing  a  proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies  that  included  lenalidomide  and  a  proteasome  inhibitor  and  have  demonstrated  disease progression on or after the last therapy (see section 5.1).

Supportive data where derived from 103 DPd-treated patients in the phase 1b study MMY1001, which was an open-label, non-randomized, multicenter study to evaluate the safety, tolerability, and dose regimen of daratumumab  IV  when  administered  in  combination  with  various  background  treatment  regimens  for multiple myeloma in either newly diagnosed patients or those who had received prior therapies, depending on the background treatment regimen.

## Efficacy data and additional analyses

A  total  of  304  subjects  (DPd:  151,  Pd:  153)  were  randomized  in  a  1:1  ratio  according  to  planned stratification factors (number of lines of prior therapy and ISS staging), and 299 subjects (DPd: 149, Pd: 150) received study treatment. At the time of the clinical cut-off date of 21 July 2020, 40.3% DPd subjects and 22% of Pd subjects were still on study treatment.

Treatment discontinuations were higher in the Pd group compared with the experimental arm, (78% in Pd arm  vs.  59.73%  in  the  DPd  arm).  Differences  appear  mainly  driven  by  the  higher  rate  of  treatment discontinuation in the Pd arm due to progressive disease (Pd: 58%; DPd: 44.3%), which is not unexpected considering  the  reported  efficacy  data  of  the  study.  A  low  proportion  of  subjects  discontinued  study treatment due to death (DPd: 6.7%; Pd: 4.7%; including 1 death due to COVID-19 in the DPd group), noncompliance with study drug (DPd: 3.4%; Pd: 8%), and AE (DPd: 2%; Pd: 2.7%).

Demographic characteristics were well balanced between the 2 treatment groups. The median age was 67 years (range: 35 to 90 years), with 18.4% of the subjects ≥75 years of age. The majority of the subjects were white (89.5%) and had an ECOG performance score of 0 or 1 (91.8%).

Of note, an imbalance between treatment arms is noted for patients with worse general condition (i.e. 6 vs. 19 patients with ECOG PS2 in the DPd and Pd arms, respectively) and in patients over 75 years of age (i.e. 25 vs. 31 patients in the DPd and Pd arms, respectively). Both are small subgroups.

Baseline disease characteristics. The majority of subjects had measurable disease in serum only (55.9%) with  IgG  (41.1%)  and  IgA  (14.5%).  Approximately  25%  of  ITT  subjects  (35%  of  those  with  available information  [DPd:  37.9%;  Pd:  32.4%])  had  a  high-risk  cytogenetic  abnormality  (presence  of  del17p, t[14;16] or t[4;14]). The distribution of ISS stages (a stratification factor at randomization) was balanced between treatment groups, with 45.1% of subjects overall reported as Stage 1, 33.2% as Stage 2, and 21.7% as Stage 3. When subjects were additionally assessed according to revised ISS (R-ISS) criteria (i.e. those with available information; n=246), a higher proportion of R-ISS Stage 3 was reported in the DPd group (16%) compared with the Pd group (11%).

The types of prior therapies for MM were consistent with standard of care for the population enrolled in the study and similar between treatment groups. All subjects were previously treated with both lenalidomide and a PI, and &gt;95% of subjects were previously treated with bortezomib therapy.

Subjects received a median of 2 prior lines of therapy, with approximately 11% of subjects receiving 1 prior line of therapy. Eighty percent of subjects were refractory to lenalidomide, 48% subjects were refractory to a PI, and 42.4% subjects were refractory to both PI and IMiD. For subjects who received only 1 prior line of therapy, all were refractory to lenalidomide and 32.4% were double refractory to both a PI and an IMiD.

Primary endpoint

<div style=\"page-break-after: always\"></div>

At  a  median  overall  follow-up  of  16.9  months  (DPd:  17.5  months;  Pd:  16.4  months)  the  addition  of daratumumab SC to Pd resulted in a statistically significant improvement in PFS with a 37% reduction in the risk of disease progression or death compared with Pd alone (HR=0.63; 95% CI: 0.47, 0.85; 2-sided p=0.0018,). The median PFS was 12.4 months for the DPd treatment group (95% CI; 8.3, 19.3) and 6.9 months for the Pd treatment group (95% CI; 5.5, 9.3), which is considered clinically relevant particularly in a population that had received a median of 2 prior treatments that included lenalidomide and a PI. Most PFS events were attributed to disease progression (46.4% in the DPd group and 61.4% in the Pd group). Data from 44.4% of subjects in the DPd group and 30.7% of subjects in the Pd group were censored for the primary endpoint analysis. The majority of these subjects were censored due to clinical cut-off. No subjects were censored for death due to COVID-19 without disease progression. No patients had received prior anti-CD38-containing therapy. The MAH has agreed with the recommendation to provide the final study report for Study MMY3013, estimated to be available by approximately Q4 2022.

Sensitivity  analyses  supported  the  findings  of  the  primary  analysis.  PFS  results  were  also  generally consistent across subgroups though interpretation of the results in some of them is limited by the small sample size, e.g. 'nonwhite' race, ≥4 and 1 prior lines of therapy, R -ISS Stage 3, and baseline impaired hepatic function. Of note, according to the HRs reported, there is some uncertainty that patients pertaining to the R-ISS Stage 3 group and those with impaired hepatic function would derive benefit from the addition of daratumumab to Pd. It is acknowledged that the confidence intervals are wide and the number of patients low.

## Key secondary endpoints

DPd showed a statistically significant higher ORR compared with the Pd group (DPd: 68.9%; Pd: 46.4%); the stratified CMH estimate of odds ratio was 2.68 with 95% CI (1.65, 4.35) and 2-sided p&lt;0.0001. The median duration of response had not been reached in the D-Pd group (range: 1 to 34.9+ months) and was 15.9 months (range: 1+ to 24.8 months) in the Pd group.

DPd also showed a statistically significant higher rate of CR (sCR and CR) or better compared with the Pd group (DPd: 24.5%; Pd: 3.9%; stratified CMH odds ratio=8.24 with 95% CI: [3.35, 20.26]; p&lt;0.0001.

The MRD negativity rate at the sensitivity threshold of 105 was 8.6% for DPd and 2.0% for Pd (odds ratio=4.71; 95% CI: 1.31, 16.88; 2-sided p=0.0102).

There is a statistical relationship between the achievement of complete response (CR), MRD negativity and PFS or OS (ESMO guidelines; Moreau et al., 2017), and thus the higher CR and MRD-negativity rates in the DPd arm are considered clinically important responses.

OS data are still immature. The MAH has agreed to provide updated survival data in the final study report for Study MMY3013, estimated to be available by approximately Q4 2022.

## Supportive study MMY1001

Comparing  studies  3013  and  1001  is  difficult  due  to  different  patient  populations,  objectives,  primary endpoints, daratumumab treatment durations, formulation (IV vs SC), and follow-up times. Generally, the results support study MMY3013.

## 2.4.4. Conclusions on the clinical efficacy

The addition of daratumumab to the combination of pomalidomide and dexamethasone translates into a significant delay in the progression of the disease in the targeted patient population, i.e. patients with multiple myeloma who have received at least one prior line of therapy with both lenalidomide, to which 80% were refractory, and a proteasome inhibitor (PI) and had demonstrated disease progression.

This  benefit  in  terms  of  PFS  is  supported  by  several  secondary  endpoints.  Importantly,  despite  the immaturity of the OS data, no evidence of detrimental effects on survival has so far been observed.

To better reflect the study population the CHMP considered that the most appropriate indication would be:

<div style=\"page-break-after: always\"></div>

'DARZALEX is indicated in combination with pomalidomide and dexamethasone for the treatment of  adult  patients  with  multiple  myeloma  who  have  received  one  prior  therapy  containing  a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at  least  two  prior  therapies  that  included  lenalidomide  and  a  proteasome  inhibitor  and  have demonstrated disease progression on or after the last therapy (see section 5.1).'

The MAH has agreed to provide the final study report for Study MMY3013 and updated survival data, estimated to be available by approximately Q4 2022.

## 2.5. Clinical safety

## Introduction

The safety population consists of data from 299 treated subjects from the Phase 3 Study MMY3013 (DPd: 149;  Pd:  150).  In  addition,  supportive  safety  data  from  Study  MMY1001,  a  Phase  1b  evaluation  of daratumumab administered in combination with Pd (N=103), are summarized in the Efficacy section.

As of the clinical cut-off date of 21 July 2020, 304 subjects were randomized into Study MMY3013. Of these, 299 subjects were treated (DPd: 149 subjects; Pd: 150 subjects) and represents the Safety Analysis Set. At the time of the clinical cut-off date, 60 subjects (40.3%) in the DPd group and 33 subjects (22.0%) in the Pd group were still receiving study treatment.

In  Study  MMY1001,  57.3%  of  subjects  discontinued  treatment  [PD  (33.0%),  AEs  (13.6%),  physician decision (3.9%), death (1.9%), and other (1%)].

## Patient exposure

In study 3013 the median duration of treatment for subjects in the DPd group (11.5 months) was 1.7 times that of the Pd group (6.6 months). The median number of treatment cycles received was 12 in the DPd group and 7 in the Pd group (Table 21).

The median daratumumab relative dose intensity in Study MMY3013 was 93.6%. The median relative dose intensity was lower in the DPd group for pomalidomide (74.3%) and dexamethasone (83.3%) compared with the Pd group (91.1% and 87.5%, respectively).

<div style=\"page-break-after: always\"></div>

Table 21: Treatment Duration and Number of Treatment Cycles; Safety Analysis Set (Studies: MMY3013 and MMY1001 DPd Cohort)

|                                                           | APOLLO (Study MMY3013)   | APOLLO (Study MMY3013)   | EQUULEUS (Study MMY1001)   |
|-----------------------------------------------------------|--------------------------|--------------------------|----------------------------|
|                                                           | Pd                       | DPd                      | DPd                        |
| Analysis set: safety                                      | 150                      | 149                      | 103                        |
| Duration of study treatment (months)                      |                          |                          |                            |
| N                                                         | 150                      | 149                      | 103                        |
| Mean (SD)                                                 | 8.9 (6.84)               | 11.7 (7.70)              | 6.3 (4.51)                 |
| Median                                                    | 6.6                      | 11.5                     | 6.0                        |
| Range                                                     | (0; 27)                  | (0; 36)                  | (0; 17)                    |
| Distribution of subjects treated in and beyond each cycle |                          |                          |                            |
| ≥1 cycle                                                  | 150 (100.0%)             | 149 (100.0%)             | 103 (100.0%)               |
| ≥2 cycles                                                 | 137 (91.3%)              | 143 (96.0%)              | 89 (86.4%)                 |
| ≥3 cycles                                                 | 129 (86.0%)              | 139 (93.3%)              | 80 (77.7%)                 |
| ≥4 cycles                                                 | 114 (76.0%)              | 131 (87.9%)              | 72 (69.9%)                 |
| ≥5 cycles                                                 | 102 (68.0%)              | 119 (79.9%)              | 64 (62.1%)                 |
| ≥6cycles                                                  | 92 (61.3%)               | 109 (73.2%)              | 54 (52.4%)                 |
| ≥7 cycles                                                 | 86 (57.3%)               | 105 (70.5%)              | 51 (49.5%)                 |
| Total number of treatment cyclesreceived                  |                          |                          |                            |
| 1                                                         | 13 (8.7%)                | 6 (4.0%)                 | 14 (13.6%)                 |
| 2                                                         | 8 (5.3%)                 | 4 (2.7%)                 | 9 (8.7%)                   |
| 3                                                         | 15 (10.0%)               | 8 (5.4%)                 | 8 (7.8%)                   |
| 4                                                         | 12 (8.0%)                | 12 (8.1%)                | 8 (7.8%)                   |
| 5                                                         | 10 (6.7%)                | 10 (6.7%)                | 10 (9.7%)                  |
| 6                                                         | 6 (4.0%)                 | 4 (2.7%)                 | 3 (2.9%)                   |
| 7                                                         | 12 (8.0%)                | 4 (2.7%)                 | 6 (5.8%)                   |
| 8                                                         | 4 (2.7%)                 | 5 (3.4%)                 | 3 (2.9%)                   |
| 9                                                         | 5 (3.3%)                 | 11 (7.4%)                | 6 (5.8%)                   |
| 10                                                        | 6 (4.0%)                 | 4 (2.7%)                 | 10 (9.7%)                  |
| 11                                                        | 4 (2.7%)                 | 3 (2.0%)                 | 2 (1.9%)                   |
| 12                                                        | 9 (6.0%)                 | 4 (2.7%)                 | 9 (8.7%)                   |
| 13                                                        | 2 (1.3%)                 | 4 (2.7%)                 | 3 (2.9%)                   |
| 14                                                        | 2 (1.3%)                 | 5 (3.4%)                 | 5 (4.9%)                   |
| 15                                                        | 3 (2.0%)                 | 5 (3.4%)                 | 3 (2.9%)                   |
| 16                                                        | 9 (6.0%)                 | 7 (4.7%)                 | 3 (2.9%)                   |
| 17                                                        | 3 (2.0%)                 | 9 (6.0%)                 | 0                          |
| 18                                                        | 5 (3.3%)                 | 6 (4.0%)                 | 1 (1.0%)                   |
| 19                                                        | 3 (2.0%)                 | 8 (5.4%)                 | 0                          |
| 20                                                        | 4 (2.7%)                 | 6 (4.0%)                 | 0                          |
| 21                                                        | 4 (2.7%)                 | 5 (3.4%)                 | 0                          |
| 22                                                        | 2 (1.3%)                 | 3 (2.0%)                 | 0                          |
| 23                                                        | 4 (2.7%)                 | 6 (4.0%)                 | 0                          |
| 25                                                        | 1 (0.7%)                 | 2 (1.3%)                 | 0                          |
| 26                                                        | 1 (0.7%)                 | 2 (1.3%)                 | 0                          |
| 28                                                        | 2 (1.3%)                 | 0                        | 0                          |
| 29                                                        | 0                        | 2 (1.3%)                 | 0                          |
| 30                                                        | 1 (0.7%)                 | 0                        | 0                          |
| 31                                                        | 0                        | 1 (0.7%)                 | 0                          |
| 32                                                        | Q                        | 1 (0.7%)                 | 0                          |
| 36                                                        | 0                        | 1 (0.7%)                 | 0                          |
| 39                                                        | 0                        | 1 (0.7%)                 | 0                          |
| Mean (SD)                                                 | 9.7 (7.22)               | 12.7 (8.05)              | 7.0 (4.70)                 |
| Median Range                                              | 7.0 (1; 30)              | 12.0 (1; 39)             | 6.0 (1; 18)                |

Key: Pd=pomalidomide -dexamethasone;DPd=daratumumab-pomalidomide -dexamethasone

Note: Percentages are calculated with the number of subjects in each group as denominators.

<div style=\"page-break-after: always\"></div>

Table 22 Total Dose and Relative Dose Intensity; Safety Analysis Set (Studies: MMY3013 and MMY1001 DPd Cohort)

|                                                       | APOLLO            | APOLLO               | EQUULEUS             |
|-------------------------------------------------------|-------------------|----------------------|----------------------|
|                                                       | Pd                | DPd                  | DPd                  |
| Analysis set: safety                                  | 150               | 149                  | 103                  |
| Total daratumumab dose received (mg)                  |                   |                      |                      |
| N                                                     |                   | 149                  | 103                  |
| Mean (SD)                                             |                   | 36520.40 (17133.624) | 17928.84 (11475.380) |
| Median                                                |                   | 36000.00             | 17280.00             |
| Range                                                 |                   | (1800.0; 82936.0)    | (20.3; 63840.0)      |
| Total daratumumab dose received (mg/kg)               |                   |                      |                      |
| N                                                     |                   | 149                  | 103                  |
| Mean (SD)                                             |                   | 474.52 (239.038)     | 223.90 (120.704)     |
| Median                                                |                   | 469.40               | 223.11               |
| Range                                                 |                   | (24.7; 1267.4)       | (0.2; 448.0)         |
| Daratumumab relative dose intensity (%)               |                   |                      |                      |
| N                                                     |                   | 149                  | 103                  |
| Mean (SD)                                             |                   | 88.89 (15.120)       | 90.12 (17.474)       |
| Median                                                |                   | 93.55                | 96.82                |
| Range                                                 |                   | (25.0; 100.0)        | (1.3; 104.8)         |
| Total pomalidomide dose received (mg)                 |                   |                      |                      |
| N                                                     | 150               | 149                  | 97                   |
| Mean (SD)                                             | 722.92 (570.712)  | 773.62 (529.099)     | 451.53 (328.791)     |
| Median                                                | 553.00            | 702.00               | 389.00               |
| Range                                                 | (0.0; 2520.0)     | (16.0; 2532.0)       | (4.0; 1264.0)        |
| Pomalidomide relative dose intensity (%)              |                   |                      |                      |
| N                                                     | 149               | 149                  | 97                   |
| Mean (SD)                                             | 83.71 (19.001)    | 73.73 (21.250)       | 74.69 (21.614)       |
| Median                                                | 91.07             | 74.34                | 77.50                |
| Range                                                 | (4.8; 100.0)      | (19.1; 100.0)        | (5.7; 100.0)         |
| Total dexamethasone equivalents dose received (mg)    |                   |                      |                      |
| N                                                     | 149               | 149                  | 103                  |
| Mean (SD)                                             | 1142.89 (984.968) | 1335.42 (1002.023)   | 752.50 (579.147)     |
| Median                                                | 840.00            | 1160.00              | 680.00               |
| Range                                                 | (40.0; 4800.0)    | (20.0; 6120.0)       | (20.0; 2800.0)       |
| Dexamethasone equivalents relative dose intensity (%) |                   |                      |                      |
| N                                                     | 149               | 149                  | 103                  |
| Mean (SD)                                             | 79.03 (24.935)    | 75.17 (25.331)       | 84.60 (17.891)       |
| Median                                                | 87.50             | 83.33                | 90.00                |
| Range                                                 | (25.0; 200.0)     | (12.5; 187.5)        | (14.3; 106.3)        |

Key: Pd = pomalidomide - dexamethasone; DPd = daratumumab - pomalidomide - dexamethasone.

Note: Dexamethasone equivalents include prednisolone and methylprednisolone.

[TSIEXP02.RTF] [NJ-54767414\\Z\\_SCSDBR\\_MMY\\_RR\\_DPD\\_2020RE\\_MMY\\_RR\\_DPD\\_2020\\PROD\\TSIEXP02.SAS] 17SEP2020, 15:50

## Adverse events

Treatment-emergent Adverse Events are summarised in Table below.

<div style=\"page-break-after: always\"></div>

Table 23: Overall Summary of Treatmentemergent Adverse Events; Safety Analysis Set (Studies: MMY3013 and MMY1001 DPd Cohort)

|                                               | APOLLO(Study MMY3013)   | APOLLO(Study MMY3013)   | EQUULEUS (Study MMY1001)   |
|-----------------------------------------------|-------------------------|-------------------------|----------------------------|
|                                               | pd                      | pda                     | pda                        |
| Analysis set: safety                          | 150                     | 149                     | 103                        |
| Any TEAE                                      | 146 (97.3%)             | 145 (97.3%)             | 103 (100.0%)               |
| At least one relateda                         | 116 (77.3%)             | 135 (90.6%)             | 100 (97.1%)                |
| Atleastonerelatedtopomalidomide               | 108 (72.0%)             | 131 (87.9%)             | 95 (92.2%)                 |
| Atleastonerelatedtodexamethasone              | 76 (50.7%)              | 93 (62.4%)              | 81 (78.6%)                 |
| Atleastonerelatedtodaratumumab                |                         | 87 (58.4%)              | 95 (92.2%)                 |
| Maximum toxicity gradeb                       |                         |                         |                            |
| Grade 1                                       | 4 (2.7%)                | 0                       | 0                          |
| Grade 2                                       | 19 (12.7%)              | 14 (9.4%)               | 1 (1.0%)                   |
| Grade 3                                       | 82 (54.7%)              | 47 (31.5%)              | 40 (38.8%)                 |
| Grade 4                                       | 30 (20.0%)              | 73 (49.0%)              | 55 (53.4%)                 |
| Grade 5                                       | 11 (7.3%)               | 11 (7.4%)               | 7 (6.8%)                   |
| Any serious TEAE                              | 59 (39.3%)              | 75 (50.3%)              | 50 (48.5%)                 |
| At least one relateda                         | 15 (10.0%)              | 40 (26.8%)              | 23 (22.3%)                 |
| At least one related to pomalidomide          | 12 (8.0%)               | 37 (24.8%)              | 18 (17.5%)                 |
| Atleastonerelatedtodexamethasone              | 9 (6.0%)                | 22 (14.8%)              | 16 (15.5%)                 |
| Atleastonerelatedtodaratumumab                |                         | 26 (17.4%)              | 17 (16.5%)                 |
| TEAEleading todiscontinuation of pomalidomide | 4 (2.7%)                | 8 (5.4%)                | 15 (14.6%)                 |
| At least one related topomalidomide           | 0                       | 6 (4.0%)                | 4 (3.9%)                   |
| TEAEleadingtodiscontinuationofdexamethasone   | 5 (3.3%)                | 6 (4.0%)                | 17 (16.5%)                 |
| Atleastonerelatedtodexamethasone              | 1 (0.7%)                | 3 (2.0%)                | 6 (5.8%)                   |
| TEAEleadingtodiscontinuationofdaratumumab     |                         | 4 (2.7%)                | 16 (15.5%)                 |
| Atleastonerelatedtodaratumumab                |                         | 2 (1.3%)                | 3 (2.9%)                   |
| TEAEleadingtodiscontinuationofstudytreatmente | 4 (2.7%)                | 3 (2.0%)                | 13 (12.6%)                 |
| Grade≥3TEAE                                   | 123 (82.0%)             | 131 (87.9%)             | 102 (99.0%)                |

Key:Pd =pomalidomide -dexamethasone; DPd =daratumumab -pomalidomide -dexamethasone.

TEAE = treatment-emergent adverse event; NCI CTCAE =National Cancer Institute Common Terminology Criteria for Adverse Events.

Eachsubjectcouldhavemorethanoneevent,andmultipleoccurrencesofeachevent,butisonlycountedonceforeachrow.

TEAEs are the TEAEs with relationship recorded on the case report form as'definitely related','probably related', and'possibly related'.Iftherelationshiptoastudydrugismissing,theTEAEisconsidereddrug-related aswell.

CTCAE version 4.03

b For each subject and each adverse event, the maximum toxicity grade is selected. Adverse events were graded according to NCI

Includes those subjects indicated as having discontinued treatment due to an adverse event on the end of treatment CRF page. Adverse events are reported using MedDRA version 23.0.

Percentages are calculated with the number of subjects in each group as denominator.

## Common Adverse Events

The most commonly reported TEAEs (≥10% in either treatment group) are presented in Table 21. TEAEs with a frequency ≥10% in either treatment group and that occurred at a ≥5% higher frequency in the DPd group compared with the Pd group included:

- Neutropenia (DPd: 70.5%; Pd: 53.3%),

- Leukopenia (DPd: 26.2%; Pd: 12.0%),

- Upper respiratory tract infection (DPd: 22.8%; Pd: 16.0%),

- Asthenia (DPd: 22.2%; Pd: 16.0%),

- Diarrhea (DPd: 22.2%; Pd: 14.0%),

- Pneumonia (DPd: 20.1%; Pd: 12.7%),

- Pyrexia (DPd: 19.5%; Pd: 14.0%),

- Lymphopenia (DPd: 14.8%; Pd: 8.0%),

- Peripheral edema (DPd: 14.8%; Pd: 7.3%).

<div style=\"page-break-after: always\"></div>

TEAEs with a frequency ≥10% and that occurred at a ≥5% higher frequency in the Pd group compared with the DPd group included anemia (DPd: 36.9%; Pd: 44.0%).

Table 24: Most Common (At Least 10%) Treatment-emergent Adverse Events by System Organ Class and Preferred Term; Safety Analysis Set (Studies: MMY3013 and MMY1001 DPd Cohort)

|                                                               | APOLLO (Study MMY3013)   | APOLLO (Study MMY3013)   | EQUULEUS(Study MMY1001)   |
|---------------------------------------------------------------|--------------------------|--------------------------|---------------------------|
|                                                               | Pd                       | DPd                      | DPd                       |
| Analysis set: safety                                          | 150                      | 149                      | 103                       |
| Number of subjects with any treatment-emergent adverse events | 146 (97.3%)              | 145 (97.3%)              | 103 (100.0%)              |
| MedDRAsystemorganclass/preferredterm                          |                          |                          |                           |
| Bloodandlymphatic system disorders                            | 118 (78.7%)              | 131 (87.9%)              | 91 (88.3%)                |
| Neutropenia                                                   | 80 (53.3%)               | 105 (70.5%)              | 81 (78.6%)                |
| Anaemia                                                       | 66 (44.0%)               | 55 (36.9%)               | 54 (52.4%)                |
| Thrombocytopenia                                              | 50 (33.3%)               | 48 (32.2%)               | 42 (40.8%)                |
| Leukopenia                                                    | 18 (12.0%)               | 39 (26.2%)               | 38 (36.9%)                |
| Lymphopenia                                                   | 12 (8.0%)                | 22 (14.8%)               | 22 (21.4%)                |
| Infections and infestations                                   | 83 (55.3%)               | 105 (70.5%)              | 72 (69.9%)                |
| Upperrespiratory tract infection                              | 24 (16.0%)               | 34 (22.8%)               | 26 (25.2%)                |
| Pneumonia                                                     | 19 (12.7%)               | 30 (20.1%)               | 13 (12.6%)                |
| Lower respiratory tract infection                             | 24 (16.0%)               | 29 (19.5%)               | 0                         |
| Bronchitis                                                    | 18 (12.0%)               | 20 (13.4%)               | 10 (9.7%)                 |
| Sinusitis                                                     | 0                        | 1 (0.7%)                 | 13 (12.6%)                |
| Generaldisordersandadministrationsiteconditions               | 79 (52.7%)               | 98 (65.8%)               | 82 (79.6%)                |
| Fatigue                                                       | 38 (25.3%)               | 38 (25.5%)               | 51 (49.5%)                |
| Asthenia                                                      | 24 (16.0%)               | 33 (22.1%)               | 15 (14.6%)                |
| Pyrexia                                                       | 21 (14.0%)               | 29 (19.5%)               | 26 (25.2%)                |
| Oedema peripheral                                             | 11 (7.3%)                | 22 (14.8%)               | 16 (15.5%)                |
| Non-cardiac chest pain Chills                                 | 5 (3.3%) 0               | 4 (2.7%) 3 (2.0%)        | 15 (14.6%) 21 (20.4%)     |
| Pain                                                          | 3 (2.0%)                 | 2 (1.3%)                 | 11 (10.7%)                |
| Gastrointestinaldisorders                                     | 52 (34.7%)               | 67 (45.0%)               | 81 (78.6%)                |
| Diarrhoea                                                     | 21 (14.0%)               | 33 (22.1%)               | 39 (37.9%)                |
| Constipation                                                  | 22 (14.7%)               | 21 (14.1%)               | 34 (33.0%)                |
| Nausea                                                        | 10 (6.7%)                | 11 (7.4%)                | 31 (30.1%)                |
| Vomiting                                                      | 3 (2.0%)                 | 8 (5.4%)                 | 22 (21.4%)                |
| Musculoskeletalandconnectivetissuedisorders                   | 62 (41.3%)               | 65 (43.6%)               | 74 (71.8%)                |
| Back pain                                                     | 14 (9.3%)                | 15 (10.1%)               | 26 (25.2%)                |
| Bone pain                                                     | 19 (12.7%)               | 14 (9.4%)                | 13 (12.6%)                |
| Muscle spasms                                                 | 7 (4.7%)                 | 12 (8.1%)                | 27 (26.2%)                |
| Pain in extremity                                             | 10 (6.7%)                | 9 (6.0%)                 | 15 (14.6%)                |
| Musculoskeletalchestpain                                      | 4 (2.7%)                 | 8 (5.4%)                 | 13 (12.6%)                |
| Arthralgia                                                    | 4 (2.7%)                 | 6 (4.0%)                 | 23 (22.3%)                |
| Nervous system disorders                                      | 36 (24.0%)               | 47 (31.5%)               | 61 (59.2%)                |
| Tremor                                                        | 13 (8.7%)                | 15 (10.1%)               | 20 (19.4%)                |
| Headache                                                      | 6 (4.0%)                 | 5 (3.4%)                 | 17 (16.5%)                |
| Dizziness                                                     | 6 (4.0%)                 | 3 (2.0%)                 | 22 (21.4%)                |
| Metabolismandnutritiondisorders                               | 42 (28.0%)               | 45 (30.2%)               | 49 (47.6%)                |
| Hyperglycaemia                                                | 19 (12.7%)               | 15 (10.1%)               | 13 (12.6%)                |
| Hypokalaemia                                                  | 7 (4.7%)                 | 12 (8.1%)                | 16 (15.5%)                |
| Decreased appetite                                            | 3 (2.0%)                 | 5 (3.4%)                 | 11 (10.7%)                |
| Respiratory, thoracic and mediastinal disorders               | 36 (24.0%)               | 45 (30.2%)               | 80 (77.7%)                |
| Cough                                                         | 10 (6.7%)                | 17 (11.4%)               | 37 (35.9%)                |
| Dyspnoea                                                      | 11 (7.3%)                | 16 (10.7%)               | 31 (30.1%)                |
| Productive cough                                              | 2 (1.3%)                 | 3 (2.0%)                 | 12 (11.7%)                |
| Nasal congestion                                              | 1 (0.7%)                 | 1 (0.7%)                 | 16 (15.5%)                |
| Psychiatricdisorders                                          | 29 (19.3%)               | 29 (19.5%)               | 47 (45.6%)                |
| Insomnia                                                      | 18 (12.0%)               | 12 (8.1%)                | 24 (23.3%)                |
| Anxiety                                                       | 8 (5.3%)                 | 4 (2.7%) 29 (19.5%)      | 13 (12.6%) 39 (37.9%)     |
| Skinandsubcutaneoustissuedisorders                            | 27 (18.0%)               |                          |                           |
| Pruritus                                                      | 6 (4.0%)                 | 4 (2.7%)                 | 12 (11.7%)                |

Key:Pd=pomalidomide-dexamethasone;DPd=daratumumab-pomalidomide-dexamethasone.

Eachsubjectcould have more than one event.and multipleoccurrencesofeachevent.butisonlycountedonceforeachrow.

TermsarecodedusingMedDRAdictionary,version23.0.

Percentagesare calculatedwith the number of subjects in each groupas denominator.

## Grade 3 or 4 Treatment-emergent Adverse Events

Grade 3 or 4 Treatment-emergent Adverse Events are summarised in Table below.

15:39

<div style=\"page-break-after: always\"></div>

No Grade 3 or 4 TEAEs occurred at a ≥5% higher frequency in the Pd group compared with the DPd group.

Table 25: Most Common (At Least 5%) Grade 3 or 4 Treatment-emergent Adverse Events by System Organ Class and Preferred Term; Safety Analysis Set (Studies: MMY3013 and MMY1001 DPd Cohort)

|                                                                            | APOLLO (Study MMY3013)   | APOLLO (Study MMY3013)   | EQUULEUS (Study MMY1001)   |
|----------------------------------------------------------------------------|--------------------------|--------------------------|----------------------------|
|                                                                            | pd                       | DPd                      | DPd                        |
| Analysis set: safety                                                       | 150                      | 149                      | 103                        |
| Number of subjects with any grade 3 or 4 treatment-emergent adverse events | 123 (82.0%)              | 130 (87.2%)              | 102 (99.0%)                |
| MedDRA system organ class/preferred term                                   |                          |                          |                            |
| Blood and lymphatic system disorders                                       | 97 (64.7%)               | 112 (75.2%)              | 87 (84.5%)                 |
| Neutropenia                                                                | 76 (50.7%)               | 101 (67.8%)              | 79 (76.7%)                 |
| Thrombocytopenia                                                           | 27 (18.0%)               | 26 (17.4%)               | 18 (17.5%)                 |
| Anaemia                                                                    | 32 (21.3%)               | 25 (16.8%)               | 28 (27.2%)                 |
| Leukopenia                                                                 | 7 (4.7%)                 | 25 (16.8%)               | 25 (24.3%)                 |
| Lymphopenia                                                                | 5 (3.3%)                 | 18 (12.1%)               | 14 (13.6%)                 |
| Febrile neutropenia                                                        | 4 (2.7%)                 | 13 (8.7%)                | 7 (6.8%)                   |
| Infections and infestations                                                | 34 (22.7%)               | 42 (28.2%)               | 29 (28.2%)                 |
| Pneumonia                                                                  | 10 (6.7%)                | 20 (13.4%)               | 9 (8.7%)                   |
| Lower respiratory tract infection                                          | 14 (9.3%)                | 17 (11.4%)               | 0                          |
| General disorders and administration site conditions                       | 10 (6.7%)                | 20 (13.4%)               | 15 (14.6%)                 |
| Fatigue                                                                    | 7 (4.7%)                 | 12 (8.1%)                | 10 (9.7%)                  |
| Asthenia                                                                   | 1 (0.7%)                 | 8 (5.4%)                 | 0                          |
| Metabolism and nutrition disorders                                         | 13 (8.7%)                | 20 (13.4%)               | 16 (15.5%)                 |
| Hyperglycaemia                                                             | 7 (4.7%)                 | 8 (5.4%)                 | 6 (5.8%)                   |
| Gastrointestinal disorders                                                 | 6 (4.0%)                 | 10 (6.7%)                | 8 (7.8%)                   |
| Diarrhoea                                                                  | 1 (0.7%)                 | 8 (5.4%)                 | 3 (2.9%)                   |
| Respiratory, thoracic and mediastinal disorders                            | 5 (3.3%)                 | 9 (6.0%)                 | 19 (18.4%)                 |
| Dyspnoea                                                                   | 1 (0.7%)                 | 4 (2.7%)                 | 7 (6.8%)                   |
| Musculoskeletal and connective tissue disorders                            | 6 (4.0%)                 | 2 (1.3%)                 | 18 (17.5%)                 |
| Back pain                                                                  | 1 (0.7%)                 | 0                        | 6 (5.8%)                   |
| Injury, poisoning and procedural complications                             | 5 (3.3%)                 | 1 (0.7%)                 | 10 (9.7%)                  |
| Fall                                                                       | 0                        | 0                        | 6 (5.8%)                   |

Key: Pd = pomalidomide - dexamethasone; DPd = daratumumab - pomalidomide - dexamethasone.

Each subject could have more than one event, and multiple occurrences of each event, but is only counted once for each row.

Terms are coded using MedDRA dictionary, version 23.0.

Percentages are calculated with the number of subjects in each group as denominator.

Treatment-emergent Adverse Events by Baseline ECOG Performance Status are presented in Table below

Table 26: Overview of Treatmentemergent Adverse Events by Baseline ECOG Performance Status; Safety Analysis Set (Study 54767414MMY3013)

|                        | Pd      | Pd      | Pd      | Pd      | DPd     | DPd     | DPd      | DPd     |
|------------------------|---------|---------|---------|---------|---------|---------|----------|---------|
|                        | 0       | 1       | 2       | Total   | 0       | 1       | 2        | Total   |
|                        | n (%)   | n (%)   | n (%)   | n (%)   | n (%)   | n (%)   | n (%)    | n (%)   |
| Analysis set: safety   | 75      | 56      | 19      | 150     | 91      | 52      | 6        | 149     |
| Any TEAE               | 74      | 54      | 18      | 146     | 88      | 51      | 6        | 145     |
|                        | (98.7%) | (96.4%) | (94.7%) | (97.3%) | (96.7%) | (98.1%) | (100.0%) | (97.3%) |
| At least one related a | 63      | 40      | 13      | 116     | 85      | 45      | 5        | 135     |
|                        | (84.0%) | (71.4%) | (68.4%) | (77.3%) | (93.4%) | (86.5%) | (83.3%)  | (90.6%) |

<div style=\"page-break-after: always\"></div>

Table 26: Overview of Treatmentemergent Adverse Events by Baseline ECOG Performance Status; Safety Analysis Set (Study 54767414MMY3013)

|                                                 | Pd         | Pd         | Pd         | Pd                 | DPd                 | DPd                 | DPd               | DPd               |
|-------------------------------------------------|------------|------------|------------|--------------------|---------------------|---------------------|-------------------|-------------------|
|                                                 | 0 n (%)    | 1 n (%)    | 2 n (%)    | Total n (%)        | 0 n (%) 81          | 1 n (%) 45          | 2 n (%) 5         | Total n (%) 131   |
| At least one related to pomalidomide            | 59 (78.7%) | 37 (66.1%) | 12 (63.2%) | 108 (72.0%)        | (89.0%)             | (86.5%)             | (83.3%)           | (87.9%)           |
| At least one related to dexamethasone           | 46 (61.3%) | 24 (42.9%) | 6 (31.6%)  | 76 (50.7%)         | 56 (61.5%)          | 35 (67.3%)          | 2 (33.3%)         | 93 (62.4%)        |
| At least one related to daratumumab             |            |            |            |                    | 60 (65.9%)          | 24 (46.2%)          | 3 (50.0%)         | 87 (58.4%)        |
| Maximum toxicity grade b                        |            |            |            |                    |                     |                     |                   |                   |
| Grade 1                                         | 2 (2.7%)   | 1 (1.8%)   | 1 (5.3%)   | 4 (2.7%)           | 0                   | 0                   | 0                 | 0                 |
| Grade 2                                         | 11 (14.7%) | 6 (10.7%)  | 2 (10.5%)  | 19                 |                     |                     |                   | 14                |
| Grade 3                                         | 45 (60.0%) | 33 (58.9%) | 4 (21.1%)  | (12.7%) 82 (54.7%) | 9 (9.9%) 30 (33.0%) | 5 (9.6%) 16 (30.8%) | 0 1 (16.7%)       | (9.4%) 47 (31.5%) |
| Grade 4                                         | 13 (17.3%) | 10         | 7 (36.8%)  | 30 (20.0%)         | 43 (47.3%)          | 26                  | 4 (66.7%)         | 73 (49.0%)        |
| Grade 5                                         |            | (17.9%)    | 4          | 11                 |                     | (50.0%)             | 1                 | 11                |
|                                                 | 3 (4.0%)   | 4 (7.1%)   | (21.1%)    | (7.3%)             | 6 (6.6%)            | 4 (7.7%)            | (16.7%)           | (7.4%)            |
| Any serious TEAE                                | 19 (25.3%) | 29 (51.8%) | 11 (57.9%) | 59 (39.3%)         | 38 (41.8%)          | 33 (63.5%)          | 4 (66.7%)         | 75 (50.3%)        |
| At least one related a                          | 6 (8.0%)   | 5 (8.9%)   | 4 (21.1%)  | 15 (10.0%)         | 23 (25.3%)          | 15 (28.8%)          | 2 (33.3%)         | 40 (26.8%)        |
| At least one related to pomalidomide            | 5 (6.7%)   | 4 (7.1%)   | 3 (15.8%)  | 12 (8.0%)          | 21 (23.1%)          | 14 (26.9%)          | 2 (33.3%)         | 37 (24.8%)        |
| At least one related to dexamethasone           |            |            | 2          |                    | 13 (14.3%)          | 8                   | 1                 | 22 (14.8%)        |
| At least one related to daratumumab             | 4 (5.3%)   | 3 (5.4%)   | (10.5%)    | 9 (6.0%)           | 17 (18.7%)          | (15.4%) 8 (15.4%)   | (16.7%) 1 (16.7%) | 26 (17.4%)        |
|                                                 |            |            |            |                    |                     |                     | 1                 |                   |
| TEAE leading to discontinuation of pomalidomide | 0          | 1 (1.8%)   | 3 (15.8%)  | 4 (2.7%)           | 3 (3.3%)            | 4 (7.7%)            | (16.7%) 1         | 8 (5.4%)          |
| At least one related to pomalidomide            | 0          | 0          | 0          | 0                  | 1 (1.1%)            | 4 (7.7%)            | (16.7%)           | 6 (4.0%)          |
| TEAE leading to discontinuation of              |            |            | 3          |                    |                     |                     | 1                 |                   |
| dexamethasone                                   | 1 (1.3%)   | 1 (1.8%)   | (15.8%)    | 5 (3.3%)           | 4 (4.4%)            | 1 (1.9%)            | (16.7%) 1         | 6 (4.0%)          |
| At least one related to dexamethasone           | 1 (1.3%)   | 0          | 0          | 1 (0.7%)           | 1 (1.1%)            | 1 (1.9%)            | (16.7%)           | 3 (2.0%)          |
| TEAE leading to discontinuation of              |            |            |            |                    |                     |                     |                   |                   |
| daratumumab                                     |            |            |            |                    | 2 (2.2%)            | 2 (3.8%)            | 0                 | 4 (2.7%)          |
| At least one related to daratumumab             |            |            |            |                    | 0                   | 2 (3.8%)            | 0                 | 2 (1.3%)          |
| TEAE leading to discontinuation of study c      |            |            |            |                    |                     |                     |                   |                   |
| treatment                                       | 0          | 1 (1.8%)   | 3 (15.8%)  | 4 (2.7%)           | 2 (2.2%)            |                     |                   | 3 (2.0%)          |
| Grade ≥3 TEAE                                   | 61 (81.3%) | 47 (83.9%) | 15         |                    | 79                  | 1 (1.9%) 46         | 0 6               | 131 (87.9%)       |
| COVID-19 related TEAE                           | 0          | 0          | (78.9%) 0  | 123 (82.0%) 0      | (86.8%) 1 (1.1%)    | (88.5%) 1 (1.9%)    | (100.0%) 0        | 2 (1.3%)          |
| COVID-19 related serious TEAE                   | 0          | 0          | 0          | 0                  | 1 (1.1%)            | 1 (1.9%)            | 0                 | 2 (1.3%)          |
| COVID-19 related non-serious TEAE               | 0          | 0          | 0          | 0                  | 0                   | 0                   | 0                 | 0                 |
| COVID- 19 related Grade ≥ 3 TEAE                | 0          | 0          | 0          | 0                  | 1 (1.1%)            | 1 (1.9%)            | 0                 | 2 (1.3%)          |

<div style=\"page-break-after: always\"></div>

Table 26: Overview of Treatmentemergent Adverse Events by Baseline ECOG Performance Status; Safety Analysis Set (Study 54767414MMY3013)

| Pd    | Pd    | Pd    | Pd    | DPd   | DPd   | DPd   | DPd       |
|-------|-------|-------|-------|-------|-------|-------|-----------|
| 0     | 1     | 2     | Total | 0     | 1     | 2     | Total (%) |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n         |

Key: Pd = pomalidomide - dexamethasone; DPd = daratumumab - pomalidomide - dexamethasone; SC = subcutaneous.

TEAE = treatment-emergent adverse event; NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse Events. \"DPd\" includes all subjects who received daratumumab, regardless of the route of administration, with pomalidomide and dexamethasone.

Each subject could have more than one event, and multiple occurrences of each event, but is only counted once for each row a. TEAEs related to at least 1 of the 3 study treatments: pomalidomide, dexamethasone or daratumumab. Study treatment-related TEAEs are the TEAEs with relationship recorded on the case report form as \"definitely related\", \"probably related\", and \"possibly related\". If the relationship to a study treatment is missing, the TEAE is considered treatment-related as well

b. For each subject and each adverse event, the maximum toxicity grade is selected. Adverse events were graded according to NCI CTCAE version 4.03.

c. Includes those subjects indicated as having discontinued treatment due to an adverse event on the End of Treatment case report form. Adverse events are reported using MedDRA version 23.0.

Percentages are calculated with the number of subjects in each group as denominator

## Adverse drug reactions (ADRs)

In Study MMY3013, the most frequently reported (≥20%) daratumumab -related TEAE as assessed by the investigator was neutropenia (28.9%). The most frequently reported pomalidomide-related TEAEs were neutropenia (DPd: 65.1%; Pd: 48.7%), thrombocytopenia (DPd: 22.8%; Pd: 22.0%), and leukopenia (DPd: 22.2%; Pd: 9.3%).

Most common ADRs with at least 5% greater incidence in the DPd Arm are summarised in Table 23.

Table 27: Adverse Reactions Reported in at Least 10% of Subjects in the DPd Arm With at Least 5% Greater Incidence in the DPd Arm; Safety Analysis Set (Study 54767414MMY3013)

|                                                        | Pd         | Pd         | Pd       | Pd       | DPd        | DPd        | DPd      | DPd      |
|--------------------------------------------------------|------------|------------|----------|----------|------------|------------|----------|----------|
|                                                        | Any Grade  | Grade 3    | Grade 4  | Grade 5  | Any Grade  | Grade 3    | Grade 4  | Grade 5  |
| Analysis set: safety                                   | 150        |            |          |          | 149        |            |          |          |
| General disorders and administration site conditions   |            |            |          |          |            |            |          |          |
| Fatiguea                                               | 58 (38.7%) | 8 (5.3%)   | 0        | 0        | 68 (45.6%) | 19 (12.8%) | 1 (0.7%) | 0        |
| Pyrexia                                                | 21 (14.0%) | 0          | 0        | 0        | 29 (19.5%) | 0          | 0        | 0        |
| Oedema peripheralb                                     | 14 (9.3%)  | 0          | 0        | 0        | 22 (14.8%) | 0          | 0        | 0        |
| Infections and infestations                            |            |            |          |          |            |            |          |          |
| Pneumoniac                                             | 41 (27.3%) | 18 (12.0%) | 3 (2.0%) | 4 (2.7%) | 56 (37.6%) | 25 (16.8%) | 5 (3.4%) | 4 (2.7%) |
| Upper respiratory tract infectiond                     | 33 (22.0%) | 3 (2.0%)   | 0        | 0        | 54 (36.2%) | 1 (0.7%)   | 0        | 0        |
| Gastrointestinaldisorders                              |            |            |          |          |            |            |          |          |
| Diarrhoea                                              | 21 (14.0%) | 1 (0.7%)   | 0        | 0        | 33 (22.1%) | 8 (5.4%)   | 0        | 0        |
| Respiratory, thoracic and mediastinal disorders Coughe | 12 (8.0%)  | 0          | 0        | 0        | 19 (12.8%) | 0          | 0        | 0        |

Key:Pd=pomalidomide-dexamethasone;DPd=daratumumab-pomalidomide-dexamethasone.

aFatigue includes asthenia,andfatigue.

cPneumonia includes atypical pneumonia, lower respiratory tract infection, pneumonia, pneumonia aspiration, pneumonia bacterial, and pneumonia respiratory syncytial viral.

bOedema peripheral includes oedema, oedema peripheral, and peripheral swelling.

dUpper respiratory tract infection includes nasopharyngitis, pharyngitis, respiratory syncytial virus infection, respiratory tract infection, respiratory tract infection viral, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, and viral upper respiratory tract infection.

eCough includes cough, and productive cough.

Note:Denominatorisbased on thenumber of subjects inthesafety analysisset.AsADR determinationhas beenbased onroundingto the nearest whole number,some preferred terms may appear between 9.5% -&lt;10% in this table where rounding is based on one decimal place. Adverse events are reported using MedDRAVersion 23.0.

A review of Study MMY3013 identified the new ADR term of syncope which now meets the pre-defined ADR threshold (reported in ≥ 10% of subjects and occurred at a higher incidence ( ≥ 5% difference) in the DPd treatment group as compared with the Pd).

The incidence of syncope was higher in the DPd group compared to the Pd group (DPd: 6.7%; Pd: 0.7%) . All cases were Grade 2 or Grade 3, and all recovered. Syncope was reported as a serious TEAE in only the DPd group (2.0%) (Table 27). These cases were confounded by medical history, including cardiac disorders and/or dehydration/procedures contributing to the events of syncope. However, daratumumab contribution to these events could not be excluded.

<div style=\"page-break-after: always\"></div>

Table 28: Treatment-emergent Serious Adverse Events That Have ≥ 2% Higher Incidence in DPd Than Pd; Safety Analysis Set (Study MMY3013)

|                                          | APOLLO   | APOLLO   |
|------------------------------------------|----------|----------|
|                                          | Pd       | DPd      |
| Analysis set: safety                     | 150      | 149      |
| MedDRA system organ class/prefeired term |          |          |
| Infections and infestations              |          |          |
| Pneumoniaa                               | 26 (17%) | 39 (26%) |
| Blood and lymphatic system disorders     |          |          |
| Neutropeniab                             | 4 (3%)   | 7 (5%)   |
| Thrombocytopeniac                        | 1 (1%)   | 4 (3%)   |
| Gastrointestinal disorders               |          |          |
| Syncope                                  | 0        | 3 (2%)   |

Key: Pd = pomalidomide - dexamethasone; DPd = daratumumab - pomalidomide - dexamethasone

aIncludes Atypical pneumonia, Lower respiratory tract infection, Pneumonia, Pneumonia aspiration, Pneumonia bacterial,

Pneumonia respiratory syncytial viral

cIncludes Thrombocytopenia

bIncludes Febrile neutropenia, Neutropenia

Adverse events are reported usingMedDRA version 23.0.

Percentages are calculated with N as the denominator, the number of safety subjects in each treatment arm.

[TSFAE40A.RTF][JNJ-54767414\\Z SCS\\DBR MMY RR DPD 2020\\RE MMY RR DPD 2020\\PROD\\TSFAE40A.SAS]

140CT2020,12:49

## Serious adverse event/deaths/other significant events

The incidence of serious TEAEs was higher for subjects in the DPd group compared to the Pd group in Study MMY3013 (DPd: 50.3%, Pd: 39.3%; Table 28).

Table 29: Most Common (At Least 2%) Treatment-emergent Serious Adverse Events by System Organ Class and Preferred Term; Safety Analysis Set (Studies: MMY3013 and MMY 1001 DPd Cohort)

|                                                                       | APOLLO (Study MMY3013)   | APOLLO (Study MMY3013)   | EQUULEUS (Study MMY1001)   |
|-----------------------------------------------------------------------|--------------------------|--------------------------|----------------------------|
|                                                                       | pd                       | DPd                      | pda                        |
| Analysis set: safety                                                  | 150                      | 149                      | 103                        |
| Number of subjects with any treatment-emergent serious adverse events | 59 (39.3%)               | 75 (50.3%)               | 50 (48.5%)                 |
| MedDRA system organ class/preferred term                              |                          |                          |                            |
| Infections and infestations                                           | 37 (24.7%)               | 49 (32.9%)               | 21 (20.4%)                 |
| Pneumonia                                                             | 12 (8.0%)                | 23 (15.4%)               | 8 (7.8%)                   |
| Lower respiratory tract infection                                     | 14 (9.3%)                | 18 (12.1%)               | 0                          |
| Upper respiratory tract infection                                     | 3 (2.0%)                 | 3 (2.0%)                 | 1 (1.0%)                   |
| Bronchitis                                                            | 5 (3.3%)                 | 1 (0.7%)                 | 0                          |
| Sepsis                                                                | 0                        | 1 (0.7%)                 | 4 (3.9%)                   |
| Blood and lymphatic system disorders                                  | 4 (2.7%)                 | 9 (6.0%)                 | 8 (7.8%)                   |
| Febrile neutropenia                                                   | 3 (2.0%)                 | 5 (3.4%)                 | 4 (3.9%)                   |
| Thrombocytopenia                                                      | 1 (0.7%)                 | 4 (2.7%)                 | 2 (1.9%)                   |
| Anaemia                                                               | 1 (0.7%)                 | 1 (0.7%)                 | 3 (2.9%)                   |
| Respiratory, thoracic and mediastinal disorders                       | 4 (2.7%)                 | 8 (5.4%)                 | 11 (10.7%)                 |
| Dyspnoea                                                              | 1 (0.7%)                 | 3 (2.0%)                 | 3 (2.9%)                   |
| Gastrointestinaldisorders                                             | 5 (3.3%)                 | 7 (4.7%)                 | 5 (4.9%)                   |
| Diarrhoea                                                             | 1 (0.7%)                 | 3 (2.0%)                 | 1 (1.0%)                   |
| Generaldisordersandadministrationsiteconditions                       | 4 (2.7%)                 | 5 (3.4%)                 | 4 (3.9%)                   |
| Pyrexia                                                               | 1 (0.7%)                 | 3 (2.0%)                 | 0                          |
| Generalphysicalhealthdeterioration                                    | 3 (2.0%)                 | 1 (0.7%)                 | 2 (1.9%)                   |
| Nervous system disorders                                              | 3 (2.0%)                 | 5 (3.4%)                 | 5 (4.9%)                   |
| Syncope                                                               | 0                        | 3 (2.0%)                 | 1 (1.0%)                   |
| Injury, poisoning and procedural complications                        | 3 (2.0%)                 | 1 (0.7%)                 | 7 (6.8%)                   |
| Fall                                                                  | 1 (0.7%)                 | 0                        | 4 (3.9%)                   |

Key:Pd=pomalidomide-dexamethasone;DPd=daratumumab-pomalidomide -dexamethasone.

Eachsubjectcouldhavemorethanoneevent, and multipleoccurrences ofeachevent,butisonlycountedonceforeachrow.

Terms are coded using MedDRA dictionary, version 23.0.

Percentagesarecalculatedwiththenumberofsubjectsineachgroupasdenominator.

[TSFAE05A.RTF][JNJ-54767414\\ZSCS\\DBRMMYRRDPD2020\\REMMYRRDPD2020PROD\\TSFAE05A.SAS]17SEP2020,

15:42

Deaths and Cause of Death and Treatment-emergent Adverse Events with Outcome Death by Preferred Term and Relationship are summarised in Tables 27 and 28 respectively.

<div style=\"page-break-after: always\"></div>

Table 30 : Deaths and Cause of Death; Safety An alysis Set (Studies: MMY3013 and MMY1001 DPd Cohort)

|                                                                           | APOLLO (Study MMY3013)   | APOLLO (Study MMY3013)   | EQUULEUS (Study MMY1001)   |
|---------------------------------------------------------------------------|--------------------------|--------------------------|----------------------------|
|                                                                           | pd                       | DPd                      | DPd                        |
| Analysis set: safety                                                      | 150                      | 149                      | 103                        |
| Total number of subjects who died during the study                        | 51 (34.0%)               | 47 (31.5%)               | 28 (27.2%)                 |
| Primary cause of death                                                    |                          |                          |                            |
| Adverse event                                                             | 12 (8.0%)                | 14 (9.4%)                | 8 (7.8%)                   |
| At least one relateda                                                     | 0                        | 4 (2.7%)                 | 1 (1.0%)                   |
| Unrelated                                                                 | 12 (8.0%)                | 10 (6.7%)                | 7 (6.8%)                   |
| Disease progression                                                       | 30 (20.0%)               | 26 (17.4%)               | 19 (18.4%)                 |
| Other                                                                     | 9 (6.0%)                 | 7 (4.7%)                 | 1 (1.0%)                   |
| Total number of subjects who died within 30 days of last study treatment  | 15 (10.0%)               | 16 (10.7%)               | 7 (6.8%)                   |
| Primary cause of death                                                    |                          |                          |                            |
| Adverse event                                                             | 12 (8.0%)                | 11 (7.4%)                | 5 (4.9%)                   |
| At least one relateda                                                     | 0                        | 4 (2.7%)                 | 1 (1.0%)                   |
| Unrelated                                                                 | 12 (8.0%)                | 7 (4.7%)                 | 4 (3.9%)                   |
| Disease progression                                                       | 3 (2.0%)                 | 5 (3.4%)                 | 2 (1.9%)                   |
| Total number of subjects who died within 60 days of first study treatment | 9 (6.0%)                 | 4 (2.7%)                 | 7 (6.8%)                   |
| Primary cause of death                                                    |                          |                          |                            |
| Adverse event                                                             | 6 (4.0%)                 | 3 (2.0%)                 | 5 (4.9%)                   |
| At least one relateda                                                     | 0                        | 2 (1.3%)                 | 1 (1.0%)                   |
| Unrelated                                                                 | 6 (4.0%)                 | 1 (0.7%)                 | 4 (3.9%)                   |
| Disease progression                                                       | 3 (2.0%)                 | 1 (0.7%)                 | 2 (1.9%)                   |

Key: Pd = pomalidomide - dexamethasone; DPd = daratumumab - pomalidomide - dexamethasone.

Study drug-related adverse events are the adverse events with relationship recorded on the case report form as \"definitely related\", \"probably related\", and \"possibly related\". If the relationship to a study drug is missing, the adverse event is considered drug-related as well.

Percentages are calculated with the number of subjects in each group as denominator.

a Includes adverse events that were related to at least 1 of the 3 study treatments: pomalidomide, dexamethasone, or

15:46

<div style=\"page-break-after: always\"></div>

Table 31: Treatment-emergent Adverse Events with Outcome Death by Preferred Term and Relationship; Safety Analysis Set (Studies: MMY3013 and MMY1001 DPd Cohort)

|                                                    | APOLLO (Study MMY3013)   | APOLLO (Study MMY3013)   | APOLLO (Study MMY3013)   | APOLLO (Study MMY3013)   | APOLLO (Study MMY3013)   | APOLLO (Study MMY3013)   | APOLLO (Study MMY3013)               | EQUULEUS (Study MMY1001)   | EQUULEUS (Study MMY1001)     | EQUULEUS (Study MMY1001)   | EQUULEUS (Study MMY1001)   |
|----------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------------------|----------------------------|------------------------------|----------------------------|----------------------------|
|                                                    |                          | pd Pomalido mide         | RelatedtoRelatedto       |                          | pda                      | pda                      | pda                                  | Pda                        | Pda                          | Pda                        | Pda                        |
|                                                    |                          |                          | Dexameth asone           |                          | Daratumu mab             | Pomalido mide            | RelatedtoRelatedtoRelatedto Dexameth | Total                      | Related toRelatedto Daratumu | Pomalido                   | Relatedto Dexameth asone   |
|                                                    | Total                    |                          |                          | Total                    |                          |                          |                                      |                            |                              |                            |                            |
|                                                    |                          |                          |                          |                          |                          |                          | asone                                |                            | mab                          | mide                       |                            |
| Analysis set: safety                               | 150                      |                          |                          | 149                      |                          |                          |                                      | 103                        |                              |                            |                            |
| Number of subjects with any                        |                          |                          |                          |                          |                          |                          |                                      |                            |                              |                            |                            |
| treatment-emergentadverseevents with outcome death | 11 (7.3%)                | 0                        | 0                        | 11 (7.4%)                | 3 (2.0%)                 | 4 (2.7%)                 | 3 (2.0%)                             | 7 (6.8%)                   | 0                            | 0                          | 1 (1.0%)                   |
| MedDRApreferredterm                                |                          |                          |                          |                          |                          |                          |                                      |                            |                              |                            |                            |
| Pneumonia                                          | 2 (1.3%)                 | 0                        | 0                        | 3 (2.0%)                 | 1 (0.7%)                 | 1 (0.7%)                 | 1 (0.7%)                             | 0                          | 0                            | 0                          | 0                          |
| Bone marrowfailure                                 | 0                        | 0                        | 0                        | 1 (0.7%)                 | 1 (0.7%)                 | 1 (0.7%)                 | 0                                    | 0                          | 0                            | 0                          | 0                          |
| COVID-19                                           | 0                        | 0                        | 0                        | 1 (0.7%)                 | 0                        | 0                        | 0                                    | 0                          | 0                            | 0                          | 0                          |
| Campylobacterinfection                             | 0                        | 0                        | 0                        | 1 (0.7%)                 | 1 (0.7%)                 | 1 (0.7%)                 | 0                                    | 0                          | 0                            | 0                          | 0                          |
| Dyspnoea                                           | 0                        | 0                        | 0                        | 1 (0.7%)                 | 0                        | 0                        | 0                                    | 0                          | 0                            | 0                          | 0                          |
| Liver disorder                                     | 0                        | 0                        | 0                        | 1 (0.7%)                 | 1 (0.7%)                 | 1 (0.7%)                 | 0                                    | 0                          | 0                            | 0                          | 0                          |
| Lowerrespiratorytractinfection                     | 1 (0.7%)                 | 0                        | 0                        | 1 (0.7%)                 | 0                        | 0                        | 0                                    | 0                          | 0                            | 0                          | 0                          |
| Respiratoryfailure                                 | 0                        | 0                        | 0                        | 1 (0.7%)                 | 0                        | 0                        | 0                                    | 1 (1.0%)                   | 0                            | 0                          | 0                          |
| Sepsis                                             | 0                        | 0                        | 0                        | 1 (0.7%)                 | 1 (0.7%)                 | 1 (0.7%)                 | 1 (0.7%)                             | 1 (1.0%)                   | 0                            | 0                          | 0                          |
| Septic shock                                       | 2 (1.3%)                 | 0                        | 0                        | 1 (0.7%)                 | 0                        | 1 (0.7%)                 | 1 (0.7%)                             | 0                          | 0                            | 0                          | 0                          |
| Sudden death                                       | 0                        | 0                        | 0                        | 1 (0.7%)                 | 0                        | 0                        | 0                                    | 0                          | 0                            | 0                          | 0                          |
| Systemic candida                                   | 0                        | 0                        | 0                        | 1 (0.7%)                 | 0                        | 0                        | 0                                    | 0                          | 0                            | 0                          | 0                          |
| Acutemyocardialinfarction                          | 1 (0.7%)                 | 0                        | 0                        | 0                        | 0                        | 0                        | 0                                    | 0                          | 0                            | 0                          | 0                          |
| Cerebralhaemorrhage                                | 1 (0.7%)                 | 0                        | 0                        | 0                        | 0                        | 0                        | 0                                    | 0                          | 0                            | 0                          | 0                          |
| Cerebrovascularaccident                            | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 0                                    | 1 (1.0%)                   | 0                            | 0                          | 0                          |
| General physical health                            |                          |                          |                          |                          |                          |                          |                                      |                            |                              |                            |                            |
| deterioration                                      | 2 (1.3%)                 | 0                        | 0                        | 0                        | 0                        | 0                        | 0                                    | 1 (1.0%)                   | 0                            | 0                          | 0                          |
| Hypertensivehydrocephalus                          | 1 (0.7%)                 | 0                        | 0                        | 0                        | 0                        | 0                        | 0                                    | 0                          | 0                            | 0                          | 0                          |
| Interstitial lung disease                          | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 0                                    | 1 (1.0%)                   | 0                            | 0                          | 0                          |
| Pleural effusion                                   | 0                        | 0                        | 0                        | 0                        | 0                        | 0                        | 0                                    | 1 (1.0%)                   | 0                            | 0                          | 0                          |
| Pneumonia aspiration                               | 1 (0.7%)                 | 0                        | 0                        | 0                        | 0                        | 0                        | 0                                    | 0                          | 0                            | 0                          | 0                          |
|                                                    | 0                        |                          | 0                        |                          | 0                        | 0                        |                                      |                            |                              | 0                          |                            |
| Progressive multifocal leukoencephalopathy         |                          | 0                        |                          | 0                        |                          |                          | 0                                    | 1 (1.0%)                   | 0                            |                            | 1 (1.0%)                   |

Key:Pd=pomalidomide-dexamethasone;DPd=daratumumab-pomalidomide-dexamethasone.

Each subject could have more than one event, and multiple occurrences of each event, but is only counted once for each row.

TEAEswithoutcomedeathareTEAEswith'fatal'recordedasoutcomeontheAdverseEventcasereportform.

Terms are coded using MedDRA dictionary,version 23.0.

Percentages arecalculatedwiththenumber of subjectsineachgroupasdenominator.

## Other significant adverse events

## Infusion-related Reactions (IRR)

IRRs were defined as systemic reactions related to daratumumab administration, regardless of the route of administration. IRRs were recorded by the investigator in the eCRF.

In  Study  MMY3013,  7  of  149  subjects  received  daratumumab  IV  administration  prior  to  Protocol Amendment 1. IRRs were reported for 5.4% of subjects in the DPd group, with pyrexia as the most common preferred term reported by subjects (2.0%). None of the 7 subjects starting treatment with daratumumab IV experienced IRRs. All IRRs reported occurred in subjects treated with daratumumab SC only. All IRRs reported were Grade 1 or 2, and none resulted in discontinuation or interruption of treatment.

## Injection-site reactions (ISR)

Localized  reactions  at  the  site  of  administration  of  daratumumab  SC  were  referred  to  as  injection-site reactions.

Injection-site reactions were reported for 3 subjects (2.0%) in the DPd group. The following preferred terms were experienced as Grade 1 for 1 subject each: erythema, rash, and contusion. None of these resulted in discontinuation or interruption of treatment.

## Cytopenia AEs

The  addition  of  daratumumab  to  Pd  in  Study  MMY3013  resulted  in  higher  incidences  of  neutropenia, lymphopenia, and febrile neutropenia compared to subjects receiving Pd alone. Overall, the incidence of cytopenia-related events was higher in the DPd group (84.6%) compared to the Pd group (78.0%).

<div style=\"page-break-after: always\"></div>

Table 32: Summary of Treatment-emergent Cytopenia Events by Preferred Term; Safety Analysis Set (Study 54767414MMY3013)

|                                                                 | pd n (%)    | pda n (%)   | DPd-SC n (%)   |
|-----------------------------------------------------------------|-------------|-------------|----------------|
| Analysis set: safety                                            | 150         | 149         | 142            |
| Number of subjects with any treatment-emergent cytopenia events | 117 (78.00) | 126 (84.56) | 119 (83.80)    |
| MedDRA Preferred term                                           |             |             |                |
| Neutropeniaa                                                    | 80 (53.33)  | 109 (73.15) | 104 (73.24)    |
| Neutropenia                                                     | 80 (53.33)  | 105 (70.47) | 101 (71.13)    |
| Febrile neutropenia                                             | 4 (2.67)    | 13 (8.72)   | 12 (8.45)      |
| Anaemia                                                         | 67 (44.67)  | 55 (36.91)  | 53 (37.32)     |
| Anaemia                                                         | 66 (44.00)  | 55 (36.91)  | 53 (37.32)     |
| Anaemia macrocytic                                              | 1 (0.67)    | 0           | 0              |
| Iron deficiency anaemia                                         | 1 (0.67)    | 0           | 0              |
| Thrombocytopeniaa                                               | 50 (33.33)  | 48 (32.21)  | 47 (33.10)     |
| Thrombocytopenia                                                | 50 (33.33)  | 48 (32.21)  | 47 (33.10)     |
| Lymphopeniaa                                                    | 12 (8.00)   | 22 (14.77)  | 19 (13.38)     |
| Lymphopenia                                                     | 12 (8.00)   | 22 (14.77)  | 19 (13.38)     |

Key:Pd =pomalidomide -dexamethasone; DPd =daratumumab -pomalidomide - dexamethasone; SC =subcutaneous.

TEAE =Treatment-emergent adverse event.

'DPd'includes all subjects who received daratumumab, regardless ofthe route of administration, with pomalidomide and dexamethasone.

a. Preferred term grouping.

Each subject could have more than one event, and multiple occurrences of each event, but is only counted once for each row.

Terms are coded using MedDRA dictionary, version 23.0.

Percentages are calculated with the number of subjects in each group as denominator.

Filename: T14.03.01-06.26.RTF / Program: T14.03.01-ByCatPt.sas (05OCT2020 21:13)

## Haemorrhagic Events

The incidence of haemorrhagic events was balanced between the treatment groups in Study MMY3013 (DPd: 4.0%; Pd: 6.0%), and the majority of events were Grade 1 or 2. One subject in the DPd group (anal haemorrhage) and 2 subjects in the Pd group (gastrointestinal haemorrhage and epistaxis) experienced Grade 3 events and one subject in the Pd group experienced a Grade 5 event (cerebral haemorrhage) resulting in death.

Two subjects (1.3%) in the DPd group and 2 subjects in the Pd group (1.3%) in Study MMY3013 received fresh frozen plasma transfusions.

The incidence of haemorrhagic events was higher (25.2%) in Study MMY1001 compared to Study MMY3013.

## Infections and infestations

Subjects in the DPd group had a higher incidence of any grade TEAE of infection (DPd: 70.5%; Pd: 55.3%; Table 24). Grade 3 or 4 TEAEs of infections were reported in 28.2% of subjects in the DPd group and 22.7% of  subjects  in  the  Pd  group  (Table  25 ).  The  most  common  (≥5%)  Grade  3  or  4  infections  included pneumonia (DPd: 13.4%; Pd: 6.7%) and lower respiratory tract infection (DPd: 11.4%; Pd: 9.3%).

## Second primary malignancies (SPM)

The rate of SPMs was balanced in both treatment groups in Study MMY3013 (DPd: 2.0%; Pd: 2.0%). A haematologic  SPM  was  reported  for  1  subject  in  the  Pd  group  (acute  myeloid  leukemia).  No  single malignancy predominated.

No SPMs were reported in Study MMY1001.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Haematology

Consistent  with  the  incidence  of  treatment-emergent  cytopenia  events  in  Study  MMY3013,  Grade  4 haematology values of low WBC (DPd: 21.6%; Pd: 4.0%), low platelets (DPd: 10.1%; Pd: 6.7%), low neutrophils (DPd: 48.0%; Pd: 20.1%), and low lymphocytes (DPd: 15.5%; Pd: 3.4%) were reported at higher incidences in subjects from the DPd group compared with the Pd group. Grade 3 haematology values of low haemoglobin were reported for 16.2% of subjects in the DPd group and 20.1% of subjects in the Pd group. There were no Grade 4 haematology values of low hemoglobin in either treatment group.

All laboratory parameters in Study MMY3013 were reviewed. No laboratory parameters had an incidence of Grade  3  or  4  values  ≥10%  except  for  haematology  parameters.  Thrombocytopenia,  neutropenia, lymphopenia, leukopenia, and anemia were listed in a separate haematology laboratory table based on haematology laboratory parameters regardless of the incidence and difference between groups (Table 32).

In Study MMY1001, the most common Grade 3 or 4 haematology laboratory abnormalities were neutrophils low (82.4%) and lymphocytes low (72.5%). Grade 3 or 4 platelets low was reported by 19.6% of subjects. Grade 3 hemoglobin low was reported for 32.4% of subjects. No Grade 4 hemoglobin low was reported.

## Clinical chemistry

The incidence of treatment-emergent Grade 3 or 4 chemistry laboratory abnormalities in Study MMY3013 was low (&lt;5%) in both treatment groups with the exception of Grade 3 low potassium (DPd: 5.4%; Pd: 3.4%).

Table 33: Treatmentemergent Haematology Lab Abnormalities; Safety Analysis Set (Studies: MMY3013 and MMY1001 DPd Cohort)

|                      |             | APOLLO(StudyMMY3013)   | APOLLO(StudyMMY3013)   | APOLLO(StudyMMY3013)   | APOLLO(StudyMMY3013)   |            | EQUULEUS(StudyMMY1001)   | EQUULEUS(StudyMMY1001)   | EQUULEUS(StudyMMY1001)   |
|----------------------|-------------|------------------------|------------------------|------------------------|------------------------|------------|--------------------------|--------------------------|--------------------------|
|                      | AllGrades   | pd Grade 3             | Grade 4                | AllGrades              | Pda Grade 3            | Grade 4    | AllGrades                | DPd Grade 3              | Grade 4                  |
| Analysis set: safety | 150         |                        |                        | 149                    |                        |            | 103                      |                          |                          |
| Anemia               | 85 (56.7%)  | 22 (14.7%)             | 0                      | 76 (51.0%)             | 23 (15.4%)             | 0          | 59 (57.3%)               | 31 (30.1%)               | 0                        |
| Thrombocytopenia     | 89 (59.3%)  | 21 (14.0%)             | 8 (5.3%)               | 111 (74.5%)            | 13 (8.7%)              | 15 (10.1%) | 77 (74.8%)               | 10 (9.7%)                | 10 (9.7%)                |
| Leukopenia           | 122 (81.3%) | 53 (35.3%)             | 6 (4.0%)               | 141 (94.6%)            | 63 (42.3%)             | 32 (21.5%) | 99 (96.1%)               | 47 (45.6%)               | 20 (19.4%)               |
| Neutropenia          | 125 (83.3%) | 64 (42.7%)             | 30 (20.0%)             | 143 (96.0%)            | 54 (36.2%)             | 71 (47.7%) | 98 (95.1%)               | 37 (35.9%)               | 47 (45.6%)               |
| Lymphopenia          | 117 (78.0%) | 44 (29.3%)             | 5 (3.3%)               | 137 (91.9%)            | 66 (44.3%)             | 22 (14.8%) | 97 (94.2%)               | 46 (44.7%)               | 27 (26.2%)               |

Key:Pd=pomalidomide-dexamethasone;DPd=daratumumab-pomalidomide-dexamethasone.

NCICTCAE=NationalCancerInstituteCommonTerminologyCriteriaforAdverseEvents.

Note:ThelaboratorytoxicitygradesarederivedbasedonNCICTCAEversion4.03.

Foreachparameter,thepercentageofsubjectsrepresentsthosesubjectsforwhomthetoxicitygradeworsenedduringtreatment comparedtobaseline;percentages arecalculatedwith the numberofsafetysubjectsineachtreatmentarm.

Foreachsubjectandeachparameter,theworsttoxicitygradeisselected

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Age

Table 34: Overview of Treatmentemergent Adverse Events by Age; Safety An alysis Set (Study 54767414MMY3013)

| T14.03.01-06.02:Overview of Treatment-emergent AdverseEvents by Age;Safety AnalysisSet(Study54767414MIMY3013)   | T14.03.01-06.02:Overview of Treatment-emergent AdverseEvents by Age;Safety AnalysisSet(Study54767414MIMY3013)   | T14.03.01-06.02:Overview of Treatment-emergent AdverseEvents by Age;Safety AnalysisSet(Study54767414MIMY3013)   | T14.03.01-06.02:Overview of Treatment-emergent AdverseEvents by Age;Safety AnalysisSet(Study54767414MIMY3013)   | T14.03.01-06.02:Overview of Treatment-emergent AdverseEvents by Age;Safety AnalysisSet(Study54767414MIMY3013)   | T14.03.01-06.02:Overview of Treatment-emergent AdverseEvents by Age;Safety AnalysisSet(Study54767414MIMY3013)   | T14.03.01-06.02:Overview of Treatment-emergent AdverseEvents by Age;Safety AnalysisSet(Study54767414MIMY3013)   | T14.03.01-06.02:Overview of Treatment-emergent AdverseEvents by Age;Safety AnalysisSet(Study54767414MIMY3013)   | T14.03.01-06.02:Overview of Treatment-emergent AdverseEvents by Age;Safety AnalysisSet(Study54767414MIMY3013)   | T14.03.01-06.02:Overview of Treatment-emergent AdverseEvents by Age;Safety AnalysisSet(Study54767414MIMY3013)   |
|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
|                                                                                                                 |                                                                                                                 |                                                                                                                 |                                                                                                                 | DPd                                                                                                             | DPd                                                                                                             | DPd                                                                                                             | DPd-SC                                                                                                          | DPd-SC                                                                                                          | DPd-SC                                                                                                          |
|                                                                                                                 | <65 years n(%)                                                                                                  | Pd ≥65 years n (%)                                                                                              | Total n (%)                                                                                                     | <65years n (%)                                                                                                  | ≥65 years n (%)                                                                                                 | Total n (%)                                                                                                     | <65years n (%)                                                                                                  | ≥65years n (%)                                                                                                  | Total n (%)                                                                                                     |
| Analysis set: safety                                                                                            | 58                                                                                                              | 92                                                                                                              | 150                                                                                                             | 61                                                                                                              | 88                                                                                                              | 149                                                                                                             | 56                                                                                                              | 86                                                                                                              | 142                                                                                                             |
| Any TEAE                                                                                                        | 57 (98.28)                                                                                                      | 89 (96.74)                                                                                                      | 146 (97.33)                                                                                                     | 57 (93.44)                                                                                                      | 88 (100.00)                                                                                                     | 145 (97.32)                                                                                                     | 52 (92.86)                                                                                                      | 86 (100.00)                                                                                                     | 138 (97.18)                                                                                                     |
| At least one related                                                                                            | 41 (70.69)                                                                                                      | 75 (81.52)                                                                                                      | 116 (77.33)                                                                                                     | 50 (81.97)                                                                                                      | 85 (96.59)                                                                                                      | 135 (90.60)                                                                                                     | 47 (83.93)                                                                                                      | 83 (96.51)                                                                                                      | 130 (91.55)                                                                                                     |
| At least onerelatedtopomalidomide                                                                               | 36 (62.07)                                                                                                      | 72 (78.26)                                                                                                      | 108 (72.00)                                                                                                     | 47 (77.05)                                                                                                      | 84 (95.45)                                                                                                      | 131 (87.92)                                                                                                     | 45 (80.36)                                                                                                      | 82 (95.35)                                                                                                      | 127 (89.44)                                                                                                     |
| Atleastonerelatedtodexamethasone Atleastonerelated todaratumumab                                                | 28 (48.28)                                                                                                      | 48 (52.17)                                                                                                      | 76 (50.67)                                                                                                      | 32 (52.46) 37 (60.66)                                                                                           | 61 (69.32) 50 (56.82)                                                                                           | 93 (62.42) 87 (58.39)                                                                                           | 29 (51.79) 37 (66.07)                                                                                           | 59 (68.60) 49 (56.98)                                                                                           | 88 (61.97) 86 (60.56)                                                                                           |
| Maximum toxicity gradeb                                                                                         |                                                                                                                 |                                                                                                                 |                                                                                                                 |                                                                                                                 |                                                                                                                 |                                                                                                                 |                                                                                                                 |                                                                                                                 |                                                                                                                 |
| Grade 1                                                                                                         | 3 (5.17)                                                                                                        | 1 (1.09)                                                                                                        | 4 (2.67)                                                                                                        | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               |
| Grade 2                                                                                                         | 8 (13.79)                                                                                                       | 11 (11.96)                                                                                                      | 19 (12.67)                                                                                                      | 5 (8.20)                                                                                                        | 9 (10.23)                                                                                                       | 14 (9.40)                                                                                                       | 5 (8.93)                                                                                                        | 9 (10.47)                                                                                                       | 14 (9.86)                                                                                                       |
| Grade 3                                                                                                         | 32 (55.17)                                                                                                      | 50 (54.35)                                                                                                      | 82 (54.67)                                                                                                      | 19 (31.15)                                                                                                      | 28 (31.82)                                                                                                      | 47 (31.54)                                                                                                      | 16 (28.57)                                                                                                      | 27 (31.40)                                                                                                      | 43 (30.28)                                                                                                      |
| Grade 4                                                                                                         | 11 (18.97)                                                                                                      | 19 (20.65)                                                                                                      | 30 (20.00)                                                                                                      | 28 (45.90)                                                                                                      | 45 (51.14)                                                                                                      | 73 (48.99)                                                                                                      | 28 (50.00)                                                                                                      | 44 (51.16)                                                                                                      | 72 (50.70)                                                                                                      |
| Grade5                                                                                                          | 3 (5.17)                                                                                                        | 8 (8.70)                                                                                                        | 11 (7.33)                                                                                                       | 5 (8.20)                                                                                                        | 6(6.82)                                                                                                         | 11 (7.38)                                                                                                       | 3 (5.36)                                                                                                        | 6(6.98)                                                                                                         | 9 (6.34)                                                                                                        |
| Any serious TEAE                                                                                                | 19 (32.76)                                                                                                      | 40 (43.48)                                                                                                      | 59 (39.33)                                                                                                      | 25 (40.98)                                                                                                      | 50 (56.82)                                                                                                      | 75 (50.34)                                                                                                      | 23 (41.07)                                                                                                      | 49 (56.98)                                                                                                      | 72 (50.70)                                                                                                      |
| At least one related                                                                                            | 2 (3.45)                                                                                                        | 13 (14.13)                                                                                                      | 15 (10.00)                                                                                                      | 14 (22.95)                                                                                                      | 26 (29.55)                                                                                                      | 40 (26.85)                                                                                                      | 13 (23.21)                                                                                                      | 26 (30.23)                                                                                                      | 39 (27.46)                                                                                                      |
| Atleastonerelatedtopomalidomide                                                                                 | 2 (3.45)                                                                                                        | 10 (10.87)                                                                                                      | 12 (8.00)                                                                                                       | 12 (19.67)                                                                                                      | 25 (28.41)                                                                                                      | 37 (24.83)                                                                                                      | 11 (19.64)                                                                                                      | 25 (29.07)                                                                                                      | 36 (25.35)                                                                                                      |
| At least one related to dexamethasone                                                                           | 1 (1.72)                                                                                                        | 8 (8.70)                                                                                                        | 9 (6.00)                                                                                                        | 6 (9.84)                                                                                                        | 16 (18.18)                                                                                                      | 22 (14.77)                                                                                                      | 5 (8.93)                                                                                                        | 16 (18.60)                                                                                                      | 21 (14.79)                                                                                                      |
| At leastonerelated todaratumumab TEAE leading todiscontinuation of                                              | 1 (1.72)                                                                                                        | 3 (3.26)                                                                                                        | 4 (2.67)                                                                                                        | 9 (14.75) 1 (1.64)                                                                                              | 17 (19.32) 7 (7.95)                                                                                             | 26 (17.45) 8 (5.37)                                                                                             | 9 (16.07) 1 (1.79)                                                                                              | 17 (19.77) 7 (8.14)                                                                                             | 26 (18.31) 8 (5.63)                                                                                             |
| pomalidomide At leastonerelatedtopomalidomide                                                                   | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 1 (1.64)                                                                                                        | 5 (5.68)                                                                                                        | 6 (4.03)                                                                                                        | 1 (1.79)                                                                                                        | 5 (5.81)                                                                                                        | 6 (4.23)                                                                                                        |
| TEAE leading todiscontinuation of dexamethasone                                                                 | 1 (1.72)                                                                                                        | 4 (4.35)                                                                                                        | 5 (3.33)                                                                                                        | 1 (1.64)                                                                                                        | 5 (5.68)                                                                                                        | 6 (4.03)                                                                                                        | 1 (1.79)                                                                                                        | 5 (5.81)                                                                                                        | 6 (4.23)                                                                                                        |
| Atleast onerelated todexamethasone                                                                              | 0                                                                                                               | 1 (1.09)                                                                                                        | 1 (0.67)                                                                                                        | 1 (1.64)                                                                                                        | 2 (2.27)                                                                                                        | 3 (2.01)                                                                                                        | 1 (1.79)                                                                                                        | 2 (2.33)                                                                                                        | 3 (2.11)                                                                                                        |
| TEAEleadingtodiscontinuationof daratumumab                                                                      |                                                                                                                 |                                                                                                                 |                                                                                                                 | 1 (1.64)                                                                                                        | 3 (3.41)                                                                                                        | 4 (2.68)                                                                                                        | 1(1.79)                                                                                                         | 3 (3.49)                                                                                                        | 4 (2.82)                                                                                                        |
| Atleast onerelated todaratumumab                                                                                |                                                                                                                 |                                                                                                                 |                                                                                                                 | 1 (1.64)                                                                                                        | 1(1.14)                                                                                                         | 2 (1.34)                                                                                                        | 1(1.79)                                                                                                         | 1 (1.16)                                                                                                        | 2 (1.41)                                                                                                        |
| TEAEleadingtodiscontinuationofstudy treatment                                                                   | 1 (1.72)                                                                                                        | 3 (3.26)                                                                                                        | 4 (2.67)                                                                                                        | 0                                                                                                               | 3 (3.41)                                                                                                        | 3 (2.01)                                                                                                        | 0                                                                                                               | 3 (3.49)                                                                                                        | 3 (2.11)                                                                                                        |
| Grade ≥3 TEAE                                                                                                   | 46 (79.31)                                                                                                      | 77 (83.70)                                                                                                      | 123 (82.00)                                                                                                     | 52 (85.25)                                                                                                      | 79 (89.77)                                                                                                      | 131 (87.92)                                                                                                     | 47 (83.93)                                                                                                      | 77 (89.53)                                                                                                      | 124 (87.32)                                                                                                     |
| COVID-19relatedTEAE                                                                                             | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 2 (2.27)                                                                                                        | 2 (1.34)                                                                                                        | 0                                                                                                               | 2 (2.33)                                                                                                        | 2 (1.41)                                                                                                        |
| COVID-19relatedseriousTEAE                                                                                      | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 2 (2.27)                                                                                                        | 2 (1.34)                                                                                                        | 0                                                                                                               | 2 (2.33)                                                                                                        | 2 (1.41)                                                                                                        |
| COVID-19relatednon-seriousTEAE                                                                                  | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               |
| COVID-19relatedGrade≥3TEAE                                                                                      | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 0                                                                                                               | 2 (2.27)                                                                                                        | 2 (1.34)                                                                                                        | 0                                                                                                               | 2 (2.33)                                                                                                        | 2 (1.41)                                                                                                        |

Key:Pd=pomalidomide-dexamethasone;DPd=daratumumab-pomalidomide-dexamethasone;SC=subcutaneous.

TEAE=treatment-emergent adverseevent;NCICTCAE=NationalCancerInstituteCommonTerminologyCriteriaforAdverseEvents.

DPd'includesall subjectswhoreceiveddaratumumab,regardlessoftherouteof administration,withpomalidomide anddexamethasone.

a.TEAEsrelatedtoatleast1ofthe3study treatments:pomalidomide,dexamethasone ordaratumumab.Study treatment-relatedTEAEs are theTEAEswithrelationshiprecordedonthecasereport form as'definitelyrelated，probablyrelated，andpossiblyrelatedIftherelationshiptoastudy treatment ismissing.theTEAEis consideredtreatment-relatedaswell.

Eachsubject could havemore than one event,andmultipleoccurrences ofeach event,butisonlycountedoncefor eachrow b.For each subject and each adverse event,themaximum toxicity gradeis selected.Adverse eventswere graded according toNCI CTCAEversion4.03.

Adverse events arereported usingMedDRAversion 23.0.

c.Includes those subjects indicated as having discontinued treatment due to an adverse event on the End ofTreatment casereport fom.

Percentagesarecalculatedwith thenumber of subjectsineachgroupasdenominator.

Filename:T14.03.01-06.02.RTF /Program: T14.03.01-SumAE\\_subgr.sas (050CT2020 21:20)

<div style=\"page-break-after: always\"></div>

Table 35: Treatmentemergent Serious Adverse Events by System Organ Class, Preferred Term and Age; Safety Analysis Set (Studies: MMY3013 and MMY1001 DPd Cohort - 1 st  part of table)

TSFAE05C:Treatment-emergent SeriousAdverseEventsbySystem Organ Class,Preferred Term andAge;SafetyAnalysisSet(Studies: MMY3013 and MMY1001DPd Cohort)

|                                                      | APOLLO       | APOLLO          | APOLLO     | APOLLO       | APOLLO           | APOLLO     | EQUULEUS     | EQUULEUS         | EQUULEUS   |
|------------------------------------------------------|--------------|-----------------|------------|--------------|------------------|------------|--------------|------------------|------------|
| Analysis set: safety                                 | <65 years 58 | pd ≥65 years 92 | Total 150  | <65 years 61 | pda ≥65 years 88 | Total 149  | <65 years 52 | pda ≥65 years 51 | Total 103  |
| Number of subjectswith any treatment-emergentserious |              |                 |            |              |                  |            |              |                  |            |
| adverseevents                                        | 19 (32.8%)   | 40 (43.5%)      | 59 (39.3%) | 25 (41.0%)   | 50 (56.8%)       | 75 (50.3%) | 25 (48.1%)   | 25 (49.0%)       | 50 (48.5%) |
| MedDRAsystem organ class/preferredterm               |              |                 |            |              |                  |            |              |                  |            |
| Infections and infestations                          | 15 (25.9%)   | 22 (23.9%)      | 37 (24.7%) | 16 (26.2%)   | 33 (37.5%)       | 49 (32.9%) | 9 (17.3%)    | 12 (23.5%)       | 21 (20.4%) |
| Pneumonia                                            | 7 (12.1%)    | 5 (5.4%)        | 12 (8.0%)  | 9 (14.8%)    | 14 (15.9%)       | 23 (15.4%) | 3 (5.8%)     | 5 (9.8%)         | 8 (7.8%)   |
| Lower respiratory tract infection                    | 7 (12.1%)    | 7 (7.6%)        | 14 (9.3%)  | 5 (8.2%)     | 13 (14.8%)       | 18 (12.1%) | 0            | 0                | 0          |
| Upper respiratory tract infection                    | 0            | 3 (3.3%)        | 3 (2.0%)   | 0            | 3 (3.4%)         | 3 (2.0%)   | 0            | 1 (2.0%)         | 1 (1.0%)   |
| COVID-19                                             | 0            | 0               | 0          | 0            | 2 (2.3%)         | 2 (1.3%)   | 0            | 0                | 0          |
| Influenza                                            | 0            | 0               | 0          | 1 (1.6%)     | 1 (1.1%)         | 2 (1.3%)   | 0            | 1 (2.0%)         | 1 (1.0%)   |
| Urinarytractinfection                                | 0            | 0               | 0          | 0            | 2 (2.3%)         | 2 (1.3%)   | 0            | 1 (2.0%)         | 1 (1.0%)   |
| Atypicalpneumonia                                    | 0            | 1 (1.1%)        | 1 (0.7%)   | 0            | 1 (1.1%)         | 1 (0.7%)   | 0            | 0                | 0          |
| Bronchitis                                           | 1 (1.7%)     | 4 (4.3%)        | 5 (3.3%)   | 0            | 1 (1.1%)         | 1 (0.7%)   | 0            | 0                | 0          |
| Campylobacterinfection                               | 0            | 0               | 0          | 0            | 1 (1.1%)         | 1 (0.7%)   | 0            | 0                | 0          |

## Safety related to drug-drug interactions and other interactions

See the Pharmacokinetics section (4.3.2).

## Discontinuation and dose modifications due to adverse events

## Adverse Events leading to dose modifications of Daratumumab

TEAEs leading to daratumumab cycle delays or dose skipping were reported in 57.1% of subjects in the DPd group. The most commonly reported (≥5%) TEAEs leading to daratumumab cycle delays or dose skipping included:

- Neutropenia (32.2%),
- Thrombocytopenia (10.7%),
- Lower respiratory tract infection (10.7%),
- Pneumonia (8.7%),
- Upper respiratory tract infection (8.1%).

## Adverse Events leading to dose modifications of Pomalidomide

TEAEs leading to pomalidomide cycle delays or dose modifications occurred more frequently in the DPd group (76.5%) compared with the Pd group (56.7%). The most commonly reported (≥5% in either treatment group) TEAEs leading to pomalidomide cycle delays or dose modifications included:

- Neutropenia (DPd: 46.3%; Pd: 23.3%),
- Thrombocytopenia (DPd: 12.1%; Pd: 6.7%),
- Pneumonia (DPd: 12.8%; Pd: 5.3%),
- Lower respiratory tract infection (DPd: 10.1%; Pd: 10.0%),
- Fatigue (DPd: 8.7%; Pd: 5.3%),
- Upper respiratory tract infection (DPd: 7.4%; Pd: 6.0%),
- Febrile neutropenia (DPd: 7.4%; Pd: 1.3%),
- Pyrexia (DPd: 6.7%; Pd: 4.7%;),
- Leukopenia (DPd: 6.0%; Pd: 0%),

<div style=\"page-break-after: always\"></div>

- Diarrhoea (DPd: 5.4%; Pd: 0.7%)

## Adverse Events leading to dose modifications of Dexamethasone

TEAEs leading to dexamethasone cycle delays or dose modifications were reported for 69.8% in the DPd group and 57.3% of subjects in the Pd group. The most commonly reported (≥5% in either treatment group) TEAEs leading to dexamethasone cycle delays or dose modifications included:

- Neutropenia (DPd: 26.9%; Pd: 6.0%),
- Pneumonia (DPd: 12.1%; Pd: 7.3%),
- Lower respiratory tract infection (DPd: 10.1%; Pd: 11.3%),
- Upper respiratory tract infection (DPd: 9.4%; Pd: 6.0%),
- Thrombocytopenia (DPd: 7.4%; Pd: 4.0%),
- Bronchitis (DPd: 7.4%; Pd: 4.0%),
- Insomnia (DPd: 5.4%; Pd: 7.3%),
- Hyperglycaemia (DPd: 4.7%; Pd: 5.3%).
- Febrile neutropenia (DPd: 4.7%; Pd: 2.0%)

## Adverse Events leading to discontinuation

<div style=\"page-break-after: always\"></div>

Table 36: Treatment-emergent Adverse Events Leading to Treatment Discontinuation by System Organ Class, Preferred Term and Grade 3 or 4; Saf ety Analysis Set (Studies: MMY3013 and MMY1001 DPd Cohort)

|                                                                                            | APOLLO(Study MMY3013)   | APOLLO(Study MMY3013)   | APOLLO(Study MMY3013)   | APOLLO(Study MMY3013)   | EQUULEUS(Study MMY1001) DPd   | EQUULEUS(Study MMY1001) DPd   |
|--------------------------------------------------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-------------------------------|-------------------------------|
| Analysis set: safety                                                                       | Pd Grade3or4            | All Grades 150          | DPd Grade3or4           | All Grades 149          | Grade3or4                     | All Grades 103                |
| Numberofsubjectswith anytreatment-emergent adverseeventsleadingtotreatment discontinuation |                         |                         |                         |                         |                               |                               |
|                                                                                            | 4 (2.7%)                | 5 (3.3%)                | 8 (5.4%)                | 11 (7.4%)               | 12 (11.7%)                    | 18 (17.5%)                    |
| MedDRAsystemorganclass/preferred term                                                      |                         |                         |                         |                         |                               |                               |
| Blood and lymphatic system disorders                                                       | 1 (0.7%)                | 1 (0.7%)                | 3 (2.0%)                | 3 (2.0%)                | 1 (1.0%)                      | 1 (1.0%)                      |
| Neutropenia                                                                                | 1 (0.7%)                | 1 (0.7%)                | 2 (1.3%)                | 2 (1.3%)                | 0                             | 0                             |
| Thrombocytopenia                                                                           | 0                       | 0                       | 1 (0.7%)                | 1 (0.7%)                | 1 (1.0%)                      | 1 (1.0%)                      |
| Infections andinfestations                                                                 | 0                       | 0                       | 2 (1.3%)                | 3 (2.0%)                | 4 (3.9%)                      | 5 (4.9%)                      |
| COVID-19                                                                                   | 0                       | 0                       | 1 (0.7%)                | 1 (0.7%)                | 0                             | 0                             |
| Lower respiratory tract infection                                                          | 0                       | 0                       | 0                       | 1 (0.7%)                | 0                             | 0                             |
| Meningoencephalitisbacterial                                                               | 0                       | 0                       | 1 (0.7%)                | 1 (0.7%)                | 0                             | 0                             |
| Mastitis                                                                                   | 0                       | 0                       | 0                       | 0                       | 1 (1.0%)                      | 1 (1.0%)                      |
| Pneumonia                                                                                  | 0                       | 0                       | 0                       | 0                       | 1 (1.0%)                      | 1 (1.0%)                      |
| Progressivemultifocal leukoencephalopathy                                                  | 0                       | 0                       | 0                       | 0                       | 1 (1.0%)                      | 1 (1.0%)                      |
| Sepsis                                                                                     | 0                       | 0                       | 0                       | 0                       | 0                             | 1 (1.0%)                      |
| Urinary tract infection                                                                    | 0                       | 0                       | 0                       | 0                       | 1 (1.0%)                      | 1 (1.0%)                      |
| Gastrointestinaldisorders                                                                  | 0                       | 0                       | 0                       | 1 (0.7%)                | 0                             | 0                             |
| Diahoea                                                                                    | 0                       | 0                       | 0                       | 1 (0.7%)                | 0                             | 0                             |
| Musculoskeletalandconnectivetissuedisorders                                                | 0                       | 0                       | 0                       | 1 (0.7%)                | 1 (1.0%)                      | 1 (1.0%)                      |
| Muscle atrophy                                                                             | 0                       | 0                       | 0                       | 1 (0.7%)                | 0                             | 0                             |
| Muscular weakness                                                                          | 0                       | 0                       | 0                       | 0                       | 1 (1.0%)                      | 1 (1.0%)                      |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)                        | 1 (0.7%)                | 1 (0.7%)                | 1 (0.7%)                | 1 (0.7%)                | 0                             | 0                             |
| Cholangiocarcinoma                                                                         | 0                       | 0                       | 1 (0.7%)                | 1 (0.7%)                | 0                             | 0                             |
| Adenocarcinoma ofcolon                                                                     | 1 (0.7%)                | 1 (0.7%)                | 0                       | 0                       | 0                             | 0                             |
| Nervous system disorders                                                                   | 0                       | 0                       | 1 (0.7%)                | 1 (0.7%) 1 (0.7%)       | 0                             | 2 (1.9%)                      |
| Peripheral sensory neuropathy                                                              | 0                       | 0                       | 1 (0.7%)                |                         | 0                             | 0                             |
| Cerebrovascularaccident                                                                    | 0                       | 0                       | 0                       | 0                       | 0                             | 1 (1.0%)                      |
| Tremor                                                                                     | 0                       | 0                       | 0                       | 0                       | 0                             | 1 (1.0%)                      |
| Psychiatric disorders                                                                      | 0                       | 0                       | 0                       | 1 (0.7%)                | 0                             | 1 (1.0%)                      |
| Mood altered                                                                               | 0                       | 0                       | 0                       | 1 (0.7%)                | 0                             | 0                             |
| Depression                                                                                 | 0                       | 0                       | 0                       | 0                       | 0                             | 1 (1.0%)                      |
| Renaland urinary disorders                                                                 | 0                       | 1 (0.7%)                | 1 (0.7%)                | 1 (0.7%)                | 0                             | 0                             |
| Acute kidney injury                                                                        | 0                       | 1 (0.7%)                | 1 (0.7%)                | 1 (0.7%)                | 0                             | 0                             |
| Cardiac disorders                                                                          | 2 (1.3%)                | 2 (1.3%)                | 0                       | 0                       | 1 (1.0%)                      | 2 (1.9%)                      |
| Angina pectoris                                                                            | 0                       | 0                       | 0                       | 0                       | 0                             | 1 (1.0%)                      |
| Atrial fibrillation                                                                        | 0                       | 0                       | 0                       | 0                       | 1 (1.0%)                      | 1 (1.0%)                      |
| Cardiacfailure                                                                             | 1 (0.7%)                | 1 (0.7%)                | 0                       | 0                       | 0                             | 0                             |
| Cardiacfailure congestive                                                                  | 0                       | 0                       | 0                       | 0                       | 1 (1.0%)                      | 1 (1.0%)                      |
| Palpitations                                                                               | 1 (0.7%)                | 1 (0.7%)                | 0                       | 0                       | 0                             | 0                             |
| Respiratory,thoracic andmediastinaldisorders                                               | 0                       | 0                       | 0                       | 0                       | 4 (3.9%)                      | 5 (4.9%)                      |
| Dyspnoea                                                                                   | 0                       | 0                       | 0                       | 0                       | 1 (1.0%)                      | 1 (1.0%)                      |
| Hypoxia                                                                                    | 0                       | 0                       | 0                       | 0                       | 1 (1.0%)                      | 1 (1.0%)                      |
| Interstitial lung disease Pleural effusion                                                 | 0                       | 0                       | 0                       |                         | 1 (1.0%)                      | 1 (1.0%)                      |
|                                                                                            | 0                       | 0                       | 0                       | 0                       | 1 (1.0%)                      | 1 (1.0%)                      |
|                                                                                            |                         |                         |                         | 0                       |                               | 1 (1.0%)                      |
| Respiratory failure Vascular disorders                                                     | 0 0                     | 0 0                     | 0 0                     | 0 0                     | 0 1 (1.0%)                    | 1 (1.0%)                      |
| Aortic dissection                                                                          | 0                       | 0                       | 0                       | 0                       | 1 (1.0%)                      | 1 (1.0%)                      |

Key:Pd=pomalidomide-dexamethasone;DPd=daratumumab-pomalidomide-dexamethasone.

Each subject couldhave more thanone event,andmultiple occurrencesof each event,butis onlycounted onceforeachrow.

NCI CTCAE=National CancerInstituteCommonTerminologyCriteriaforAdverseEvents.

TEAEsleading todiscontinuation of at leastone of the study treatment components are theTEAEswith'drugwithdrawn'recorded as action takenontheAdverseEvent casereport form. Adverse events weregraded according toNCI CTCAEversion4.03.

Percentages are calculatedwith the numberof subjectsin each groupas denominator.

Terms are coded using MedDRA dictionary,version 23.0.

## Post marketing experience

Daratumumab SC has only recently been authorized for use in the US, EU and other countries worldwide.

Postmarketing  safety  information  is  available  for  daratumumab  IV  and  from  a  commercially  available rHuPH20 formulation, Hylenex.

A cumulative review was performed on all post-marketing spontaneous cases of daratumumab IV and all events received by the Global Medical Safety (GMS) global safety database cumulatively through 31 March 2020. The results suggest that the drug's post-marketing safety profile is consistent with the known safety profile of daratumumab as a single agent or in combination therapy.

Overall, review of post-marketing spontaneous reports did not identify any new safety signal.

<div style=\"page-break-after: always\"></div>

rHuPH20 is the active ingredient of Halozyme's commercial product Hylenex recombinant (hyaluronidase human injection), hereafter referred to as HYLENEX, which was approved in December 2005 by FDA for marketing  in  the  U.S.  HYLENEX  is  a  tissue  permeability  modifier  indicated  as  an  adjuvant  in  SC  fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs, and in SC urography, for improving resorption of radiopaque agents (HYLENEX PI 2016).

The MAH has provided information about post-marketing experience for SC daratumumab up to 31 January 2021. There is limited information since SC formulation was approved in the US and EU in May and June 2020,  respectively.  The  estimated  exposure  to  SC  daratumumab  is  7,413  person-years  and  to  IV daratumumab is 112,010 person-years. From the global safety database, 7,257 events have been further analysed but including both IV and SC formulations. The most commonly reported PTs for overall AEs and AEs with a fatal outcome were generally in line with the widely reported in all daratumumab studies. Frome these 7,257 events, 160 reported SC administration of daratumumab but no relevant differences have been observed in reported PTs for them and the overall safety population. No new safety signals have been identified  from  this  updated  safety  data  which  seems  to  confirm  the  similar  safety  profile  of  the  SC formulation, with the exception of those related to the administration route

## 2.5.1. Discussion on clinical safety

The safety profile of daratumumab, in combination with pomalidomide and dexamethasone, for patients with relapsed or refractory multiple myeloma who have received, at least, one prior line of therapy with both lenalidomide and a proteasome inhibitor (PI), is based on the results from the open-label Phase 3 Study  MMY3013,  APOLLO  study.  Supportive  data  from  the  cohort  of  subjects  who  received  the  same treatment combination in the Phase 1b Study MMY1001 have been provided. In this previous study, patients had received at least 2 prior lines of therapy.

The  adverse  event  profile  of  daratumumab  with  Pd  was  consistent  with  the  known  safety  profiles  of daratumumab and Pd regimens alone. Syncope was added as a new ADR: As an SAE this occurred in 2% in the DPd arm and 0 in the Pd arm and overall 6.7% and 0.7%, respectively. Syncope Grade 3 occurred in 4% (there were no grade 4).

The most clinically important adverse events (all grades, preferred terms) more frequently reported in the DPd arm compared to the Pd arm in study 3013 were neutropenia (70.5% vs 53.3%), diarrhoea (22.1% vs 14.0%), and pneumonia (20.1% vs 12.7%), see Table 24.

Focusing on maximum toxicity grade, 87.9% of subjects in the DPd group reported any Grade ≥ 3 TEAE while this figure was 82% in the Pd treatment group. Higher differences between both groups were found in neutropenia (67.8% DPd vs 50.7% Pd), leukopenia (16.8% vs 4.7%), pneumonia (13.4% vs 6.7%), lymphopenia (12.1% vs 3.3%) and febrile neutropenia (8.7% vs 2.7%). As previously observed with other daratumumab combinations, differences were mostly driven by haematological AEs.

The incidence of SAEs was higher in the DPd group (50.3%) compared to the Pd group (39.3%). The most common preferred terms were: Pneumonia (DPd: 15.4%, Pd: 8.0%) and Lower respiratory tract infection (DPd: 12.1%, Pd: 9.3%).

Cytopenias and infections are well-known AEs for both daratumumab and pomalidomide and thus, not unexpectedly, occurring more frequently in the DPd arm.

The number of subjects with any Grade TEAEs leading to treatment discontinuation was 11 (7.4%) in the DPd arm and 5 (3.3%) in the Pd treatment arm. For Grade 3 or 4, this proportion was similar (5.4% DPd vs 2.7% Pd) and also higher for the experimental treatment.

TEAEs with an outcome of death were similar between treatment groups (DPd: 7.4%; Pd: 7.3%).

The incidence of haemorrhagic events in study 1001 was six times higher than in study 3013. There were no fatal haemorrhagic events and no cerebral haemorrhagic events in the DPd arm in any of these studies. The patients in study 1001 had a median of 4 prior treatments compared to 2 prior treatments in study

<div style=\"page-break-after: always\"></div>

3013. The median age was 64 and 67, respectively. Differences in baseline and disease characteristics likely contributed to the difference in haemorrhagic events between study MMY3013 and MMY1001. The MAH showed that difference in haemorrhagic events observed between studies was primarily driven by Grade 1 events, which are of low clinical significance. In general, the incidence of TEAEs was lower or consistent in Study MMY3013 compared to Study MMY1001. Study MMY1001 represented a more heavily pre-treated study population with a median of 4 prior lines of treatment (compared to a median of 2 prior lines for Study MMY3013). This could in part explain the higher rates of TEAEs observed in Study MMY1001 despite a shorter treatment duration than Study MMY3013.

Infections are known ADRs for daratumumab, which in study 3013 in combination with Pd clearly increases with age as opposed to what is seen in the Pd arm (Table 34). The SmPC includes a warning to alert physicians to the higher incidence of serious adverse reactions in elderly patients. Among patients with relapsed and refractory multiple myeloma, the most common serious adverse reactions that occurred more frequently in elderly were pneumonia and sepsis.' This is considered sufficient information to minimise the risk in this age group.

## 2.5.2. Conclusions on clinical safety

Safety is generally unchanged from previous studies.  Deaths due to TEAEs were comparable between the two arms, but the median age of the study population was 67 years (and a median of 4.4 years after diagnosis), so outside clinical trials SAEs and deaths due to infections would be expected to be higher. Overall, the safety profile of daratumumab in this new combination can be considered in line with the already known safety profile.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The CHMP endorsed the Risk Management Plan version 8.2 with the following content:

## Summary of the safety concerns

Table 37 . Summary of the Safety Concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                    |
|------------------------------|---------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Interference for blood typing (minor antigen) (positive indirect Coombs' test) Hepatitis B virus reactivation |
| Important potential risks    | None                                                                                                          |
| Missing information          | None                                                                                                          |

## Pharmacovigilance plan

No additional pharmacovigilance activities apply. No updates to this section were introduced by the MAH. The  targeted  follow-up  questionnaire  to  collect  additional  information  concerning  AE  associated  with interference and transfusion reactions is maintained.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table 38. Summary Table of Risk Minimization Activities and Pharmacovigilance Activities by Safety Concern:

| Interference for blood typing (minor antigen) (positive indirect Coombs' test)   | Routine risk minimization measures: • SmPC Section 4.4 and 4.5 • PL Section 2 Additional risk minimization measures: • Distribution of educational materials and Patient Alert Cards to HCPs and blood banks as described in the PL, in Annex II, D.   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • A guided targeted follow-up questionnaire to collect additional information concerning adverse events associated with interference and transfusion reactions. Additional pharmacovigilance activities: • None.   |
|----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hepatitis B virus reactivation                                                   | Routine risk minimization measures: • SmPC Sections 4.4 and 4.8; • PL Sections 2 and 4; Additional risk minimization measures: • Distribution of a DHPC to HCPs who prescribe daratumumab was issued in the EU member states in June 2019.             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None. Additional pharmacovigilance activities: • None.                                                                                                                                                           |

DHPC = Direct Healthcare Professional Communication; HBC = hepatitis B virus; HCP = healthcare professional; PL = package leaflet; SmPC = Summary of Product Characteristics .

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC of the subcutaneous formulation are updated.  In addition section 4.8 of the SmPC for the intravenous formulation is also updated based on the pooled safety analysis. The Package Leaflet is updated in accordance. Version 8.5 of the RMP has also been submitted.

## 2.7.1. User consultation

A justification for not performing additional user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

- Full user testing in compliance with the above-mentioned legislative requirements was performed (n=20  participants)  on  the  package  leaflet  developed  for  DARZALEX  for  the  initial  Marketing Authorisation Application.
- An additional user testing (n= 10 participants) was conducted for a bridging report on the package leaflet developed for the Line extension Application of the DARZALEX subcutaneous formulation.
- The package leaflet included in this current application has the same format as the one previously approved.

<div style=\"page-break-after: always\"></div>

- With the currently proposed indication extension, minimal changes have been introduced to the package leaflet and the proposed changes reflect language and a format that is consistent with that in the currently approved leaflet for the subcutaneous formulation.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

The  proposed  addition  to  the  existing  indication  statement  in  section  4.1  of  the  Summary  of  Product Characteristics (SmPC) is as follows (proposed text in bold) :

'DARZALEX is indicated in combination with pomalidomide and dexamethasone, or as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.'

The Applicant has, upon request, separated the indication for the current application from the previous indication  regarding Darzalex  monotherapy, replaced 'IMID' with 'lenalidomide', removed ' relapsed or refractory' and clarified the indication after one and two prior therapies .

'DARZALEX is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients  with  multiple  myeloma  who  have  received one  prior  therapy  containing  a  proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies  that  included  lenalidomide  and  a  proteasome  inhibitor  and  have  demonstrated  disease progression on or after the last therapy (see section 5.1)'

## 3.1.1. Disease or condition

Multiple  myeloma  is  an  incurable  malignant  plasma  cell  disorder  diagnosed  annually  in  approximately 160,000 patients worldwide (Bray 2018). The median age at diagnosis is 72 years.

Multiple myeloma is characterised by osteolytic lesions, usually in the pelvis, spine, ribs, and skull. Lesions are  caused  by  expanding  plasmacytomas  or  by  cytokines  secreted  by  myeloma  cells  that  activate osteoclasts  and  suppress  osteoblasts.  Increased  bone  loss  may  also  lead  to  hypercalcemia.  Solitary extraosseous plasmacytomas are unusual but may occur in any tissue, especially in the upper respiratory tract. In many patients, renal failure is present at diagnosis or develops during the course of the disorder and is caused by the deposition of light chains in the distal tubules or by hypercalcemia. Patients also often develop anemia due to kidney disease or suppression of erythropoiesis by cancer cells, but sometimes also due to iron deficiency.

## 3.1.2. Available therapies and unmet medical need

Different classes of drugs are approved for multiple myeloma (alkylators, steroids, proteasome inhibitors [PIs],  immunomodulatory  agents  [IMiDs],  histone  deacetylase  inhibitors  [HDACIs]  and  monoclonal antibodies).  Among  these  treatment  options,  lenalidomide  (an  IMiD)  and  bortezomib  (a  PI)  have  a prominent  role.  Both  are  approved  and  used  as  frontline  treatment  of  multiple  myeloma  and  used  in combination with other drugs at relapse. Lenalidomide is also approved as maintenance therapy after ASCT in patients with newly diagnosed multiple myeloma. Patients who have been treated with lenalidomide and a PI are a challenge to treat as they have already been exposed to 2 major drug classes. Patients who relapse during ongoing treatment or within 60 days of last dose of lenalidomide are per IMWG definition 'lenalidomide  refractory'  and  represent  an  additional  challenge  for  choosing  an  effective  subsequent treatment choice.

<div style=\"page-break-after: always\"></div>

Patients with exposure to lenalidomide and a PI as well as patients refractory to lenalidomide have a high unmet medical need, and new effective and convenient treatment options are needed (Moreau 2019).

## 3.1.3. Main clinical studies

The purpose of the pivotal phase 3 study MMY3013 was to evaluate the efficacy and safety of DPd to Pd in subjects with relapsed or refractory multiple myeloma having received prior lenalidomide and an IMiD (96% had received bortezomib) using the primary endpoint of PFS based on IMWG criteria.

Daratumumab was given SC (7 patients received IV before amendment 2). Pd dose was given according to Imnovid SmPC. Treatment continued until PD or unacceptable toxicity.

Subjects were randomized 1:1 to DPd or Pd. Randomization was stratified by number of lines of prior therapy and ISS stage. The study was open-label. An IDMC conducted the interim analysis. The study was initiated in June 2017 in centres in 12 European countries. Data cut-off July 2020. In the DPd arm and the Pd arm 151 and 153 patients, respectively, made up the ITT population.

Supportive data where derived from 103 DPd-treated patients in the phase 1b study MMY1001, which was an open-label, non-randomized, multicenter study to evaluate the safety, tolerability, and dose regimen of daratumumab  IV  when  administered  in  combination  with  various  background  treatment  regimens  for multiple myeloma in either newly diagnosed patients or those who had received prior therapies, depending on the background treatment regimen.

## 3.2. Favourable effects

At  a  median  overall  follow-up  of  16.9  months  (DPd:  17.5  months;  Pd:  16.4  months)  the  addition  of daratumumab SC to Pd resulted in a statistically significant improvement in PFS (HR=0.63; 95% CI: 0.47, 0.85; 2-sided p=0.0018,). The median PFS was 12.4 months for the DPd treatment group (95% CI; 8.3, 19.3) and 6.9 months for the Pd treatment group (95% CI; 5.5, 9.3), which is considered clinically relevant particularly in a population that had received a median of 2 prior treatments that included lenalidomide and a PI. The results were generally consistent across multiple sensitivity analyses, and across pre-specified subgroups.

The result for the primary endpoint is supported by the key secondary endpoint ORR (including sCR and CR rates) and rate of MRD negativity, that were significantly better in the DPd arm compared to the Pd arm.

## 3.3. Uncertainties and limitations about favourable effects

The response rate is better in the DPd arm, with a higher rate of CR and also with a greater depth of response (MRD negativity). With this in mind continuing with a long-term maintenance treatment with daratumumab can be questioned in this RRMM population, as prolonged exposure to anti-CD38 could result in the emergence of long-term resistance or relapses that could potentially not respond to further treatment with anti-CD38 targeted therapy. It is acknowledged that even if these are relevant questions they cannot be addressed at this stage considering the design of the MMY3013 study. Results from the LYNX study (MMY2065), an ongoing, randomized, open-label, 2-arm, multicenter, phase 2 study evaluating the efficacy and safety  of  treatment  with  D-Kd  versus  carfilzomib  and  dexamethasone  (Kd)  alone  in  patients  with relapsed or refractory multiple myeloma (RRMM) who have received 1-2 prior lines of therapy (at least one of  which  included  daratumumab  intravenous  [IV]  therapy)  to  evaluate  daratumumab  retreatment,  are awaited, which will give further data of a potential benefit of retreatment with daratumumab after prior daratumumab use.

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

The  adverse  event  profile  of  daratumumab  with  Pd  was  consistent  with  the  known  safety  profiles  of daratumumab and Pd regimens alone.

The most clinically important adverse events (all grades, preferred terms) more frequently reported in the DPd arm compared to the Pd arm in study 3013 were neutropenia (70.5% vs 53.3%), diarrhoea (22.1% vs 14.0%), and pneumonia (20.1% vs 12.7%).

The frequency of Grade 3 or 4 TEAEs was higher in the DPd group compared with the Pd group (DPd: 80.5%; Pd: 74.7.0%). The incidence of serious TEAEs was higher in the DPd group (50.3%) compared to the Pd group (39.3%). The most common (≥5%) serious TEAEs reported were pneumonia (15.4% vs 8.0%) and lower respiratory tract infection (12.1% vs 9.3%).

The incidence of SAEs was higher in the DPd group (50.3%) compared to the Pd group (39.3%). The most common preferred terms were: Pneumonia (DPd: 15.4%, Pd: 8.0%) and Lower respiratory tract infection (DPd: 12.1%, Pd: 9.3%).

The number of subjects with any Grade TEAEs leading to treatment discontinuation was 11 (7.4%) in the DPd arm and 5 (3.3%) in the Pd treatment arm. For Grade 3 or 4, this proportion was similar (5.4% DPd vs 2.7% Pd) and also higher for the experimental treatment.

Syncope was added as a new ADR: As an SAE this occurred in 2% in the DPd arm and 0 in the Pd arm and overall 6.7% and 0.7%, respectively. Syncope Grade 3 occurred in 4% (there were no grade 4).

## 3.5. Uncertainties and limitations about unfavourable effects

Median duration of treatment was longer in DPd arm, 11.5 vs 6.6 months for patients treated with Pd. The MAH has provided exposure-adjusted incidence (EAIR) rates for both MMY3013 and DPd cohort in study MMY1001. As expected, incidences for TEAEs remain higher for the DPd arm but, when analysing the respective EAIRs, the imbalances seem less prominent suggesting that longer exposure plays a key role in the high AEs rates observed. Still, DPd combination shows higher incidences for some important TEAEs like infections and neutropenia.

Some imbalances were observed regarding baseline ECOG performance status. The MAH has submitted upon request a table including TEAEs incidences by baseline ECOG values to rule out any particular trend among subjects included (Table 26). The detailed results do not match the hypothesis that higher ECOG would lead  to  higher  AEs  incidence  rates.  Not  in  all  cases  subjects  with  ECOG  1  reported  higher  AEs incidences than subjects with ECOG 0. Although most of PTs were more commonly reported in subjects with ECOG 2, the small sample size of this subgroup (DPd: 6 subjects; Pd: 19 subjects) does not allow any definitive  conclusion  to  be  drawn.  Overall,  safety  profile  of  this  new  combination  does  not  seem  to  be affected by patients' ECOG PS.

There is limited information since SC formulation was approved in the US and EU in May and June 2020, respectively. The MAH has provided information about post-marketing experience for SC daratumumab up to 31 January 2021. From the global safety database, 7,257 events have been further analysed but include both IV and SC formulations. The most commonly reported PTs for overall AEs and AEs with a fatal outcome were generally in line with the widely reported in all daratumumab studies. From these 7,257 events, 160 reported SC administration of daratumumab but no relevant differences have been observed in reported PTs for them and the overall safety population.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 39: Effects Table for DPd vs PD ; study MMY3013 (data cut-off: 21 July 2020)

| Effect                 | Short description      | Unit                   | Treatment: DPd         | Control: Pd            | Uncertainties/ Strength of evidence                                                                                                                         | Referen- ces           |
|------------------------|------------------------|------------------------|------------------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| Favourable Effects 1   | Favourable Effects 1   | Favourable Effects 1   | Favourable Effects 1   | Favourable Effects 1   | Favourable Effects 1                                                                                                                                        | Favourable Effects 1   |
| PFS                    | Median PFS             | Mo.                    | 12.42                  | 6.93                   | HR; 0.36                                                                                                                                                    | Table 15               |
|                        |                        |                        | *(8.34, 19.32)         | *(5.52, 9.26)          | *(0.47, 0.85)                                                                                                                                               |                        |
| ORR                    | sCR+CR+VGPR +PR        | %                      | 68.87                  | 46.41                  | OR: 2.68                                                                                                                                                    | Table 16               |
|                        |                        |                        | *(60.64, 76.15)        | *(38.32, 54.64)        | 4.35) Median duration of response not yet reached for the DPd arm (range: 1 to 34.9+ months) and was 15.9 months (range: 1+ to 24.8 months) in the Pd group |                        |
| MRD                    | MRD negativity         | %                      | 8.61                   | 1.96                   | OR: 4.71                                                                                                                                                    | Table 17               |
|                        |                        |                        | *(4.66, 14.27)         | *(0.41, 5.62)          | *(1.31, 16.88)                                                                                                                                              |                        |
| Unfavourable Effects 1 | Unfavourable Effects 1 | Unfavourable Effects 1 | Unfavourable Effects 1 | Unfavourable Effects 1 | Unfavourable Effects 1                                                                                                                                      | Unfavourable Effects 1 |
| Infecti ons (SOC)      | All grades             | %                      | 70.5                   | 55.3                   |                                                                                                                                                             | Table 24               |
| Neutro                 | All grades AE          | %                      | 70.5                   | 53.3                   |                                                                                                                                                             | Table 24               |
| penia                  | SAE                    | %                      | 32.9                   | 24.7                   |                                                                                                                                                             | Table 28               |
|                        | Laboratory, Gr4        | %                      | 48.0                   | 20.1                   |                                                                                                                                                             |                        |

Abbreviations: *; 95% CI, CI; confidence intervals, CR; complete response, HR; hazard ratio, Mo.; months, OR; odds ratio, PFS; progression-free survival.  1 ITT: N=151 and 153 and for safety N=149 and 150 (DPd and Pd, respectively).

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The median PFS was 12.4 months for the DPd treatment group (95% CI; 8.3, 19.3) and 6.9 months for the Pd treatment group (95% CI; 5.5, 9.3), which is considered clinically relevant particularly in a population that had received a median of 2 prior treatments that included lenalidomide and a PI. Although the number of patients with only 1 prior line was limited, the PFS point estimate was comparable to the overall group. Furthermore, there is a need for a line of therapy with another MoA in clinical practice for patients that are refractory to lenalidomide and have received a PI in first line.

There is a statistical relationship between the achievement of complete response (CR), MRD negativity and PFS or OS (ESMO guidelines; Moreau et al., 2017), and thus the higher CR and MRD-negativity rates in the DPd arm are considered clinically important responses.

Safety is generally unchanged from previous studies. Cytopenias and infections are well-known AEs for both daratumumab and pomalidomide and thus, not unexpectedly, occurring more frequently in the DPd arm. Infections are known ADRs for daratumumab. The rate of infections in study 3013 in the DPd arm clearly increases with age as opposed to what is seen in the Pd arm Increasing rate of adverse events with age is noted in the SmPC.

<div style=\"page-break-after: always\"></div>

It is of concern, that infections are common and higher with age. Deaths due to TEAEs were comparable between the two arms, but the median age of the study population was 67 years (and a median of 4.4 years after diagnosis), so outside clinical trials SAEs and deaths due to infections could be expected to be higher considering that the median age at diagnosis for multiple myeloma patients is 72 years in Europe. However,  these  risks  to  a  large  extent  can  be  managed  with  the  warnings  included  in  the  product information.

## 3.7.2. Balance of benefits and risks

The improvement in PFS is considered clinically relevant. Well-known adverse events such as infection and neutropenia are frequent as well as a higher incidence of these AEs with increasing age. The benefits to patients from the prolongation of PFS by DPd treatment therefore outweighs the risks associated with its use.

The MAH has revised the wording of the indication to better reflect the target population and has also accepted  to  include  it  separately  from  the  one  covering  the  use  of  daratumumab  in  monotherapy. Furthermore, 'IMID' has been replaced with 'lenalidomide' and ' relapsed or refractory' has been removed.

The following wording has been agreed:

'DARZALEX is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1).'

## 3.7.3. Additional considerations on the benefit-risk balance

## 3.8. Conclusions

The overall B/R of Darzalex is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication for Darzalex subcutaneous formulation to include combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy ; as a consequence, sections 4.1, 4.2,

<div style=\"page-break-after: always\"></div>

4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. In addition, section 4.8 of the SmPC for the intravenous formulation is also updated based on the pooled safety analysis. The Package Leaflet is updated in accordance. Version 8.2 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Darzalex is not similar to Imnovid, Farydak, Kyprolis, Ninlaro  and Blenrep within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Darzalex-H-C-004077-II-0044

## Attachments

1. SmPC, Annex II, Labelling, Package Leaflet (changes highlighted) as adopted by the CHMP on 20.05.2021.

## Appendix

1. CHMP AR on similarity dated 20/5/2021

<div style=\"page-break-after: always\"></div>

## Reminders to the MAH

1. In accordance with Article 13(3) of Regulation (EC) No 726/2004 the Agency makes available a European Public Assessment Report (EPAR) on the medicinal product assessed by the Committee for Medicinal Products for Human Use. The EPAR is first published after the granting of the initial marketing authorisation (MA) and is continuously updated during the lifecycle of the medicinal product. In particular, following a major change to the MA, the Agency further publishes the assessment report of the CHMP and the reasons for its opinion in favour of granting the change to the authorisation, after deletion of any information of a commercially confidential nature.

Should you consider that the CHMP assessment report contains commercially confidential information, please provide the EMA Procedure Assistant your proposal for deletion of commercially confidential information (CCI) in 'track changes' and with detailed justification by &lt;No date in SIAMED&gt;. The principles to be applied for the deletion of CCI are published on the EMA website at https://www.ema.europa.eu/en/documents/other/heads-medicines-agencies/europeanmedicines-agency-guidance-document-identification-commercially-confidential-information\\_en.pdf

In addition, should you consider that the CHMP assessment report contains personal data, please provide the EMA Procedure Assistant your proposal for deletion of these data in 'track changes' and with detailed justification by &lt;No date in SIAMED&gt;. We would like to remind you that, according to Article 4(1) of Regulation (EU) 2016/679 (General Data Protection Regulation, 'GDPR') 'personal data' means any information, relating to an identified or identifiable natural person (the 'data subject'). An identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person.

It is important to clarify that pseudonymised data are also considered personal data. According to Article 4(5) of GDPR pseudonymisation means that personal data is processed in a manner that the personal data can no longer be attributed to a specific data subject without the use of additional information (e.g. key-coded data).

Accordingly, the name and the patient identification number are two examples of personal data which may relate to an identified or identifiable natural person. The definitions also encompass for instance: office e-mail address or phone number of a company, data concerning health, e.g. information in medical records, clinical reports or case narratives which relates to an identifiable individual.'

2. The MAH is reminded to submit an eCTD closing sequence with the final documents provided by Eudralink during the procedure (including final PI translations, if applicable) within 15 days after the Commission Decision, if there will be one within 2 months from adoption of the CHMP Opinion, or prior to the next regulatory activity, whichever is first. If the Commission Decision will be adopted within 12 months from CHMP Opinion, the closing sequence should be submitted within 30 days after the Opinion. For additional guidance see chapter 4.1 of the Harmonised Technical Guidance for eCTD Submissions in the EU.
3. If the approved RMP is using Rev. 2 of the 'Guidance on the format of the RMP in the EU' and the RMP 'Part VI: Summary of the risk management plan' has been updated in the procedure, the MAH is reminded to provide to the EMA Procedure Assistant by Eudralink a PDF version of the 'Part VI: Summary of the risk management plan' as a standalone document, within 14 calendar days of the receipt of the CHMP Opinion. The PDF should contain only text and tables and be free of metadata, headers and footers.